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INTRODUCTION
This thesis focuses on the development and validation of indicators that can be used to 
measure the quality of cancer care. The fïrst chapter starts with a short description of the 
impact of cancer, the leading cause of death in our society. Next, cancer care for patients 
and the role of guidelines in the management of patients with cancer will be described. 
Guidelines aim to improve the quality of care, however, patients are not always receiving 
care in adherence to guidelines. Indicators can be used to measure the quality of care. The 
paragraph “Measuring the quality of care” in this chapter gives an overview of the use of 
quality indicators to gain insight in the degree of care quality that cancer patients receive. 
For an optimal use of these indicators, the validity and reliability is very important. Next, 
the criteria for valid and reliable quality indicators are described. This chapter concludes 
with the outline of this thesis that exists of two parts: Part I - Development of quality 
indicators for cancer care and Part II -  Validation of quality indicators for cancer care
C a n c e r
In many parts of the world, cancer is a major public health problem. About 12.7 million 
cancer patients were diagnosed in 2008 worldwide. In the top ten of most diagnosed 
cancers per year are lung cancer with an estimated 1.608.880 cases, breast cancer with
1.383.500 cases, colon and rectum cancer with 1.233.700 cases and non-Hodgkin 
lymphoma (NHL) with 355.900 cases.1 The incidence rates of these malignancies are still 
rising.2,3 This rise is attributed to lifestyle factors, such as changing dietary and smoking 
habits (e.g. increase of female smokers), obesity and decreasing physical activity.3 As a 
result, in some countries, population based cancer programs (colorectal and breast cancer) 
have been activated. Despite this incidence rise, survival rates for lung, colorectal and 
breast cancer and NHL in general have improved during the last decades.3 Better access to 
specialized diagnostics (screening included), staging and treatment are believed to play a 
role. 3 But still, in economically developed countries, cancer is the leading cause of death 
and the second leading cause in developing countries.
In the Netherlands, about 40000 patients are newly diagnosed each year with lung cancer, 
colorectal cancer, breast cancer and NHL.4 All four are among the top ten of most prevalent 
cancers, of which breast cancer with 13.283 cases and colorectal cancer with 12.319 cases 
are the most common.5 In the Netherlands, every year 19.221 patients die with lung, 
colorectal, breast cancer or NHL.4
C a n c e r  c a r e
Many medical disciplines, such as radiology, pathology, surgery, radiotherapy and medical 
oncology are involved in the care for cancer patients in hospitals. This care can be roughly 
categorized into diagnosis, staging, treatment and follow-up and the organization of cancer 
care. For every category, patients with cancer should receive care that is according to their 
needs and that is effective to cure their disease or to maximize survival. However, the 
diagnostic and treatment options are constantly revised due to new developments in cancer
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care, which makes the care for cancer patients very complex. As the Institute of Medicine 
(IOM) of the United States reports for health care in general: there is more to do, more to 
know and more people are involved, this certainly accounts for the care for cancer patients.6 
To improve the performance of the health care system in the 21st century, the IOM 
identifïed six aims: health care should be provided to patients that is safe, effective, patient- 
centered, timely, effïcient and equitable (table 1). 6 These aims are also very important for 
cancer patients. A cancer survivor (also researcher) underlines the importance of patient- 
centered cancer care as follows:
“There is no doubt that superior technical quality led to my remission, but it was the 
superior interpersonal quality, the patient-centered relational aspects o f my care, that kept 
my spirits alive at a time when the very same evidence-based chemotherapy had 
transformed me into a disabled, helpless individual who could not talk, eat, or even lift his
neck for several days”.7
Table 1. Six aims for the health care system o f the 21st century according to the Institute of 
Medicine.
A im D escrïn tion
S a fe  care Avoiding injurieü iü patients firom tbc care that irKcrwJcd to help tbcm.
Effective care Providmg services based ctt scfcntific fcaowledge i.o al! who could bw.efïi, and 
refrasning frons providine services to those not iikeiv fo benent.
Patient-centered  care Providing carc that is respectfu l o f  and rcsponsivc to individual paticnt 
p references. nccds, and values, and cnsuring  that patiënt values gu ide  ail 
clin ical decisions.
Timely cs/re Rcdücicg waits and soraeiimes harmral dobys for bcth shose who receive acd 
those wfto J»ive care.
E ffic iën t care Avoiding waste tif equipm eM , ïüpislies. ideasand cn?rgy.
Equiiabie care Providing care (hst does aot vsty m qucliiy besaisc ofiKMoaal chsractod?tics 
such as Render, etbnicity, geograpbic iocalion, and socioeconomic status.
C a n c e r  g u i d e l i n e s
With new developments in cancer care, it is difficult to stay up to date for clinicians and 
patients about the best care options. This leads to questions of how to assure that care is 
provided to cancer patients according to most recent evidence. To assist medical 
professionals and patients with decisions about appropriate healthcare according to latest 
scientifïc evidence, national and international guidelines with evidence-based 
recommendations are developed for different types of cancer.8'22 The guideline 
recommendations for the various cancer types clearly describe the care that patients need 
for diagnosis, staging, treatment and follow-up and the organization of their care. These 
guidelines should be able to increase effectiveness and efficiency of care by preventing 
under-, over- and misuse of care and decrease variation in performance between 
professional teams and providers/ institutions. In summary, they aim to improve the quality 
of care by bridging the gap between what is known from scientifïc studies and what is 
performed in daily practice.
However, patients are not always receiving care as recommended in guidelines: the 
publication and dissemination of guidelines do not directly ensure good quality of care.23 
For patients with cancer, different studies have shown that guideline adherence is often
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suboptimal and that adherence varies between hospitals and between care providers.24"30 In 
addition, the focus on patient-centered care and especially on psychosocial care needs more 
attention to further improve the quality of care for cancer patients.31"34 This indicates that 
there is room for improvement in hospital care for cancer patients.
M EA SU RIN G  THE QUALITY OF CARE
A fïrst step towards implementing guidelines, is to gain insight into the care that is actually 
provided to patients with cancer.35 By measuring the adherence to guidelines on different 
aspects of cancer care as diagnosis, staging, treatment and follow-up and the organization 
of care, it should become clear whether improvement is needed in the care process for these 
patients. Implementing the guidelines makes sure that patients receive care according to 
best scientific knowledge and should therefore improve the quality of care.
For the measurement of guideline adherence, quality indicators are essential.36 They are 
defïned by Lawrence et al. as follows: they are “measurable elements of practice 
performance for which there is evidence or consensus that they can be used to assess and 
change the quality of care provided.”37 An indicator usually consists of a numerator and 
denominator. The denominator describes the patients to whom the care should be applied to 
and the numerator the patients who have actually received the care as recommended. An 
example of an indicator for cancer care is given in table 2. The quotiënt between the 
numerator and the denominator is the indicator score.
Table 2. Example ofa  quality indicator for patients who are newly diagnosed with cancer
Numerator Number o f patients with breast cancer who are treated within 5 weeks after 150 
the fïrst hospital visit
Denominator Number o f patients with breast cancer 200
Indicator score 75%
Since the start of this thesis, several typifications in indicators and quality of care 
measurements have been made. One example is the distinction between performance and 
clinical indicators. Indicators that are suitable for extemal reporting of the quality of care, 
to The Health Care Inspectorate for example, are called performance indicators, and 
indicators that are more suitable for intemal quality improvement, for example, indicators 
that measure clinical activities of medical professionals in hospitals, are called clinical 
indicators.38 Also, distinctions have been made between quality indicators that are generic 
measures (applicable to most patients) or disease-specifïc indicators that only apply to 
patients with the same diagnosis. Another well-known classifïcation was introduced by 
Donabedian in 1988. He stated that quality measurements with indicators could be 
classifïed in three categories: structure, process and outcome.39 A description of each of 
these three categories with examples for cancer care are described in table 3.
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Table 3. General meaning o f structure, process and outcome in relation to cancer care.
General meaning Cancer care indicators
Structure Structure denotes the attnbutes of settings 
in which care occurs This include-, the 
attnbutes o f matenal resources (such as 
facilities, equipment), o f huraan resources 
and of organization structure (such as 
medical staff organization).*
Indicators may re late for example to the 
qualificatmn of medical surgeons who 
pertorm tumor resections, or, to the 
organization of multidisciplinary meetings to 
drscuss patients who are newly diagnosed 
vs ith cancer.
Process Process denotes what is actually done in 
giving and receiving care. It includes the 
patiënt’s activities in seeking care and 
carrying it out as well as the practitioner’s 
activity in making a diagnosis and 
recommending or implementing 
treatment.40
An example o f a process indicator for cancer 
care is: patients with non-Hodgkin 
lymphoma should receive imaging of neck, 
thorax and abdomen and bone marrow 
examination (biopsy and aspirate) for 
staging.
Outcome Outcome denotes the eflects o f care on the 
health status o f patients and populations4C
Outcomes such as full recovery (complete 
remission), survival, quality o f life and 
patient’s satisfaction are often used as 
indicators for the assessment o f the quality 
o f cancer care.
A more recent view on quality measurements is that of Porter who advocates that achieving 
high value for patients (value being defined as outcome relative to costs) must become the 
main goal to improve health care delivery. He distinguishes between several types of 
outcomes. According to his concept, outcomes can be categorized, for any medical 
condition, according to a three-level hierarchy, in which the top level is the most important 
for patients. For cancer care, the highest level is the health status achieved or retained, for 
example the survival of patients. The middle level concerns the process of recovery (for 
example time to recovery and treatment-related discomfort), and the lowest level relates to 
sustainability of health (recurrences). These outcomes should include the health 
circumstances most relevant to patients and should be measured on several levels in order 
to improve the quality of care.40 Another recent typifïcations are PROMs (patient-related 
outcome measures). PROMs are routinely used in clinical research to assess the experience 
of cancer patients in terms of Quality of Life or the severity of their symptoms such as 
nausea or xerostomia.41 However, also in clinical practice PROMs can be useful: they may 
detect physical or psychological problems, may facilitate the patient-care provider 
communication and may increase patiënt’s satisfaction with health care.42
While some may advocate outcome measurements, others promote the use of process 
indicators to measure and improve the quality of care. Process indicators are easy to 
interpret and clearly show where improvement is needed and therefore are often used for 
intemal improvement activities in a hospital or hospital department.43,44 The disadvantage 
of using process indicators is that they usually need updating and involve more effort to 
measure than outcome indicators. After summarizing the advantages and disadvantages, 
most authors concluded that the choice to measure either process, structure or outcome
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measures, depends on the practical implications for which they are used (who are the target 
users and what is the purpose?).43’44 In addition, Donabedian stated that these categories are 
not in competition with each other, rather: good structures may lead to good processes, and, 
good processes may result in desired outcomes.39
Q u a l i t y  i n d i c a t o r s  f o r  c a n c e r  c a r e
Indicator deveiopment
The first step in measuring the quality of care is to develop a set of quality indicators. A 
method for the deveiopment of quality indicators is the RAND modifïed Delphi 
procedure.26,45 This method facilitates a systematic process of creating quality indicators 
based on guidelines and combines evidence-based information with expert opinions. It is 
now a renowned method, however, at the start of this thesis, indicators were also developed 
in unsystematic manners with a greater risk of incomplete or invalid sets.
In 2005, when the studies in this thesis started, only few indicator sets were available for 
cancer care that were developed using a systematic method like the RAND modifïed Delphi 
procedure. At that time, international indicator sets were developed and published for 
colorectal, prostate and ovarian cancer, sometimes however with a focus on a single area of 
care, such as surgery or end-of-life care.46'52 Moreover, some indicators were not evidence- 
based.53 For patient-centered cancer care, breast cancer and non-Hodgkin lymphoma, no 
indicators were published. Thus, although solid guidelines were available on how to treat 
and diagnose patients with a specific type of cancer,10'13’18"21’54'57 few measures were 
available to measure this. Furthermore, the indicators that were developed were not 
measured yet to show exactly where improvements were needed.
Indicator validation
For an optimal use of the indicators they have to meet criteria for validity and reliability. 
For all measurement instruments, it is important to evaluate their validity: is the instrument 
measuring what it intends to measure? For example, a weighing scale should measure the 
weight of an object standing on the scale but not the surrounding temperature as an 
example. Next to validity, it is important to assess whether the instrument is reliable. For 
example, a weighing scale should not falsely indicate extra pounds to the actual weight, 
leading to false conclusions. There are several criteria that indicate to validity and 
reliability. In health care, these criteria are well known and often assessed for measurement 
instruments such as questionnaires.58 They are often related to quality indicators as well, as 
is described below.
Face validity Face validity refers to whether at first impression to the opinion
of experts, the set of indicators is useful to assess the quality of cancer care.59 Face validity 
can be assessed during or after the RAND modifïed Delphi procedure by asking the expert 
who are developing the indicators whether they fïnd the indicators face valid. This is 
relevant for practice because indicators that are believed to measure the quality of care, will 
have more impact when measured compared to indicators with no face validity.
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Content validity When it is plausible that all indicators cover relevant aspects of
cancer care and the indicators are developed using a systematic method in which all 
relevant information (scientifically and practical) has been processed, the indicators are 
considered content valid.60 The RAND modified Delphi method combines evidence and 
expert opinions, and is based on clinical guidelines and an extensive literature search, 
which assures that all relevant information was processed during the development process.
Construct validity The indicators must be able to demonstrate the underlying
factors that influence the quality of cancer care. If one hypothesizes for example that high 
volume hospitals deliver better quality of care than smaller hospitals, the indicators should 
be able to demonstrate differences in indicator scores between the different hospitals if this 
hypothesis is true. 59,60 For this type of validity, a fair hypothesis is the key. However, this 
is not easy to assess, as has been demonstrated for the above mentioned hypothesis.61 This 
leads to difïïculties in studying this type of validity.
Criterion validity The indicators should be able to correlate with some other
measures of quality of care (ideally a ‘golden Standard’ which has been accepted in the 
field). 59,60 An often proposed method for validating process indicators, for example, is to 
study their association with disease related outcomes. For cancer care, there are now few 
studies that associate processes of care, measured with quality indicators, with survival. For 
breast cancer care for example, Cheng et al. showed that 100% adherence to indicators was 
associated with improved survival.25 For endometrial cancer, adequate staging was related 
with survival, as was the examination of lymph nodes after resection of colon cancer.62,63
Case mix stability In measuring the quality of care using indicators, the indicator
scores may be influenced by characteristics of the underlying population (case mix). Patiënt 
factors such as poor health status and comorbidities influence the performance on outcome 
indicators, but may also influence the performance on process indicators. For example, the 
ability of a patiënt to receive Standard chemotherapy ultimately depends on his or her 
physical and psychological status. However, it is not known if and to what extend such 
factors influence the performance on process indicators.
Discriminative ability Sometimes indicators are measured for which a large part of the 
study population will have a similar score. These indicators with invariable scores will not 
be able to discriminate between care providers and therefore contain less information. In 
other words, indicators with discriminative ability will provide more precise information on 
the quality of care then indicators with no discriminative ability.64
Missing data Calculating reliable indicator scores starts with the use of reliable
data. Missing data for indicators may bias the results and therefore, the number of missing 
data should be reported.
Inter-rater reliability When two different registration employees are extracting data, it 
may affect the indicator scores by subjective interpretation of the information in the 
medical records. Therefore, the level of agreement between the employees should be 
assessed after performing duplicate registrations.
At the start of this thesis, limited studies conceming the assessment of the quality of cancer 
care with indicators were published. However, nowadays there are studies that have
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measured indicators for lung, head and neck, prostate and pancreas cancer and melanoma in 
a practice test. 24’26’28’29,65,66 Indicator scores were calculated and compared across care 
providers. Low indicators scores, or variation between care providers, gave clear 
indications to where improvements were needed. However, testing of the indicators on the 
above-mentioned criteria has received little attention. Only few studies in recent years have 
tested criteria for validity and reliability of indicators.27,65,67 One reason for this is that the 
type of data that is necessary to validate the indicators, for example data on survival, may 
simply not be available. Moreover, even though criteria for validity and reliability are 
known from research on questionnaires, it does not mean that there is a clear workable 
protocol to follow for the validation of indicators. To develop such a protocol, much more 
research is needed to show in a stepwise model how to perform indicator validation.
T h i s  t h e s i s
Important goals for the 21st century according to the IOM are that care is safe, effective, 
patient-centered, timely, efficient and equitable. This thesis describes research in the field 
of the development and validation of indicators that can be used to assess and improve the 
quality of cancer care. Each of the studies contribute to the aims of the IOM and provides 
more knowledge on how to assess the quality of care using indicators and how to assess the 
validity and reliability of these indicators.
The main research questions for this thesis are:
Part I Development of quality indicators for cancer care_____ In the area of
What are the differences in evidenee-based guidelines of two Equitable care 
neighboring countries and are there consequences if  indicators 
are based on national guidelines?
Chapter two
Is it possible to develop generic indicators for patient-centered Patient-centered Chapter three
cancer care? care
How should quality o f care indicators for patients with a Effective care 
specific cancer type be developed and measured?
Chapter four
Part II Validation of quality indicators for cancer care
Do process indicators conceming timely and multidisciplinary Timely care and Chapter five
cancer care need case mix corrections? equitable care
Can quality indicators be used to assess the level of integrated Efficient care Chapter six
cancer care?
Do process indicators for patients with cancer relate to Effective care 
outcomes?
Chapter seven
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OUTLINE
Part 1- Development of quality Indicators for cancer care
Because equity is an important aim to improve health care and indicators are developed 
based on guidelines, the first part of this thesis concerns a study on the comparability of 
national guidelines for breast cancer care. Chapter 2 describes the comparison of two 
Dutch and two German guidelines on the diagnosis and treatment of breast cancer care on 
three aspects: 1) the methodological quality of the guidelines, 2) the recommendations in 
the guidelines and 3) the use of evidence for these recommendations.
In the first part, the development of indicators for patient-centered cancer care and for NHL 
is also described. The development of generic evidence-based indicators for patient- 
centered cancer care using a RAND modified Delphi method including both patients and 
medical professionals is described in Chapter 3. The aim of the study described in 
Chapter 4 was to develop a set of guideline-based indicators to measure important 
processes in NHL guidelines that need improvement.
Part 2 ■- Validalion of quality Indicators for cancer care
Quality indicators are frequently used to compare the quality of care across care providers. 
Outcome indicators are usually corrected for case mix. This avoids that conclusions are 
incorrectly drawn based on the scores. Process indicators are usually not corrected. 
Chapter 5 describes the effect of case mix correction on three process indicators on timely 
and multidisciplinary care. In Chapter 4 the influence of case mix factors on indicator 
scores are evaluated for NHL.
Using a new method, a pattem analysis in which the measurements of multiple indicators 
are combined into a composite score, we measured the level o f integration of care processes 
in Chapter 6 for patients with non-metastasized colon cancer.
Factors such as age and disease stage may predict the survival for patients with cancer but 
so may the quality of care as measured with indicators. The study in Chapter 7 assessed 
the relationship between process indicators for NHL and the outcome measure, 5 year 
overall survival and therefore provides more knowledge on criterion validity of indicators. 
In all practice tests of this thesis, missing data and inter-rater reliability were measured.
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A b s t r a c t
Background: To encourage transborder cooperation in breast cancer care in Europe, we 
explored possibilities with the German-Dutch border area as an example.
Methods: Evidence-based breast cancer guidelines were searched and compared on the: 1) 
methodological quality (with AGREE (Appraisal of Guidelines for Research and Evalua- 
tion)), 2) content of recommendations and 3) evidence use.
Results: The methodological quality of the German (n=2) and Dutch guidelines (n=2) was 
generally sufficiënt and comparable, although the applicability and the editorial independ- 
ence was not clearly documented in the Dutch guidelines. Regarding the content analysis, 
German recommendations were taken as a reference point, because of the highest AGREE 
scores. Twenty-one of 25 recommendations discussed in both guidelines were correspond- 
ing and 4 were different, 32 were not mentioned in the Dutch guideline. The guidelines 
shared little evidence (<11 %).
Conclusion: We conclude that there are possibilities to encourage transborder cooperation. 
The clinical context of our results should be examined by measuring the actual care in both 
countries preferably with quality indicators.
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INTRODUCTION
Breast cancer is the most common type of cancer among women in Europe with an inci­
dence of 335.000 new cases per year and it is the second leading cause of cancer deaths in 
women.1 Diagnostics and treatment for breast cancer have expanded tremendously in the 
last three decades making it diffïcult for clinicians to remain up to date conceming the most 
evidence based diagnostics and treatment options. To assist practioners and patients on 
decisions about appropriate health care, national and international evidence-based guide­
lines are developed all over the world for specific care topics, including for the care of 
breast cancer.2
Guideline developers aim at the improvement of the quality of care by rationalizing clinical 
recommendations.3 6 They support these recommendations with the best evidence from 
published scientific research. However, even though scientific evidence is easily available 
using online publication databases such as Medline, research shows that recommendations 
from national guidelines of various countries may differ on numerous medical conditions 
including cancer.7"16 Different use and interpretation of research evidence,7’10 use of insuffi­
ciënt or lacking evidence14,17 and cultural factors 18are suggested to contribute to these dif- 
ferences in recommendations.
Unfortunately, differences between national guidelines may discourage cooperation in care 
between countries, whereas regional transborder cooperation may improve two dimensions 
of quality of care namely accessibility and effectiveness.19 Without borders as barriers, 
patients will be able to access all available structures and processes of care in their region 
and efficient use of resources and care consumption may balance over and under capacity. 
In addition, the effectiveness of care can be improved by exchanging knowledge and exper­
tise between caregivers. However, to enable transborder cooperation in health care, partici- 
pating countries should agree on the care that ought to be offered to patients.
In order to encourage transborder cooperation in breast cancer care in Europe, we explored 
possibilities, with the German-Dutch border areas as an example. A limited cooperation on 
radiotherapy treatment already exists for patients with breast cancer in these areas. We 
examined whether German and Dutch guidelines on breast cancer were comparable regard- 
ing three aspects: 1) the methodological quality of German and Dutch evidence-based 
breast cancer guidelines, examined with the international Appraisal of Guidelines for Re­
search and Evaluation instrument (AGREE)20; 2) the content of German and Dutch guide­
line recommendations; 3) the use of evidence, analyzed to reveal the background of possi- 
ble differences.
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M e t h o d s
Seleciïon of guidelines
Dutch and German guidelines on breast cancer were searched by means of a literature study 
(1998-June 2005) in the MEDLINE database using the thesaurus term combination breast- 
neoplasms and practice-guidelines. This search was refïned with the terms Dutch, Nether- 
land* and German* and with similar keywords however translated in Dutch and German 
such as mammakarzinom*, brustkrebs, leitlinie*, borstkanker, mammacarcinoom and 
richtlijn. In addition, a web based search followed on sites from German and Dutch insti- 
tutes that are involved in guideline development: w w w .ikcnet.nl,www.oncoline.nl, 
w w w .s e n o lo g ie .o rg ,w w w .a w m f- o n l in e .d e ,www.kresbgesellschaft.de and 
www.leitlinien.de. We included only evidence-based guidelines in this study, meaning 
systematically developed guidelines that are based on evidence from published scientific 
research.
Evaluating the quality of the guidelines
An expert panel determined the quality of each guideline using the AGREE instrument. 
This instrument is an intemationally validated, generic tooi to assess the methodological 
quality of guidelines on 23 items.20 The items are divided into six domains. Each domain is 
related to a separate dimension of the quality of guidelines: scope and purpose (3 items on 
the overall aim of the guideline), stakeholders’ involvement (4 items on the extent to which 
the views of target users is represented), rigor of development (7 items on the methods used 
for formulating and gathering evidence), clarity and presentation (4 items on the format of 
the guideline), applicability (3 items pertaining to possible barriers for applying the guide­
line) and editorial independence (2 items conceming possible conflicts of interests). The 
panel consisted of four appraisers: two German and one Dutch clinical specialist and one 
Dutch researcher. All panel members worked in hospitals situated in the German-Dutch 
border area Euregio Rhine-Waal and were specialized in oncology. Relevant parts were 
translated into German and Dutch before the evaluation.
The four appraisers independently scored each item of the AGREE instrument on a four- 
point Likert scale ranging from 4 (strongly agree) to 1 (strongly disagree). Subsequently, 
they met at a consensus meeting to discuss each item that deviated more than one point in 
the scores obtained. The final step involved an overall judgment about the usefulness of 
each guideline using a four-point categorical scale consisting in: strongly recommend, rec- 
ommend (with provisos or alteration), would not recommend or uncertain.
A standardized score was calculated for each guideline, for each domain of AGREE. The 
item scores of all appraisers were added up to calculate the standardized scores as: [(ob­
tained score - minimum possible score)/(maximum possible score - minimum possible 
score)]* 100 percent. The maximum and minimum possible score= the number of items* 
the number of appraisers* 4 (strongly agree), or, *1 (strongly disagree).
The degree of agreement between the appraisers was determined after the consensus meet­
ing by means of the Intraclass Correlation Coëfficiënt for agreement (ICCagreement).21 An 
ICCagreement larger than 0.4 was considered acceptable.
Evaluating the content of the recommendations
All recommendations with supporting references were extracted from the text and sorted 
according to three care topics for both countries: screening, diagnostics and treatment of 
breast cancer. Since only a few German recommendations were sorted according to the 
topic diagnostics and since there was no clear link between the supporting references and 
German recommendations on screening, we decided to compare the content of recommen­
dations on treatment only. The German or Dutch treatment guideline with the highest 
AGREE scores was taken as a reference point in this analysis. All recommendations with 
high levels of evidence, level la,b and c studies according to the Oxford Centre of Evi- 
dence-based medicine (for example publications on systematic reviews of randomized 
controlled trials) were selected.22 The panel members assessed whether the treatment rec- 
ommendations as given in the guideline were entirely, partially, or not in agreement with 
the treatment recommendations of the other guideline, or, if they were not mentioned at all. 
In addition, the panel members substantiated each appraisal. The results and argumentations 
were collected and were presented to the panel in order to reach consensus.
Evaluating the evidence use
To compare the use of evidence in the guidelines, it was analyzed how many references 
were shared between the German and Dutch guidelines on treatment recommendations. In 
addition, the country of origin of the evidence used was analyzed. These analyses were 
performed for those references that were used as evidence for the recommendations con- 
ceming the treatment of breast cancer. These references (in this article named the relevant 
references) were searched in Pub med and loaded into separate databases for each country. 
The program Reference manager (version 11.0) examined the absolute number of relevant 
references that overlapped between the German and the Dutch database. The counüy of 
origin of these relevant references was analyzed by determining the address of the first 
author.
Subsequently, only the relevant references of German and Dutch treatment recommenda­
tions that were compared in the content analysis were analyzed correspondingly. This way, 
we could examine the overlap in evidence use of recommendations with high levels of 
evidence.
Finally, it was examined for how many German and Dutch treatment recommendations that 
were mentioned in both guidelines, similar evidence was used in the guidelines.
A shared score was calculated to determine the overlap in evidence use by taking: [number 
of shared references/ total number of different relevant references] * 100 %. The total 
number of different references is the total number of Dutch relevant references plus the 
total number of German relevant references minus the number of shared references. This 
number is corrected for the references that could not be shared because of different publica- 
tion years.
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RESU LTS
Seleeiion of guidelines
We found four evidence based guidelines matching our search criteria: two in Germany 
(published in 2003 and 2004)23’24 and two in the Netherlands (2000 and 2004).25'26 The 
guidelines varied considerably regarding length and the number of (relevant) references and 
recommendations. The Dutch guidelines both used the same grading scale based on the 
scale from AHRQ (Agency for Healthcare Research and Quality) to value the evidence 
used. The two German guidelines each used a different scale (a scale of the American Soci­
ety of Clinical Oncology (GE I, table 1) and the Oxford Centre of Evidence Based Medi- 
cine (GE II, table 1)). Also, the presentation of the recommendations differed between the 
four guidelines (table 1). For all four guidelines, it was not always clear which evidence 
was used for the recommendations nor was the strength of evidence always clear.































































* A total o f 57 different recommendations with high evidence levels could be identified from these paragraphs.
3 Dutcli guideiine on screening and diagnostics;h Dutch guideline on treatment;c German guideline eri screening, 
German guideline on diagnostic, treatment and follow-up.
AHRQ, Agency for Healthcare Research and Quality; ASCO, American Society for Clinical Oncology; OC EBM, 
Ox ford Centre o f Evidence Based Medicine
♦•The presentation of the recommendaticns, the for,nat, was sonetimes different between the four guidelines and 
as a result, the recommendation degree and level o f evidence was applied differently in some cases.
Evaluating the quality of the guidelines
The coëfficiënt of agreement for all appraisers on the quality of the guidelines was accepta- 
ble (ICCagreement= 0.83) as a result of a successful consensus meeting. Table 2 shows that all 
German and Dutch guidelines were appreciated with middle to high standardized domain 
scores (52 -100%) for the four domains ‘scope and purpose’, ‘clarity and presentation’, 
‘stakeholder involvement’ and ‘rigor of development’. In addition, in the general judgment 
of the appraisers, the Dutch and German guidelines were recommended or strongly recom- 
mended.
Appraisal with the AGREE instrument revealed, however, large differences between the 
German and Dutch guidelines on the domain scores of ‘editorial independence’ and ‘appli- 
cation’. In the Dutch guidelines the organizational and financial consequences of the appli- 
cation of the guidelines were barely discussed and no conflicting interests of members of 
the workgroup were documented.
COMPARABILITY OF BREAST CANCER GUlQgLINES | 29
Also, there seemed to be some flaws in the methodological quality of the Dutch guidelines. 
They did not explicitly indicate which search strategy was used to collect the literature, nor 
did they mention which criteria were used to in- and exclude literature. In addition, the 
methods that were used to essay recommendations were scarcely described.
All Dutch and German guidelines failed on one quality item of the domain ‘stakeholders 
involvement’, none of them was tested for further validation by target users before publica- 
tion.
Table 2. Quality domain scores assessed with AGREE for German and Dutch breast cancer 
guidelines
Standardized Scores (%)
•N L ! bNL fl CGEI “CE Ii
•Scope and purposc 83 97 89 100
Slakebolder im oivem ent (59 73 71 54
i<igoi o f dËVcloprrtt.Tit 52 65 75 •>9
Ciarity and presentation 73 83 81 90
AppÜeability 25 14 42
EdUoriai independencs 29 46 88 96
c Dutch guidelaie on screening and dkgnostics:0 Duich guideline on treatment;* German' guideline on screening, “ 
German guideline or, diagnostic, treatment trad foilow-up.
Table 3. Country o f origin o f the majority o f the relevant references
Relevant references (%) of ireatinent recommmdations
GE ï-tL CA IT UK US
German guideline 4% <4% 4% 8% 16% 43%
Dutch guideline 2% 17% 7% 3% 10% 35%
Abbrcviations: GE, Germany; ML, the NeShertands; CA, Canada; ; ï .  Itsly; ü i ,  United Kingdom; US, United
States
Hvaluating the content o f recommendations
The German guideline on treatment was taken as a reference point in this evaluation, be- 
cause of the highest AGREE score. This German guideline summarized the treatment of 
breast cancer in 92 short paragraphs. A total of 57 different recommendations supported 
with references with evidence level la  to c could be identifïed from these paragraphs. These 
57 German recommendations were compared with all Dutch recommendations that could 
be identifïed from 23 paragraphs on treatment in the Dutch guideline. The panel members 
determined that 25 of the 57 German recommendations were also mentioned in the Dutch 
paragraphs. Thus, 32 German recommendations with high evidence levels were not men­
tioned in the Dutch paragraphs. The panel assessed that 21 of the 25 recommendations 
mentioned in both guidelines were entirely or partially similar and that 4 recommendations 
were not in agreement between the two countries (table 4). Firstly, adjuvant therapy with 
Tamoxifen for patients with Ductal Carcinoma in Situ (DCIS) was not recommended in the 
Dutch guidelines, whereas the German guideline seemed to advocate this treatment because 
of the risk reductions for invasive recurrences and contra lateral carcinomas. Secondly, a 
margin width of more than 5 mm was recommended in Germany for DCIS surgery but
3 0 1 C h a p t e r  2
according to the Dutch guideline developers a more than focally tumor positive margin only 
was a reason for re-surgery. Adjuvant combination chemotherapy with anthracyclines was 
administered independently of the nodal status in Germany and dependently in Holland. 
Finally, the Dutch guideline developers seemed to recommend trastuzumab in combination 
with anthracyclines where the German guideline did not recommend combining 
anthracycline and trastuzumab.
Evaluating the evidenee use
Only 19 relevant references were shared between the German and Dutch guideline on 
treatment of breast cancer, whereas the number of different references was 354 (157 + 216- 
19). Both guidelines were published in 2004. The shared score was 5% ([19 /354]* 100%).
Table 3 illustrates the country of origin of the majority of the relevant references. The larg- 
est proportion of relevant references of both German and Dutch recommendations on 
treatment originated from the United States and from the United Kingdom. Guideline de­
velopers however, tended to prefer references from their own countries as well.
On recommendations included in the content analysis (generally high levels of evidenee), 
133 references could possibly be shared between the two countries. The number of shared 
references was 14 and the shared score was 11% ([14/ (98+49-14)] * 100%).
For 10 out of the 25 recommendations that were mentioned in both German and Dutch 
guideline, similar evidenee was used. Eight of these recommendations were corresponding 
with regards to their content however, for two of these recommendations there was no 
agreement between the two countries.
DlSCUSSION
This is the first study to examine the comparability of German and Dutch guidelines on 
breast cancer in order to explore possibilities for European cooperation in care. The main 
finding of this study was that the methodological quality of all guidelines was largely com- 
parable (with the exception of the editorial independency and the applicability o f the Dutch 
guidelines) and sufficiënt: the Dutch as well as the German guidelines were recommended 
for use in practice. This increases the possibility that the care that was recommended in the 
guidelines will actually be applied in clinical practice. Furthermore, the treatment recom­
mendations that were discussed in both guidelines were largely overlapping, which implies 
that patients will receive largely the same care in both countries, at least for the treatment of 
breast cancer. We found, however, 4 recommendations for which there was no agreement 
between the two countries. Adjuvant therapy with Tamoxifen for patients with DCIS was 
not recommended in the Dutch guidelines, whereas the German guideline seemed to advo­
cate this treatment. Secondly, a margin width of more than 5 mm was recommended in 
Germany for DCIS surgery but according to the Dutch guideline developers, margins that 
were more than focally tumor positive only were a reason for re-surgery. Adjuvant combi­
nation chemotherapy with anthracyclines was administered independently of the nodal 
status in Germany and dependently in Holland. Finally, the Dutch guideline developers 
seemed to recommend trastuzumab in combination with anthracyclines where the German 
guideline did not recommend combining anthracycline and trastuzumab. In addition, ap-
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proximately half of the German recommendations with high evidence levels were not men- 
tioned in the Dutch guideline. One could suggest from these results that this might hinder 
transborder cooperation in care, however, at first, it is important to know whether or not 
these differences are (clinically) relevant.
Assuming that the recommended care would be applied exactly as described, German spe- 
cialists would use a more aggressive policy for breast cancer care then Dutch specialist for 
at least three of the four different recommendations. Taking this comparison to an interna­
tional level, however, it shows that the German recommendations were actually similar to 
recommendations developed under a European consensus, in contrast to the Dutch.27,28 
Furthermore, some Dutch recommendations that were contradictory to the German were 
supported with weaker evidence and sometimes it was unclear which references were used 
as evidence. However, to make clear comments on the clinical relevancy of these differ­
ences, one should first know what really happens in clinical practice regarding these rec­
ommendations.
Previous studies on the comparability of guidelines on other disorders ascribed the differ­
ences in the content of recommendations to the use of weak or different evidence, possibly 
resulting from a bias in selecting literature,10 or to lacking evidence.7,14’17 Researchers also 
doubted the methods that were used to select the evidence,11'13 which increases the possibil- 
ity for a selection bias. This could also be an explanation in our study, the evidence was 
hardly overlapping between the German and Dutch guidelines on treatment, even though 
the guidelines were of the same publication year and the references examined were those 
with high evidence levels. We found that the developers gave a preference to publications 
from their own country and that the methodology for collecting and selecting evidence was 
not clearly described in the Dutch guidelines.
Regarding the quality of our guidelines, the domain scores in this study were comparable to 
the quality scores of other cancer guidelines from previous research.11,29 It was interesting 
that the range for the scores for the domains “Applicability” and “Editorial independency” 
was very widespread. We suggest that the unequal division of items over the domains could 
have possibly influenced the standardized scores. The fewer items are assigned to a domain, 
as for example at the domain "Editorial independency" (n=2), the more likely it seems to 
receive an extreme high or low domain score.
What was remarkable in this study, was that some of the contradictory treatment recom­
mendations relied on similar publications. Thus, besides the evidence used, other factors 
may lead to differences. When examining these publications, the research results seemed to 
be clear however not sufficiënt for an instant practical application. The therapeutic effects 
of anthracycline in combination with trastuzumab were well defmed in one publication, 
however no treatment advice was given because of the serious side effects. In judging the 
evidence and formulating recommendations, guideline developers may have to take into 
account the potential (side) effects, as well as patiënt preferences, cost-effectiveness and 
availability of (fïnancial and material) resources.
There are indications that the outcome of such considerations might differ between coun- 
tries because of cultural differences15,18; as societies differ with regards to their culture, so 
will their decision-making differ.30 According to Hofstede et al. societies may differ along
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four cultural dimensions. One of these dimensions is uncertainty avoidance (the extent to 
which individuals within a culture are made nervous by situations that are unstructured, 
unclear, or unpredictable). Cultures with strong uncertainty avoidance are aggressive and 
security-seeking.30 Christiaens et al. performed a study that reported the need for safety of 
German guideline authors.18 It is possible that differences on this cultural dimension that 
affected decision-making are present between Germany and the Netherlands. However, the 
question remains in our study, whether German developers have been too aggressive or 
whether the Dutch have been too tolerant on some of the contradictory recommendations. 
The influence of various cultural factors has to be explored more vigorously in order to 
improve the understanding of guideline generation and adherence.
The German and Dutch guidelines for breast cancer in this study were sufficiënt and gener- 
ally comparable with regards to their content conceming the recommendations discussed in 
both guidelines. Half of the German recommendations were not mentioned in the Dutch 
guideline. Further research should be done to outline whether the differences we found are 
of major or minor clinical relevance. Using a systematic procedure, for example the RAND 
modified Delphi method, the role of the missing, corresponding and non-corresponding 
recommendations can be clarified. Furthermore, those recommendations that are most 
relevant can be used as quality indicators. With quality indicators the actual delivery of care 
can be measured. It would be interesting to gain insight on the actual care that is applied in 
relation to what guidelines recommend. The development of such indicators for breast 
cancer care could be an important step in encouraging transborder cooperation.
In conclusion, despite some differences in the methodological quality and the content of the 
guidelines, the latter probably because of cultural influences, we can say that there are pos- 
sibilities to encourage transborder cooperation in breast cancer care between Germany and 
the Netherlands.
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Table 4. Content analysis o f  recommendations on the primary treatment and treatment of 
metastasized breast cancer
T r e a tm e n t Germany Recom- The Neüierlands Recom-
m e n d a tto n  .m endstio ii 
_____________________ d c g rc e t_____________________________d e g rc e t
Surgery
C o m p l e t e  ex c is io n  o l ' t h e  t u m o r  
wJiLii ooi advanecd 
Margin widih:
>1 mm for invasive cancer or 
intraductal eomconent 
>  5 mm for Ductal Carcinoma In 
Situ(DCIS)
Axiilary disscction levo; I, II for 
invasive cancer (inv. ca.)
as  d ia g n os t ie s
as fherapy
R adio th erapy
after Breast Cor.serving Surgery 
(BCS) for DCIS
for DCIS < 2 cm. low gratie. 10 mm 
margin width
ffter BCS for invasive cancer 
Dose 50 Gy (whole breast); in 
fractions ( 1.8-2.0 Gy), boost dose in 
numerous cases 
afte.L mastecfomy 
M d k a i  therapy
Adjuvant therapy with tan-oxifer. 20 
mg/ day, 5 years for patients HR+ 
and ir.v.ca
A d ju v a n t  t h e r a p y  w i th  t a m o x i f e n  
f o r  D C I S
post-menopausai pt and HR+ and 
cootraindicatiocs fcr Tamoxifen. 
doctor may use aromatase-inhibitors 
3rd generation
A djuvant therapy with taxanes is 
allow ed  for patients N +
Adjuvant combi-cherootherapy with 
antliracyciinc
independent on the mxlal status 
Ablation of ovariar function for 
pre-menopasisal patients KR+ can 
replace ciienctherapy (a greater 
effect with tamoxifen) 
GnKH-jEtalojsiteii > 2 years 
Dose elevation of cyciophospha- 
mide o»- doxorubicin dces not 
improve effcetiveness 
Aiin)ia!suai i o f  cheirjotis«i3!>>■ in 
recomnwnde tl do sages 





recom m ended I
recommended 1
recommended** 1
















part. recommend- 3 
ed:
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Treatm ent Germ auy Rsoom- The Neilierlands Recoui-
mendation inendatfou 
______________ degreet_________________________ d asrss t
örganizafional
Endocrine therapy should start after recommended 1 n.m.
ending chemotherapy
Sequentiai Lhcmothcrapies ar»: ocmduded
S.!iO\V»j
Endocrine therapy is allowed simul- conciuded 
taneously with radiothsrapy
Estimatiixg tbc therapeutic d 'Im  of 
hcnnone therapy, trastuTunian. recommended
GnRH-analoges 
HR- status, Hs;r-2-Ncu-status. 
menopauzai sTatus 
Estimating the prognoses:
with the pTNM-status, recommended
with uPA en PAI-1 when NO recommended
M etastasi/ed  breast cancer
Sysicmic ihcrapy in combi, with 
radintherapy tbr inoperable ad- 
vanccd cancer
rec-omroomk-d i rccontmcnded
laboratory and imaging diagnostics 
should be used when there is a 
clinical suspicion for a metastases.
recommended 1 n.m.
A combi. ol'endocrine therapy and 
chemotherapy can increase remis-
sion (%). but alsii leads to a highcr 
toxicity
concluded ! n.m.
Cytostatic mono-chemotherapy for 
small complaints, slow tumor 
growdi or inefiïciency of endocrine 
therapy
recommended 1 n.m.
Cytustatu; poiv ctam o ihcnpy  for 
heavy coiJiplaiötó, aggrtfssivtt itunor 
griiv.-ih
ivcommetiüttd 1 n.m
ïh e  status of the primary tumor as a 
i'eference point for trastuzumab 
treatment
recommended 1 n.m.
Aromatase inhibitoiü is Ist step 
endocrine therapy ibr poslmenopau- 
sal patients
recommended** 1 reeommeiuicii* !
Ablation o f ovarian function for 
pre-menopausal patients HR+ with 
Tamoxifen
recommended 1 n.m.
Por Her-2-Ncu status-1-, irastuzumab 
tn combinatiim with chemotherapy
recommended** 1 recommended* * 5
not with anthracycline recommended** 1 not recommend- 3 
edst l
or mono after Uuuutos and 
£.fi ?!'iracyc .‘in cs§
recommended 1 [(.m.
Neo-adjuvant therapy Standard for 
patients with advanced, primary 
inoüerable or inflammatory cancer
recommended 1 recommended 3
tior:c mcüistasie” and radiu'dictapy 
lor:
Locale pain recommended** 1 recommended** 1
n.m.
n.m.
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Siubi! j(v cndaiigenmint recoramendcd 1 n.m.
M obility limitations recommended 1 n.m.
Fracturcs reciwmiended 3 r.m.
Post-surgery recommended 1 n.m.
Bone metastases and surgicat
therapy for:
Fractures recommended 1 n.m.
lastable vertebra fi-actures recommended 1 n.m.
Spinal c f  radlcular compressions recommended 1 n.m.
Fractures o f the lower extremities recommended 1 n.m.
Trtcrapy wiih biphpspïiujiiitrs
Hypercalcemia recommended 1 n.m.
itoncpam  r.aurcd by m dastascs rocirnimendcd** 1 reeonimendcd4*
Csteolytica! metastases recommended 1 9n.m
Th erapy- i n tJ nee d m 3 n i fe st recommended 1 n.m
osteoporoses
Interdisciplinary evaluation of recommended 1 n.m.
surgical therapy for skeletal metas-
tascs
Follow-up
Mammography every year recommended 1 part. recommend-
___ ___ ______ ________ _ ____________ _____  ed10
Aobreviations: GnRH, Gonsdotropin Releasing Hormone; KR+, hormone receptor positive; N-:-, node positive; 
NO, noae negativo; pTNM, primary Tumor Nodes, Metastases; uPA, urokinase plasminogeen activator; PAI-1, 
piasminogeen activator inhibito.r-1; combi,, combination; Her-2-neu, human epidermal growth factor 2; part.* 
partiaily; n.m., not mentioned; Similar references have been used for the German and Dutch recommendations,
-------------- =  recommendations are not corresponding; { recommendation degrees were used according to scales
jrom the Dutch guidelines, based on tke scale from AHRQ, 1 to 4 (high ïc low), equivalent to the scale values 
from CC EBM (from A to D, high to low).
! more than focally tumor positive margins are a  reason for re-surgery for D C IS
2 in principle only if  a Sentinal Node Biospy (SNB) cannot be psrformed
3 Only when SNB was net possible or when SNB results are tumor positive 
‘ is also depeudent on the menopausal status and Her-2-nea status
5 No adjuvant therapy for DCIS and BCS
6 For premenopausa! patients and Her-2-neu status +
7 Indications is also dependent on the nodal status, age, tumor size and CBR-grade
Trastuzumab with anthracycline ittcreases the chance for remission, lengthens the disease free survival and total 
survival
5 For osteoporoses is baing referred to the guideline o f osteonoroses
10 Till age 60 every year, after age 60 eveiy 2 year and after 75 individually adjusted
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A b s t r a c t
Background: Despite growing attention to patient-centered care, the needs of cancer pa­
tients are not always met. Using a RAND modifïed Delphi method, this study aimed to 
systematically develop evidence-based indicators, to be used to measure the quality of 
patient-centered cancer care as a first step toward improvement.
Methods: First, key recommendations were identified from literature and were distributed 
over 5 domains of patient-centered cancer care: communication, physical support, psycho- 
social care, after-care, and organization of care. Generic key recommendations, with best 
available evidence, were selected from guidelines. A multidisciplinary panel of patients and 
medical professionals (n = 14) rated and prioritized these recommendations in a written 
procedure. Subsequently, the panel discussed the recommendations at a consensus meeting.
Results: Key recommendations were identified for communication (n = 32), physical sup­
port (n = 13), psychosocial care (n = 25), after-care (n = 11), and organization of care (n = 
11). For all domains, recommendations based on high-level evidence were identified except 
for after-care and physical support. The panel developed 17 indicators conceming criteria 
for communication and informed consent, evaluation of communication skills, provision of 
information, examination of emotional health, appointment of a care coordinator, physical 
complaints, follow-up, rehabilitation, psychosocial effects of waiting times, and self- 
management.
Conclusions: A set of 17 indicators for patient-centered cancer care resulted from this 
study. Evidence support was available for most indicators. This set provides an opportunity 
to measure and improve the quality of patient-centered cancer care. It is generic and there- 
fore applies to many patients.
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INTRODUCTION
Over the last decades, growing medical scientifïc knowledge, increased complexity of care 
and a more active and demanding attitude of the patiënt have led to a major change in 
health care delivery, namely a shift from provider-centered to patient-centered care. The 
Institute of Medicine (IOM) identified patient-centeredness as one of six key aims for the 
health care system of the 21st century and states that patients should be able to count on 
receiving care that meets their needs and is based on the best scientifïc knowledge.1 The 
IOM defïnes patient-centered care as: ‘Healthcare that establishes a partnership among 
practitioners, patients, and their families (when appropriate) to ensure that decisions respect 
patients’ wants, needs and preferences and that patients have the education and support they 
need to make decisions and participate in their own care’.2
Despite improved cure rates, cancer remains a life-threatening disease. Patients may react 
with anxiety, depression and disbelief at the diagnosis of cancer. The importance of good 
patient-centered cancer care is described by a researcher and cancer survivor as follows: 
‘There is no doubt that superior technical quality led to my remission, but it was the superi­
or interpersonal quality, the patient-centered relational aspects of my care, that kept my 
spirits alive at a time when the very same evidence-based chemotherapy had transformed 
me into a disabled, helpless individual who could not talk, eat, or even lift his neck for 
several days’.3
In daily practice, the needs of patients with regard to patient-centered care are often not 
fully met. Walton et al. identified unmet needs in patients diagnosed with gynecological 
cancer and concluded that a patient-focused, comprehensive and integrated approach to 
supportive cancer care is desired.4 Problems with continuity and coordination of care, espe- 
cially after the primary treatment, were observed as well.5 Furthermore, there is a rising 
awareness that psychosocial care is essential for patient-centered health care6,7 and that the 
integration of psychosocial care as part of routine care can lead to an improvement in the 
quality of life for patients and their families.8
To assist professionals in the difflcult task of providing optimal patient-centered health 
care, recommendations on patient-centered cancer care, for example on communication, 
psychosocial and physical support have been published in national and international evi- 
dence-based guidelines for several tumor types.9"14 Nevertheless, publication and distribu- 
tion of guidelines does not ensure a good quality of patient-centered care.15 The first step 
toward improving the quality of patient-centered cancer care is to gain insight into current 
practice16 by using quality indicators. Quality indicators are defïned as measurable elements 
of practice performance for which there is evidence or consensus that they can be used to 
assess and change the quality of care provided to the patiënt.17
A renowned method for the development of quality indicators is the RAND modified Del­
phi procedure.18 This method facilitates a systematic process of creating quality indicators 
and combines evidence-based information with expert opinion, by using a multidisciplinary 
panel of both healthcare professionals and patients. These characteristics make the RAND 
modified Delphi procedure an appropriate method for the development of generic quality 
indicators for patient-centered cancer care.
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In the light of promoting ‘evidence-based medicine’ for patient-centered cancer care as 
well, this study aimed to develop a generic set of evidence-based quality indicators for 
patient-centered cancer care by deploying a RAND modified Delphi procedure involving 
both patients and care providers from multidisciplinary cancer care.
M e t h o d s
A three-step selection process was used to develop a set of quality indicators for patient- 
centered cancer care (Figure 1). Key recommendations from guidelines that described pa­
tient-centered cancer care were selected and processed into a written questionnaire.
Selection o f  92 key  recom m endations from guidelines and literature
A. Communication B Physical support C Psychosocial care D  After care: E Orgamzatian
n -32  n=13 n=25 n ^ lJ  n = ll
STEP 1: Individual ratm g o f key recom mendations by the e \p e rt panel
Potential
High n = 19
Low n = 27
Uncertain n = 46
Newly added n = 3
J
STEP 2: Panel consensus m eeting: acceptance o f  31 key recom mendations
Potential
High n - 19
Low n =3
Uncertain n = 6
A’ewfv added n = 3
Final set o f  17 quality indicators for patient-centered cancer care
4 Communication B. Physteal support: C  Psychosocial care D. After care: E Orgumzation
n~6 Ti—1 n -2  n^3 n~5
Figure 1. FJowchart for the selection process o f quality indicators.
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Selection of key recoimnendations
A comprehensive literature search was conducted to identify key recommendations for 
patient-centered cancer care. MEDLINE, the Cochrane Library and the Internet were con- 
sulted for national and international guidelines, published by medical organizations and 
govemmental institutions. Guidelines were included if published betweenl995 and April 
2009. Generic key recommendations with best available evidence were selected from 
guidelines. The key recommendations were distributed over five important domains of 
patient-centered cancer care: Communication, Physical support, Psychosocial care, After 
care and Organization of care. Psychosocial care deals with psychosocial problems arising 
from cancer and physical support is care provided to relieve physical symptoms due to 
disease, or as a result of therapy, such as anti-emetics in case of nausea.
The key recommendations in the questionnaire were rated by a multidisciplinary national 
panel of 14 experts: two surgeons, two medical oncologists, three patients or patiënt repre- 
sentatives, one radiotherapist, one general practitioner, one nurse-practitioner, one nurse, 
one psychologist and two social workers. Patiënt representatives were included by ap- 
proaching the Dutch Federation of Cancer Patients Organizations (NFK). Others were nom- 
inated by their professional societies.
Step 1 Indivtdual rating of key recommendations by the expert panel
Step one entailed sending a tabulated list of key recommendations to the members of the 
expert panel. Each recommendation was presented as follows: ‘The health care provider 
should...’.
Firstly, the panel members were instructed to individually rate the key recommendations on 
a nine point scale (one for lowest up to nine for highest) by asking: ‘Please rate on a scale 
from one to nine to what extent the execution of this action is a good measure for the quali­
ty of patient-centered cancer care’. To support their choice, panel members were provided 
with the source and evidence level of each key recommendation. The evidence underlying 
the key recommendations was classified into four levels: level I (systematic review/RCTs), 
level II (RCT), level III (comparative studies) and level IV (case studies or expert opinion). 
Subsequently, panel members were asked to prioritize the key recommendations for each 
domain, by ranking the best five key recommendations (or three depending on the number 
of key recommendations in the domain). In addition, panel members were encouraged to 
propose new quality indicators that supplemented one of the five domains.
The results of Step 1 were processed into a summary report to facilitate Step 2 (Panel con­
sensus meeting). In this report, the indicators were categorized into three categories accord- 
ing to their potential to be used as quality indicators: a category of indicators with high 
potential, low potential or uncertain potential. The potential of each recommendation was 
assessed using the ratings (on the nine point scale) and rankings (prioritizing in the top five) 
from the first step.
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Analysis of step 1
Per recommendation, the experts’ ratings were summarized into a median rating and the 
rankings were calculated into an overall ranking score. To calculate this overall ranking 
score, a recommendation ranked first, second, third, fourth or last in the top fïve received 
five, four, three, two or one point(s) respectively. The overall ranking score was expressed 
as the percentage of the maximum score that could be obtained (an overall ranking score of 
100% indicates that all panel members ranked the recommendation as first, whereas 0% 
means that none of the panel members ranked this recommendation).
Then, the recommendations were categorized. Recommendations in the category with high 
potential were those with a high median rating and with a high overall ranking score. Rec­
ommendations were placed into the category of low potential when they had a low median 
rating and a low overall ranking score. The cutoff for a high median rating was set at eight 
or higher and for the overall ranking score at 20% or higher (see Table 1). A cutoff point of 
eight for the median score was associated with face validity and good reproducibility and 
reliability.18 A low median rating and a low overall ranking score (low potential recom­
mendations) included a median rating below 8 and an overall ranking score below 20%. 
The category of uncertain recommendations consisted of recommendations with dubious 
results: for example, a high median rating but a low overall ranking score and vice versa. In 
addition, we placed recommendations for which ratings were highly conflicting between 
panel members in this category as well. For this, the level of agreement between panel 
members was assessed. Panel members were defined as being in agreement if at least 70% 
of the ratings feil within the same tertile (e.g., 1-3, 4-6 or 7-9) (Figure 2a). Less than 70% 
of the scores in the same tertile was an indication of no agreement. Disagreement was de- 
frned if at least 30% of the scores in both the bottom (1-3) and top (7-9) tertiles (Figure 
2b).19 Analysis of the inter-rater reliability was performed by calculating the intra-class 
correlation coëfficiënt (ICC), using SPSS 16.0.2. This measure was an indication of the 
consistency of all ratings between panel members.
Table 1. Classifying key recommendations into categories o f high, low, and uncertain po­
tential after step 1 according to their median rating and overall ranking score
Median rating
Overall ranking score (%)
> 8 < 8
>20 High potential Uncertain
•=' 20 Uncertain Low potential
0 Low potential Low potential
Step 2 Panel consensus meeting
Panel members were invited to the consensus meeting to discuss results from step one and 
to criticize the key recommendations face to face. The personalized summary report pro- 
vided panel members with the opportunity to compare their individual scores to the overall 
distribution of scores and to discuss reasons for disagreement or conflict situations. The 
goal of the meeting was not to force consensus, but to distinguish between well-founded 
disagreement and disagreement based on misunderstanding or irrational motives. The fol-
lowing options were explained to the panel members: acceptance of a key recommendation 
as a quality indicator, rejection, adjustment of key recommendations or merging multiple 
key recommendations into a single quality indicator.
A
tertile 1 tertile 2 tertile 3
I I I I I----------------------1
Likert rating scale1 1 2 3 4 5 6 7 8 9
No. o f ratings2 2 1 5  7
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1. Nine-point scale to rate each recommendation.
2. Distribution of ratings of panel members (n—14) on the nine-point scale, among three tertiles.
B tertile 1 tertile 2 tertile 3
I I I I f-------------------------------- 1
Likert rating scale1 1 2 3 4 5 6 7 8 9
No. o f ratings2 4 5 2 2 1
1. Nine-point scale to rate each recommendation.
2. Distribution of ratings of panel members (n=14) on the nine-point scale, among three tertiles.
Figure 2A avd B. Exampïes o f agreement and disagreement between panel members resulting frcm individual 
ratings In  step 1.
Step 3 Approval of the final set
Eventually, a set of quality indicators was developed that passed the first round of individu­
al rating as well as the second round discussion. This set of quality indicators was sent to 
the expert panel by e-mail for final approval. All panel members, including those not pre­
sent at the meeting, were provided with a last opportunity to make remarks and were asked 
to approve the final set. Comments were discussed by the authors and last revisions were 
made.
R e s u l t s
Selection of key recommendations
The selection procedure resulted in 92 key recommendations (Figure 1), collected from 
evidence-based guidelines and literature.9’11’14,20"35 The key recommendations were assigned 
to the fïve domains of patient-centered cancer care: 32 were assigned to the domain Com- 
munication, 13 to Physical support, 25 to Psychosocial care, 11 to After care and 11 to 
Organization of care. O f all 92 key recommendations, 65 were supported with level I, II or 
III evidence (systematic review, RCTs or comparative studies) and 27 were supported with 
level IV evidence (case studies or expert opinion).
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For most indicators for the domain Physical support (for 8 out of 13 key recommendations) 
and for After care (for 9 out of 11 recommendations), recommendations were supported 
with evidence level IV. Key recommendations for the domain Communication and almost 
all recommendations for the domains Psychosocial care and Organization of care were 
supported with higher evidence (level I, II, III).
Step 1 Individuai rating of key recommendations b y  the expert panel
The 92 key recommendations obtained from the selection procedure were rated by the ex­
pert panel in step 1. All panel members retumed the completed form with the key recom­
mendations before the start of the consensus meeting. According to the categorization of 
key recommendations, 19 key recommendations feil in the category of high potential, 46 
were classified as uncertain and 27 as having low potential. Three new key recommenda­
tions were proposed by the expert panel covering the subject of patiënt autonomy, the psy­
chosocial effects of waiting times on the patiënt and self-management. Consistency in rat­
ings between panel members was assessed by calculating the intra-class correlation coëffi­
ciënt (ICC) for all fourteen panel members. The ICC of 0.853 (95% Cl 0.799-0.897) indi- 
cated good consistency in ratings between panel members.36
Step 2 Panel consensus meeting
At the consensus meeting, where a medical oncologist, a surgeon, two patients, a psycholo- 
gist, a nurse practitioner and a general practitioner (7/14) were present, 95 key recommen­
dations were presented to the expert panel in an individuai summary report.
All key recommendations with high potential according to step 1 (n=19) were accepted in 
the final set and 9 key recommendations with uncertain or low potential that were strongly 
related to these indicators with high potential were added to the set. The 3 indicators that 
were newly proposed by the panel in step 1 were also accepted. Thus, a total of 31 key 
recommendations were accepted.
Subsequently, the panel merged 19 key recommendations to 5 more generic formulated 
quality indicators (Table 2). For physical support for example, the panel considered it not 
appropriate to choose between key recommendations dealing with specific psychosocial or 
physical problems, for it depends on the needs of the individuai patiënt which problems 
require special attention. Recommendations were therefore merged into one indicator. Fur- 
thermore, some recommendations were very much relating, for example on criteria for 
good communication. The panel members decided to collect all relevant key recommenda­
tion on criteria for good communication and merged them into one indicator. Table 2 shows 
the results from step 1 for six of these criteria that were subsequently merged in Step 2. 
Eventually, this led to indicator A l, which was approved by the entire panel in Step 3. 
Merging all 31 key recommendations ultimately resulted in a core set of 17 quality indica­
tors for patient-centered cancer care (Table 3).
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Table 2. Description o f  the development process from step 1 (individual rating) to step 3, 
resulting in a final set o f  quality indicators
STEP 1 STEF 2 STEP 3
Rating and ranking Panel consensus Final quality
___________________________ meeting_________ indicator ______
Key recommendation in summary Evidence Agree Potential Adjustments after
______________________________  iQvela reent_____________ discussioa______________________
M Co>ranwrivatiim '  " "
Asking open-enüeü questions
Summarizing and repeaiing infbnnatfen 
Giving most important information first 
A.üjusting infcrmatioü to individual patiënt 
Explaining medical terminology 


























l'rovidilis a room with adfcquale p rh acy  










Evaluate ccmnranicative skills professionals I no low adjusted A3
Information: pmbtibility u f  recovvry 
Information: physical and emotional impact
Ask i f received Information is adequate 
Check if Information in iimlerstood 





















Respect Uie autcnomy of the patiënt New key reconffiiendation 
(added in step 2)
merged
A ctenuiate uptimal pa.iliat.ivt: care IV yes high adjmsted A 5
Provide a Hst o f sources o f information n yes uncertain adjusted A 6
Dnmuin 3 Phynit al titpport
Frsscribing anti-emetics 








Daniriin (  Psychosocial tvnv
Psychosocial and emotional weilbeing ï yes high replaced
R ifera! in case c-f xtix&.y rff deprtssinn i yes {'.ig.il nficïsu'^ci Cl
Information: psychosocial support i yes higli revised
Ast. the pasieut aboui ho/her so tia l actwork in yes high replaeed C'2
Domain D  After care
Time end aucntwn durir.g fWlow-up vs&it» - yes liigK Dl










Domain E  Organization o f  patient-centered care
One care provjder operaies as a coordiiiator i yes iiigh El
Maximal waiting time GP-hospital o f 5 days in yes high E2
Diagru»tic prew s» o f m a x in i t iw e d ts HI yes hir-n revised E3
Attention for psychosocial effects o f waiting New key recommedation (added in step 2) 
times
E4
Stiroulate aad  support « I f  «saasjscineBt i^v v  ks'v ïecRttunedafion (orfd&d ia  -.-.irri 2) 1.0
Abbreviations; I, systcmatic revi~w/RCTs; II, RC" ‘; III, comparative studies; IV, crise studies and expert opinion. 
a Evidence level 
b see table 3
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S tep 3 Approval of the final sei
All experts received the results of the consensus meeting by e-mail for approval. One ex­
pert, who was not able to attend the consensus meeting, hesitated to approve the final set. 
This expert’s opinion was that high performance on all indicators is not feasible because the 
set is too extensive, and he feared legal and financial consequences as well. One expert 
wanted to leave the decision for approval to the Dutch Federation of Cancer Patients Or- 
ganizations (NFK) and there was one non-responder who already gave his consent at the 
consensus meeting. All other 11 experts approved the final set of quality indicators for 
patient-centered cancer care.
Table 3. Final set o f  quality indicators accepted after step 2
Domain _  _____  ________ ___ ___  _ _ ____  -______
A Commumctition
h  I . Tbc iKsitlicaix' provider should mcut tïic tbllowing criteria for good ooinimmiciiliou:
a. Makiiig use of opea-erided questions In u cunvcnatioo. wilh the paticnL
b. SumrnarSv.ini» and rvjjeating irrtpivttaiit: irifonristtïr>n. 
r,. Git Jjig Üsc itiob! urportsid  jnroïffistiua firsf.
ci. Adiiisiing rafonr'üSioii to ihc condilir-n iJtie jnoivtduai patiënt.
L «plaining mcdic-al ietTninoiogy w ifcepsAütrit 
f. Adlustiiig iiitbnïi.atiofi to the baguagc «fUio piKJajl <sï;;i wiier; ticcessary providing information 
in ihe «aiive language o f ibe patiënt.
A2. The Healthcare provider should guarantee the following precoriditions for a suitable conversation:
a. Providing a room with adequate privacy, with enough time for an accurate conversation.
b. Involving family and friends in the conversation, by inviting the patiënt to bring someone to ap- 
pointments.
A3. Cixnituinicaiivc skills o f all heahhearc providets should regularJy bc evalusted and fccd-bsut 
s h o u id g iv e n .
A4. The healthcare provider should guarantee the foliowing preconditions for an informed consent:
a. Giving verbal information about die probability of recovery.
b. Giving verbal information about the possible physical and psychosocial impact o f diagnosties and the 
treatment on the patiënt.
c. Asking the patiënt if  he/she received adequate verbal and writtcn information.
d. Asking the patiënt if  he/she understood the provided information.
e. Asking the patiënt if  he/she is satistïed with the invo lvement in decision making.
f. Respecting the freedom of choice of the patiënt throughout the complete process o f care and treat­
ment and guarantee the autonomy of the patiënt.
A>. ll‘ns> iruistivs optwsns are availabte., 8w heahbeart pr«vid«r shuaid crophasteir thal then&twn» v'.-iJ! 
rsccivc optinia! paüiativs cate and that ibe hcabbcare prsvkfcr '.vil! not Jcave « k  psfisirt to ais/hsï fatc.
A6. Depending on the setting, the healthcare provider should hand over a list o f sources o f information 
to the patiënt that is adjusted to the condition of the patiënt. 
fi Phyxicat support
B I. The healthcare provider should make an inventory of complaints and problems that hinder the 
patiënt, search for causes, educate the patiënt on this subject and start medical or non-medical treatment 
with use of relevant medical disciplines.
C Psychosocial care
C l. The healthcare provider should gather information on the psychosocial and emotional health status 
of the patiënt on important moments in the process o f care and adequately refer to specialists, depend­
ing on the diagnosed problems.
02. The carc i'to ’-idi.'i sbou'd inrwTMiion on 1 ""Ci ernotrofta! h^afth
family asd frkntl* oftiic naders! acd adajuasdy reier spccinliscs, depending • n tb*; distgnoscd pnhr
lem s.
j0 After Care _ _____________ _ _________________ _____________ _________
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0 1 ■ I '<■- heakhcare  provider  should jgfnaraiito^ suiTicitfiil ïim e and aucntioii to ihe paiiem during ap- 
po im m em s  atler t l iepri jnary trealment has fïnished.
D2. The healtb.carfc provider shculd infoms the patiënt on the most important complaints that can occur 
aiter primary treatment has finished and that can be a sigr o f prcgrescion of the disease.
Q3 rhc  healthcarc provider should intorm the patient on possihilific-s !br rchabilitation in ihe region
üinï ji desircd. üsc patiënt »vjJl bu rcfetred tu these rehabilitatiswi ooeïojvs.
E  Organhafwn o f  patUnt-centered care
L i One hcaltheare provider shnxld be instaUeef «5 coordinator of care, to guaramce continu ity ol'csre 
for the palieni.
E2. 1 he maximal waifir.g tone betweer. the visit to the genera! praotit'oner and the first visit to the 
hospita! should be five working ciays.
E.-i- The niaxtmal duianon of the diagnostic process should be in accordanoe with the professional 
measiini-i 'or ihe spcfific t o e  üf tancr.r
E4. fhs neslthcare provider shonld pay attenUoii to "J’e psychosocial effects c f  waiting tunes on the 
paaent and adequateiy reply to this.
D epcndingon the tndividuul patient, the healthcarc provider should stimujale seif-roanagement and 
______ offer the proper information and support.
D i s c u s s i o n
Using an expert panel of patients and medical professionals, this study systematically de- 
veloped a set of 17 generic quality indicators for important domains of patient-centered 
cancer care: Communication, Physical support, Psychosocial care, After care and Organiza- 
tion of care. The entire set of 17 indicators describes key points of patient-centered cancer 
care and provides useful information for practitioners on processes and structural aspects of 
patient-centered cancer care that may need improvement.
To our knowledge, this is the first study to develop evidence-based patient-centered indica­
tors for cancer care using a combined panel of medical professionals as well as patients and 
their representatives. In a previous study, Ouwens et al. developed patient-centered quality 
indicators using a semi-structured method that incorporated 37 interviews with cancer pa­
tients. This resulted in the acceptance of all recommendations that were extracted from 
guidelines, because all 56 recommendations were perceived as being important measures of 
patient-centered cancer care by the patient panel. In our study, we lunneled to a compact set 
of indicators that provide key points of patient-centered cancer care and used a systemati­
cally method to do so, using a three step RAND modified Delphi-method with a combined 
panel of medical professionals and patients.
Research shows that the composition of the expert panel will be of influence on the out­
come of the development process. If only one discipline of healthcare professionals is in- 
cluded in the expert panel, there is a high level of agreement in ratings between panel 
members. ’ In our panel of patients and medical professionals, there was disagreement on 
a number of indicators. However, this stimulated interaction during the consensus meeting. 
Discussing reasons for disagreement led to a better understanding between our panel mem­
bers and led to a more complete set of indicators. For example, at first, there was disagree­
ment on indicators in the domain of communication. During the discussion, however, panel 
members came to agree on these indicators, which resulted in the creation of two quality 
indicators that consist of criteria for good communication and informed consent.
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Previous research has also indicated a difference in physicians’ and patients’ attitude when 
developing indicators; patients rate indicators based on their conception of optimal care, 
whereas physicians also keep practical aspects such as feasibility in mind.40 However, we 
noted that patients are very well capable of considering the practical aspects of quality 
indicators. During the consensus meeting patients participated actively in the discussion 
about measuring quality of care in practice. Also, one recommendation conceming coping 
strategies of the patiënt initially received a high score, but was rejected during the meeting 
because a patiënt argued that it is not feasible for a healthcare provider to always be aware 
of coping strategies, at all times during the treatment. This change would not have been 
made without the interaction between patients and healthcare providers. Moreover, we 
know that patients and their representatives often lack the professional knowledge that is 
needed to assess medical-technical quality issues in indicator development.41 However, we 
focused on patient-centeredness, with much emphasis on the needs of the patiënt. In this 
case the patiënt is the ultimate expert, and therefore of great value to the expert panel. In 
our study, patiënt involvement led to new indicators that would otherwise not have been 
included in the final set. The patients in our expert panel suggested additional indicators on 
attention to psychosocial effects of waiting times and stimulation of self-management of 
patients. It has also been demonstrated by other researchers that involving patients in the 
development of indicators on themes such as support, communication and follow-up is 
profitable and may result in additional indicators.37
Remarkable at the consensus meeting was that the subject of discussion was not so much 
the content of the indicators: both patients and medical professionals shared the same 
thoughts on what is important in patient-centered cancer care, namely delivering care that is 
adjusted to the patient’s needs. We noticed that the most important subject of discussion 
was how to measure quality indicators for patient-centered cancer care. For example, the 
panel agreed that in measuring the quality of patient-centered cancer care, the patients’ 
perspective is important. As Stewart et al.stated before: observations on patient-centered 
cancer care can only give a solid indication about the quality of patient-centered care when 
supported by the patient’s view.42 However, the panel also pointed out a certain subjectivity 
when patients were asked for their experiences with the delivery of patient-centered care. 
The panel discussed this and subsequently aimed to more consciously develop indicators 
that were concrete and were also measurable through audio or video analysis, as can be 
seen in other studies.43’44 This will provide care givers with direct starting points for im- 
provement, which may eventually lead to better outcome measures on patiënt level. 5’
The set of quality indicators in this study was developed to be generic, thus applicable to 
patients with all types of cancer. We noticed that structural attention to patient-centered 
cancer care in tumor specifïc guidelines is mostly lacking. However, this study shows that it 
is possible to develop generic recommendations for patient-centered cancer care. Therefore, 
efforts in describing patient-centered cancer care can be combined to develop a generic 
guideline on patient-centered cancer care. We believe that involving patients as well as care 
providers in the development of such a generic guideline will improve the patient- 
centeredness of cancer care.
It is the combination of evidenee and expert opinion that provides a set of well-founded 
quality indicators. Involving all stakeholders, that is both patients and health care profes­
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sionals involved in multidisciplinary care, this should support a broad acceptance and ap- 
preciation of the quality indicators, as can be seen in guideline developments.47
Despite our extensive review of literature, relevant key recommendations for patient- 
centered care may have been overlooked. However, the expert panel was encouraged to add 
key recommendations in the first rounds. Indeed, the panel proposed and finally accepted 
three new quality indicators on self-management of the patiënt, patiënt autonomy and on 
the psychosocial effects of waiting times on the patiënt. No other indicators were proposed, 
which is an indication of the completeness of the set.
After sending the final set of indicators to the expert panel, one of the panel members 
feared that high performance on all indicators in the set will not be feasible because of the 
extensiveness of the set and feared financial or legal consequences. However, proposing 
consequences on indicator performance to improve the quality of care is not something that 
we prefer, certainly not as a first step to improve the quality of care. This set of quality 
indicators has principally been developed as a tooi to assess and improve the quality of 
patient-centered care. For the improvement of the quality of care, we suggest that the model 
of Grol et al.is used. Firstly, the quality indicators should be operationalized and meas­
ured in practice, to assess the feasibility and the current situation with regard to patient- 
centered cancer care. Subsequently, stakeholders should be involved to assess the validity 
of the indicators and to assess how improvement should be facilitated in case improvement 
is needed. The latter is done by asking stakeholders for factors that hamper or aid best per­
formance of care. With this information, a tailored strategy to improve the quality of pa- 
tient-centered cancer care can be developed. We strongly suggest that, if any consequences 
are imposed, this should not be done until after these steps and that it will be done in col- 
laboration with medical professionals and patients.
Future research has to establish whether practicing patient-centered cancer care according 
to this set of quality indicators positively influences outcome measures. For example, im- 
proving the communication between care providers and patients may result in higher pa­
tiënt satisfaction and may enhance the quality of life of patients with cancer. For each indi­
cator in the set, the relation between adherence to the care that is described by the indicator 
and outcomes on patiënt level should be examined to assure further validity of the indica­
tors. In addition, after re-formulating and merging information, some quality indicators may 
need a re-evaluation of evidence. High-level scientifïc evidence was hardly available for the 
domains After care and Physical support and future research should focus on these im­
portant aspects of patient-centered cancer care.
In conclusion, using a systematic RAND modifïed Delphi method, we have created a gener­
ic set of 17 patient-centered quality indicators for cancer care. To our knowledge, this is the 
first time that patient-centered quality indicators for cancer care have been developed with 
an expert panel involving all relevant stakeholders. The availability of these systematically 
developed indicators creates possibilities for hospitals and other medical centers to assess 
and improve the quality of patient-centered cancer care.
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A b s t r a c t
Background: Patients with cancer are not always treated according to available guidelines. 
Factors such as age and comorbidities are frequently used as arguments for nonadherence. 
The aim of this study was to measure guideline adherence with guideline-based indicators 
for patients with non-Hodgkin's lymphoma (NHL) and to examine the need for improve- 
ment, considering relevant arguments.
Methods: A RAND-modified Delphi procedure was used to systematically develop NHL 
indicators. We evaluated their improvement potential (defïned as < 90% score) in a random 
sample of patients with NHL (N = 431) diagnosed in 2006-2007 in 22 hospitals in the 
Netherlands with data from medical records. Multilevel logistic regression analyses were 
used to estimate the relationship between indicator scores and factors: comorbidity index 
(combined with age), stage, patient's objections, and lymphoma type. Scores were adjusted 
for significant factors.
Results: Of the 20 indicators developed, 16 had improvement potential. Scores were lowest 
for assessment of International Prognostic Index, 21%; imaging of neck, thorax, and abdo­
men and bone marrow examination during the diagnostic process, 23%, and after chemo- 
therapy, 37%; adequate pathology reporting, 11%; and multidisciplinary discussion of pa­
tients, 21%. Scores for eight indicators were better for patients with a low Charlson index, 
stage III or IV disease, no objections to care, and aggressive lymphoma. After adjustments, 
adherence to all but one indicator (administration of the combination of rituximab and cy- 
clophosphamide-doxorubicin-vincristine-prednisone) remained < 90%.
Conclusions: In the Netherlands, almost all indicators for NHL needed improvement. This 
should be evaluated in other countries as well. International efforts should be undertaken to 
improve the quality of care of this ofiten curable malignancy.
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In tro d u ctio n
Malignant lymphomas constitute a heterogeneous group of more than 30 malignant diseases 
of the lymphoid tissue. One main disease is Hodgkin’s lymphoma; the others are classified 
as non-Hodgkin lymphomas (NHLs). Six subtypes of NHLs account for 80% of the preva- 
lence; namely, difïuse large B-cell lymphoma (30%), follicular lymphoma (22%), marginal 
zone cell lymphoma (8%), small lymphocytic lymphoma (7%), peripheral T-cell lymphoma 
(7%), and mantle cell lymphoma (6%).' With an estimated 65,980 new cases per year, NHL 
is the fifth most common malignant neoplasm in the United States.2
The NHLs can be subdivided into the so-called indolent and aggressive lymphomas on the 
basis of histological subtypes and clinical behavior. Survival is poor for patients with ag­
gressive NHL when treatment is suboptimal. Fortunately, appropriate treatment can result 
in complete remission for most patients with aggressive NHL. Only a few of the indolent 
NHLs are curable, but therapy commonly results in sustained control of the disease.3"5 The 
choice of therapy should therefore be adjusted to the behavior of the malignancy.
Diagnostic and treatment options for NHL have increased in the last decades, which makes 
it difficult for clinicians to stay up to date about the evidence-based options. National and 
international evidence-based guidelines for NHL have been developed to assist physicians 
and patients with decisions about appropriate healthcare.6'12 In general, the publication and 
dissemination of guidelines do not ensure good quality of care.13 The first step to improve 
the quality of care is to gain insight into current practice14 by means of quality indicators. 
Quality indicators are defïned as “measurable elements of practice performance for which 
there is evidenee or consensus that they can be used to assess and change the quality of care 
provided”.15 Studies in oncology, in which indicators were used to measure quality, show 
that guideline adherence was often suboptimal and that adherence varied between hospitals, 
indicating to room for improvement.16-21
Care providers often argue that factors such as poor health status and comorbidities may 
account for suboptimal guideline adherence. For example, when Standard chemotherapy is 
recommended, its administration ultimately depends on the patient’s physical and psycho- 
logical status. A previous study of non-small-cell lung cancer concludes that tumor stage, 
comorbidities, and age are important determinants of guideline adherence22 Therefore, 
arguments for nonadherence must be examined to assess whether and to what extent they 
influence indicator scores before any conclusions about adherence to guidelines can be 
drawn.
This may be the case for NHL as well, although no indicators have yet been developed. The 
aim of this study was to systematically develop a set of guideline-based indicators to meas­
ure important processes and structures in NHL guidelines that need improvement after 
assessment of arguments for nonadherence.
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Deveiopment of indicators for NHL
We used the systematic RAND-modified Delphi method23 to develop indicators for NHL. 
We briefly describe the procedure for developing indicators here; it has been described in 
detail elsewhere.16,24 We selected key recommendations from the available national and 
international evidence-based guidelines for NHL and worked them into a written question­
naire. Three domains covered the important areas of cancer care: Diagnosis and staging, 
Treatment and follow-up, and Organization and coordination o f  care. All key recommen­
dations were distributed over these domains, and each recommendation was associated with 
evidence as formulated in the guidelines.
A multidisciplinary, national panel of 14 experts, all specializing in the care of patients with 
NHL (two pathologists, four radiotherapists, and eight hematologists or intemists) rated the 
key recommendations in the questionnaire. The experts individually rated each recommen­
dation as an indicator for quality of care on a scale of 1 (inferior indicator) to 9 (excellent 
indicator). They also prioritized the five best recommendations in each domain. The experts 
were encouraged to modify and update recommendations as they thought necessary.
The questionnaire results were discussed in a face-to-face consensus meeting. Each panel 
member received a personalized feedback report with individuai and group results (median 
rating and prioritization) per recommendation at the start of this meeting, and the level of 
agreement between experts was presented. Agreement between the experts was defmed as 
all ratings for a recommendation being within the three-point range of the median rating 
(one or two outliers were allowed).25 For example when the median rating is 7 and all other 
ratings are among 6, 7 or 8 there is agreement. Disagreement was defmed as three or more 
ratings being within one of the two wider tertiles (for example 4 ratings among 1,2 or 3 and 
all other ratings among 7,8 or 9).26 In this feedback report, the recommendations were or- 
dered in groups of high, low, or uncertain potential for measuring quality of care in accord- 
ance with median ratings and prioritizations from the first round. At the consensus meeting, 
the high-potential recommendations were discussed for acceptance; and those with low 
potential, for rejection. In the case of uncertain potential, the necessity of revisions for 
acceptance was discussed.
After these two rounds, all panel members received the results of the previous rounds by e- 
mail for final approval. Subsequently, the research team (LW, RH, PO, and JR) operation- 
alized the recommendations into indicators (defming numerators and denominators) for 
measurement.
Measurement of indicators for NHL
Indicator performance was measured in an observational study in coordination with the 
Comprehensive Cancer Centers (CCCs) Limburg, North and East. The CCCs maintain a 
cancer registry in the Netherlands that is based on the coding systems of the World Health 
Organization (WHO) and the International Association of Cancer Registries, so that inter­
national comparisons of data are possible.
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In total, 19 regional and 3 university hospitals in the north, southeast, and east of the Neth- 
erlands participated in the study. 431 Patients who were diagnosed with NHL in 2006-7 
were randomly included in the study. On average 30 new NHL cases were diagnosed in 
each hospital in 2006. Per hospital, patients were listed according to day of birth and 18-20 
patients were registered list wise per hospital.
Data collection
Trained registration employees collected data from medical records using registration 
forms. The data were processed and verified by means of intelligent document software 
(Teleform) into databases. Standard registry data were used: date of birth, gender, date of 
incidence, morphology and stage. Additional data consisted of the date and type of diagnos- 
tic procedures (pathological tissue examination, imaging techniques, and blood counts), 
starting date, type of therapy, response to therapy, multidisciplinary consultation, and re- 
porting. Factors that are often used as arguments for nonadherence were also extracted from 
medical records: the number and type of comorbidities, performance status, Ann Arbor 
stage, any objections patients had to recommended care, and NHL type.
Analyses
To assess the reproducibility of the data collection, two registration employees inde- 
pendently registered 30 records from three hospitals in duplicate. The reproducibility of the 
indicator scores was calculated with intraclass correlation coeffïcients for consistency 
(ICCConsistency) and agreement (ICCagreement)- ICCconsistency is used when one is interested to see 
whether a consistent differentiation in indicator scores (ranking) is present between observ- 
ers, the ICCagreement also accounts for systematic differences between observers (thus not 
only ranking but also similarity of indicator scores).27 A score greater than 0.6 indicates 
reliable reproducibility.28
In d i cator scores
We calculated an indicator score as the percentage of patients who received care as recom­
mended in the guidelines. For indicators including several aggregated items, we calculated 
additional subpercentages for each. Scores were calculated for the entire population but also 
for a homogeneous group of patients with diffuse large B-cell lymphoma (DLBCL).
Improvement potential was defined as an indicator score <90%.29 Next to this, significant 
differences in guideline adherence between regions also indicated improvement potential. 
We hypothesized that the presence of significant differences in the quality of care between 
regions is a signal that improvement is possible and needed, at least for the lowest scoring 
region(s). We tested whether regional differences in indicator scores were present using 
univariate Chi-square tests. We used SPSS (16.0) for Chi-square tests; p <.05 (two-sided) 
was considered significant.
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Axsuments for nonadherenceo
We first studied the single relation between actual indicator scores and factors that are often 
used as arguments for nonadherence: comorbidities and age [Charlson index: <median 
versus >median (weighted index combined with age30)], performance status (0—1 versus 2— 
431), Ann Arbor stage (stage I or II versus stage III or IV) patiënt preferences (no objections 
versus objections to recommended care) and type of lymphoma (aggressive versus indolent) 
using univariate analyses (chi-square tests). Factors that had a significant relation with 
indicator scores were tested in multivariate multilevel logistic regression analysis.
A multilevel model was used to account for the nested structure of our data with individual 
patients (level 1) nested within hospitals (level 2). Regions were added to the model as 
covariates. Odds ratios with calculation of 95% confidence interval described the associa- 
tion between indicator scores and factors. Patients were excluded from the analyses in case 
data were missing on indicators or factors and missingness was ignorable. The latter was 
defined as when missing data was low (<5%) or when data was missing completely at ran- 
dom (for this, the association of missing data with observed data on gender, age, lymphoma 
type, comorbidity index, patiënt preferences and Ann Arbor stage was checked with 
univariate two-sided Chi-square tests). We used Mplus (version 5.21) for multilevel anal­
yses. Mplus used maximum-likelihood parameter estimates with Standard errors that were 
robust to non-normality and non-independence of observations. The Standard errors were 
computed using a sandwich estimator.
To demonstrate to what extent these factors explain suboptimal adherence, we recalculated 
the indicator scores. Scores were recalculated by stratification: scores were calculated for 
the group of patients for whom arguments for nonadherence were present and for patients 
for whom no arguments were present. We expected that scores for patients without argu­
ments for nonadherence were above 90%. In case multiple factors were related to a single 
indicator, we combined the different factors into one categorical variable and stratified the 
scores for the different categories.
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Figi’re 1. Developir.ent o f quality indicators for non-Hodgkin’s iyorohoma.
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R esults
Table 1. Patiënt characteristics o f  the total study population and by cancer center region
Total (N=431) _ . . . .  J ^ g 'o n  (%_)_
Characteristic N % 1 2 3
CJassifk:;:tu>TV * Difilise largc B-e«H Syaphojfis 147 34 38 30 30
Follicular lymphoma Hl 59 i9 15 25
Srnall lymptiocytic lymplioma 4V n 12 14 7
Ivlantle cell lymphoma 32 7 i1 4 3
Marginol zone cell lymphoma 30 7 X 4 8
Pcriplicrai T-ccIl lymphoma S *> 1 '1 3
Other dassificaiion 84 20 i l 31 25
Type** Aggressive 215 50 57 42 45
Indolent 216 50 44 58 55
Agc 66 yetrs r. 14 : 66 ‘ 66’ 65 *
Gen der Male 241 56 60 56 49
Female 190 44 40 44 51
Ann Arbor Stage I or U (35 44 45 41 44
Staye 111 or IV 171 5 6 55 59 56
Unknown 2
Comorbidity index£ 0-4 223 52 49 56 54
>4 2G4 48 51 44 46
Unknown 4
Performance st«1us‘ 0 l 80 88 H4 95 90
>1 11 <6 5 10
Unknown 340
Patients’ preferences Objections 14 6 4 8 5
No objections 406 94 96 92 94
Unknown 1
Hospitals 22 ICO
Hospital size 0-250 beds 5 23 27 17 20
250-500 bsds 7 32 36 17 40
>500 beds 10 45 36 65 40
Ne. ofunivïrsity h;v,f 1 no 33 33
“ mean ± Standard deviation
¥Performance classificaticm according to WHO or Kamofsky 
£\Veighteü comorbidity index combined with age 
**Regional differences: p < 0.05
Deveiopment and measurement o f indicators for NH L
Figure 1 presents the results of the indicator deveiopment. In total, 99 recommendations for 
NHL were collected from six evidence-based NHL guidelines.6,7’9'n In the first round, the 
panel of 13 experts (one non-responder) rated 20 recommendations as potentially good 
quality indicators, 20 had uncertain potential and 57 had low potential. In total, 11 new 
recommendations were added by panel members in this round. The consensus meeting, in 
which seven experts from all the relevant disciplines were present, resulted in the ac­
ceptance of 33 recommendations. After presenting the results by e-mail, all experts accept­
ed the 33 key recommendations. The research team operationalized these key recommenda­
tions into indicators. Fifteen indicators were closely related and were merged into 7 indica­
tors as the consensus meeting recommended. Indicators with poor applicability were reject- 
ed (indicators for a low-prevalence group of patients; grade I or II, stage I or II follicular
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lymphoma). The final set consisted of 20 indicators (Tables 2-A). The reproducibility of the 
data collection was good: an ICCagreemcnt of 0.96 and an ICCconsis,ency of 0.96, as seen from 
the duplicate registration.
Study population
Table 1 presents the characteristics of 431 patients. Prevalence of subtypes of NHL resem­
bles the prevalence of the general population. There were no significant differences be­
tween the regions, except for lymphoma type (indolent or aggressive). On hospital charac­
teristics, regions were similar (in each region one university hospital was included).
Indicator scores
Diagnosis and staging In this domain, improvement potential was identified for five of 
the seven indicators (Table 2). The two lowest indicator scores were for the use of all rec- 
ommended staging techniques (23%) and the assessment of the International Prognostic 
Index for the aggressive type of NHL (21%). All recommended staging techniques included 
computed tomography (CT) scans of the neck, thorax, and abdomen, as well as bone mar- 
row biopsy and aspirate. The subpercentage for CT of the neck area was generally low 
compared to other subpercentages of this indicator: 35% (Table 2, 4A-E). Scores for the 
other three indicators with improvement potential in this domain varied between 80% and 
88%. For the homogeneous group of patients with DLBCL, scores were mostly similar, 
except for CT scanning: 93 and 91% for scanning of thorax and abdomen respectively 
compared to 76 and 76% for the total population. However, performance of all recom­
mended techniques was 27% for patients with DLCBL (table 2, 4A-E).Regarding variation 
in guideline adherence among regional care providers, there were significant differences in 
the performance of recommended staging techniques (highest: 32% and lowest: 13%, p  
.000).
Treatment and follow-up All six indicators showed potential for improvement. The lowest 
scores were for the CT scanning (or positron emission tomography (PET)) and bone mar- 
row examinations in stage IV cases for evaluating responses to chemotherapy (37% for 
total population and 46% for patients with DLBCL; Table 3). The other indicators in this 
domain with improvement potential covered the evaluation of a response to therapy (scores 
between 61% and 67% for the total population and for DLBCL) and the administration of 
the combination of rituximab and cyclophoshamide-doxorubicin-vincristin-prednisone (R- 
CHOP) chemotherapy to patients with DLBCL (76%). In addition, there were significant 
differences between regions in the reporting of response (highest score: 69% and lowest 
score: 49%, p  .021) and lesions before (possible) therapy (highest score: 74% and lowest 
score: 47% ,p  .010).
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Table 2. Indicator scores fo r  the total study population and the subgroup o f  patients with 
diffuse large B-cell lymphoma and regional differences fo r  the quality domain Diagnostics 
and staging. __________________________
% Indicator Nominator Missing Exciuded Regional differences
Indicator score data ____  (% indicator score)
N o  D escrin tio n  Total DLBCL Total DLBCL Total DLBCL Total DLBCI R 1 R 2  R 3 P*
i Diagnosis .! <w fcfetoiogii»! 
esam ioaiiaa <>n ai; excision or 
biopsy
g-j ïft 214 94 • 2‘ï '  ?>4
.....
V4 9:\
A. '! iwologleül cxami'satiun 97 97 307 146 1 1 123’ 284' 9S 94 99
B Hxcisioa or wide raciskm wopsy 82 76 214 103 94 44 123" 2841 77 94 82
2 Patients were staged according to 
Ann Arbor dassification
80 84 308 147 C 0 123“ 284° 82 77 78
3 Diagnosis (V>r NUL, based on 
morpliology and immune phenc- 
type (molccular elonality only 
suppienienutry)
99 99 283 135 25 12 123* 284c 99 97
A Morphologv 100 99 2 KV 136 19 I i 123* 284' 100 100 99
I? Immune phonotype «9 99 291 138 17 9 123" 284' 99 97 99
C Moleeular clomility only supplc- 100 vy 285 137 23 10 123* 284" 100 100 100
n'icrusry
4 Staging techniques should include 23 27 429 146 2 1 0 284' 32 13 13 .000
A
CT scans o f neck, thorax, and 
abdomen; bone marrow aspirate; 
and bone biopsy:
'Neck scan 35 47 431 147 0 0 0 284' 49 27 17 .000
B Thorax scan 76 93 431 147 0 0 0 284° 82 61 82 .000
c Abdomen scan 76 91 431 147 0 0 0 284' 80 62 82 .000
D Bone marrow aspirate 69 60 430 146 1 1 0 284° 74 55 76 .001
£ Eone marrow biopsy 83 83 429 146 2 1 0 284' 89 74 81 .003
5 h s ocsMDCSt o f ïntcrn ni>ona) F rug 2! 25 2 i.4 146 1 l 21</ ’ 284f TT 16 25
nostic Index for piitionls v. ith
atafessive NHL
6 Assessment o f lactate dehydrogen- 
ase vslue
92 97 429 146 2 1 0 284' 94 91 90
7 Exammation o f blood coants 88 90 430 !46 1 ! 0 284' S9 83 93
A Lcukucytc coiidi 99 99 430 146 1 1 0 284- 99 97 99
B l.enkotylc diJlercBtiiitinü 89 90 430 146 1 1 0 284' 90 85 93
C 'niron'irKüiyic cow u 99 99 430 146 1 1 0 2X4"' 100 97 99 .02
U HcnMtalobut i 00 99 430 i 46 1 £ 0 2S4; KSO i Wi
Abbreviatioiis: DLBCL, diffuse large B-cell lymphoma; CT, Computed tomography; NHL, non-Hodgkin lym­
phoma; R, region
* regional differences (P values only given when difference is significant according to two-sided Chi-square test)
“leukemia and Waldenström macroglobulinemia
bindolent lymphoma type
cnot diffuse 'large 3-cell lymphoma
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Table 3. Indicators scores fo r  the total study population and the subgroup o f  patients with 
diffuse large B-cell lymphoma and regional differences fo r  the quality domain Treatment 
andfollow-up
% ’udioator Nominator Missing Exciuöed Regional diïfcrences
Indlcatcr score___________ data (% indicator score)
N o . D escn p fao a____________________________ Tutal DL3CL Total DLBCL Total DLBCL Total DLBCL r !  R ?  R 3-------p * ~
8 Rcpwting al’ tos-ponsc to tfjm py 
iisiagittüts: con njRiissiurs 
(unconfirmed), partial remission.
61 ?.<) 2i;l ■ 'i 1 tj 338“ 69 49 60
stable disease. progression.
recurrence
9 Lssions documented in radioio- 63 66 252 '08 3 0 176” 323"'e 65 47 74
gy report
A Locations o f lesions on CT scans 
reperted fccfore (ncssible )thera-
98 100 253 108 2 0 176b 323be 99 100 93
py
3  Sizes o f lesicas on CT scans 
reported before (possible) thera-
74 7S 252 1C8 3 0 '7 6 b 323b'e 74 60 85
py
C Sizes o f lesions on CT scans 
reported ir. millimeters before
64 6ó 252 108 3 0 176b 323b' 65 47 76
Cpossible) therapy.
Hl Lesions docwieuwd in radiolo- 67 67 S9 46 9 2 333' 383“ 66 52 80
gy report 
A Locations o f lesions on CT scans
reptnled a tk r therapy
95 98 91 47 7 1 333‘ 3S3“ 95 ion ioo
B Sizes» oflesuins on CT scans 
repórted after tlicrnpy 
C Si/e.s nfleisions cm CT scans 
























11 Rc-evaiuation after chemcthera- 
py with CT scans (or PET); bone
37 46 195 103 35 14 2011 314de 42 23 38
marrow aspirats; and bone 
biopsy (in stsgs IV cases)
A Patients reoeived CT scan before 
chemotherapy
SO 99 230 115 0 2 201d 3144e 94 78 39
B Patients received CT scan or 70 79 205 106 25 11 201d 314ie 74 60 70
positron emission tomography 
after chemotherapy
C Bone marrow was re-evaluated 
by performing bone marrow
54 62 224 112 6 5 201d 314de 60 40 53
aspirats after chemotherapy (ia 
stage IV cases)
D Bone marrow was re-evaluated 
by bone biopsy afcer chemother­
61 75 223 114 7 3 20 Id 314d,i 65 51 51
apy (in stage IV cases)
1 2 PatitWts o, ivji d rïii,-;o Urge ü-e.s'1
Jympiwrea -csivtvl uteiw& cr- 
#py w öi ritu\«Rfib-ClfOP
76 146 1 2 $4' 77 74 76
13 Dosï o f rituximab ■ CHOP was 
not reduced or reason for reduc-






Abbrcviadons: DLBCL, diffuse large B-cell lymphoma; CT, Computed tomography; PET, positron emission 
tomography; CtiOP, cyciophosharride-doxorubiciii-vincristia-prednisone; R, region
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* regional differences (P values only given when difference is significant according to two-sided Chi-square test) 
“patients not treated 
bno lesions or CT scans
‘patients not treated or; no lesions or CT scans after treatment 
“patients not treated with chemotherapy 
‘not diffuse large B-cell lymphoma
W  diffuse large B-cell lymphoma and not treated with rituximab-CHOP
Organization and coordination o f  care Five of the seven indicators showed improve­
ment potential (Table 4). The two lowest scores were for the registration of five items as 
recommended in the pathology report (11% for total population and 12% for patients with 
DLBCL) and the discussion of cases in multidisciplinary consultation (21% for total popu­
lation and 26% for DLBCL). Other indicators with improvement potential in this domain 
were the recommended diagnostic period of three weeks (45% for total population and 50% 
for DLCBL) and the recommended interval of two weeks from the diagnostic period to the 
start of treatment (55% and 63% for total population and DLBCL respectively). There were 
significant regional differences in the integrated reporting of pathology results (best score. 
97% and poorest score: 62%; p  .000) and multidisciplinary consultation (highest score: 
30% and lowest score: 18%; p  .027).
Table 4. Indicator scores fo r  the total study population and the subgroup o f  patients with 
diffuse large B-cell lymphoma and regional differences fo r  the quality domain Organiza­





Excluded Regional differences 
(% indicator score)
No. Description Total DLBCL Total DLBCL Total DLBCL Total DLBCL R1 R2 R3 P*
14 Sïïü-uing and rw eiving ofunüxw ) 
bJcfisy mstettai
94 H i24 51 1*4 :.!•
123-284- 94 91 96
15 Integrated reporting o f  pathology 
techniques
88 88 286 136 22 11 123“284c 97 62 93 .000
16 r'Kthoiogy report. AU five iicnib 
ceportirtt !A-E)
! i i :ï 280 134 28 13 123’ 28V 12 18
93
5
A- Orijrin o f  l i s s u e  d o e u m s M e d 91 92 287 136 21 :• 123“284' 92 88
B '1 i s s u e  c i i a ia c t e r i s t i c s  d o e u -  
mented
S-7 63 288 137 20 10 123J2.S*4'- 45 82 58 .000
C liiopsv method dociimeiHed 7{> 76 308 147 0 0 123-2N41 81) 7!
D Rcccipt of' n ia te r ia l  docu­
ment cd
41 35 286 137 22 10 123*284' 33 60 38 001
E NJiiied w helher tissue was 
frozen
27 23 286 : 37 22 10 I23'''284‘ 30 30 16
17 Patients discussed in multidisci­
plinary consultations
21 26 428 147 3 0 0 284° 18 30 18 .027
18 RcsuEts o f  paiboiogy fcnc.wn 
hefore Uie start c f  ifsaimen.t
93 94 267 120 2ft 9 1 38 302' 92 93 93
19 Diagnostic period o f  3 weeks 
after the first visit to the hospital
45 50 420 144 11 3 0 284° 43 47 47
20 S u ü i  o f  t!i«apy  v- : i h i t  2  v. e e k t  
a ik r  tbc d i a g n o s t ic  p e r io d
55 63 267 120 26 9 13Sb3Ü2“ 61 44 56
Abbreviations: DLBCL, diffuse large B-cell lymphoma; R, region
* regional differences (P values only given when difference is significant according to two-sided Chi-square test) 
a leukemia and Waldenström macroglobulinemia 
b leukemia and Waldenström macroglobulinemia or not treated 
c not diffuse large B-cell lymphoma 
d not diffuse large B-cell lymphoma or not treated
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Ai-guments for nonadherence
Multilevel logistic regression analyses (Table 5) showed that four factors (comorbidity 
index, Ann Arbor stage, patient preferences, and type of lymphoma) influenced the scores 
of eight indicators from all three domains. The factor “performance status” was excluded 
from analysis because it was missing for 340 of the 431 patients in the study population. 
Missing data on other factors and indicators performance was <5% except for indicators 11 
and 12. However, for these indicators, data were missing completely at random. A low 
Charlson index (0—4 (median is 4)), Ann Arbor stage III or IV, no objections to recom- 
mended care, and aggressive type o f lymphoma were associated with higher indicator 
scores. The type of lymphoma influenced scores most frequently. After recalculation, the 
stratified scores of indicators with improvement potential did not exceed 90% with one 
exception. A group of patients, namely, DLBCL patients with a comorbidity index of 0-4 
(i.e., young without comorbidities), who did not object to recommended care, received R- 
CHOP in 91% (Table 5). Before recalculation, this was 76% for all DLBCL patients (Table
Table 5. Factors that influence scores o f  eight indicators in multilevel analyses
__Indicator____________ Factors o f influence__________ No. OR [95% CI1 Ir.d. score (%V
Diagnoxu ant! stciging
2 0.04 Staging according to 
Ann Arbor classifica- 
tion
4 0,17 Imaging (CT scans)
and bonc examina-
ii.au
5 0.11 Assessment o f Inter­
national prognostic 
inucv















index > 4 
missing 




Tum or stage 
Ann Arbor stage III or IV 




imaging and bone 
examination
Rituximab-CHOF 
for diffuse lsrge B- 
celi lymphoma





i? atieats’ preferences 
ïrdex 0-4 and no objections 
Index 0-4 and objections 
Index > 4 and r.c objections 
















0 22 [0.08-0.64] 50
Rel' 30
0.47 [0.32-0.69) 15







0.34 [O.i 5-0.76] 21
67 Ref 9i
3 0.20 [0.02-2.22] 67
68 0.20 [0.06-0.65] 68 
8 0.03 [0.00-0.29] 25
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No. ICC Indicator____________ Factors of influence__________Na. OR [95% Cl] ind. score (%)__
O rganization  a n d  coordination  o f  ctirc
Type of lymphoma 
Tumor stage
19 0.01 Patients were diay- Agiittósive wid stage III or IV 110 Riet' '■>
nosed within 3 Aggresstve. and stage 1 or 11 90 Ö.44 [0.21-0.93 J 4!
weeks Indolent and stage ïll or IV 56 0.41 10.22 (I.75J 3R
Indolent mid stage I. or 11 45 ö .!i {U.04-Ü JO] IS
___________ ______ ________ ims :in.;_______________ ?________ _ _________________
£Weighted comorbidity index combined with age, ♦missing completely at randem, ¥Stratified score 
ICC, intra-hospital correlation coëfficiënt; CHOP, cyclophosharaide-doxombicin-vincristin-prwtaisone;
Cl, confidence interval; CT, computed tomography; OR, odds ratio; Ind., indicator 
Only factors are presented that have a statistically significant influence on indicator scores
DlSCUSSION
To our knowledge, this is the first study that has systematically developed and measured 
NHL guideline-based indicators covering important processes and structures for the do­
mains Diagnosis and staging, Treatment andfollow-up and the Organization and coordina­
tion o f  care. Improvement potential was found for 16 of the 20 indicators: for diagnostic 
techniques, treatment evaluation, reporting of medical information, time management and 
multidisciplinary care. This was observed for the total study population but also in the sub- 
group analyses for DLBCL patients. Improvement potential was not only identifïed because 
of low indicator scores, but also because of significant variations between care providers.
Although care providers argued that guideline adherence is suboptimal because of patient- 
and tumor-related factors, this study shows that taking into account such factors does not 
the change conclusions on the need for improvement. Indeed, the performance of eight 
indicators was better for young patients with few comorbidities (Charlson index 0-4), Ann 
Arbor stage III or IV, aggressive lymphoma type, and for patients who did not object to any 
recommended care. However, improvement potential remained after recalculation for all 
indicators, except for the administration of R-CHOP. The indicators in this study are there- 
fore useful for gaining insight into current practice for implementing guidelines and im- 
proving the quality of care. If the indicators are to be used to compare the quality of care 
between hospitals, adjustments on the indicator scores might be needed, depending on the 
extent of differences between hospital populations.
Previous observational studies on patients with follicular lymphoma and elderly patients 
with NHL from the United States indicated that patients who were eligible for treatment, 
based on clinical guidelines, were not always receiving it.32’33 Moreover, variations in the 
use of chemotherapy by patiënt and tumor characteristics and geographic areas were also 
demonstrated.32 These studies in the United States and our study in the Netherlands give the 
first implications that international efforts should be taken to improve the care for this often 
curable disease. Innovative in our study is that we measured indicators for the entire care 
process and the organization of care. However, more research is needed in other countries 
as well for further confirmation.
Similarly to our study, studies of prostate, pancreas, lung, and head-and-neck cancer show 
that indicator scores reveal improvement potential for most indicators.16 Our results
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showed the lowest scores of all these studies, which underlines the need for improving 
NHL care. Cheng et al. show the clinical relevance of guideline adherence in a study of the 
relation between adherence and survival.21 They show that better adherence to guidelines is 
related to better overall survival and progression-free survival for patients with breast can­
cer.
What was remarkable in this study, was that standardized prognostic information such as a 
performance status or International Prognostic Index was missing in most medical records. 
Other studies have emphasized the need for a more complete registration of medical infor­
mation as well.32,33 We feel that both information/ documentation management and perfor­
mance of adequate care processes are important for the quality of care and that both may 
impact outcome.
In this study, indicator scores lower than 90% were associated with the processes and struc- 
tures that need improvement. This cut-off is rather arbitrary, and, from a clinical viewpoint, 
any score lower than 100% may address the need for intemal quality improvement. As a 
second indication of improvement potential, we therefore examined differences in guideline 
adherence between regions as well.
Although we randomly selected patients per hospital, we noted that in one region signifi- 
cantly more patients with aggressive lymphoma were included. A minority of hospitals in 
this region were not included in the study. One could suggest that this has led to a selection 
of hospitals treating mainly patients with aggressive lymphomas and that this could bias the 
regional differences we found for indicators because some scores are influenced by histo- 
logical subtype. However, in our study, only one indicator that was influenced by subtype 
had regional differences: CT scanning during the diagnostic process. Performance for this 
indicator was very poor (23%), and improvement is needed in all three regions, regardless 
of population differences.
Our guideline-based indicators form important steps for the continuation of care, and inad- 
equacy may affect the entire NHL care process. Hence, suboptimal adherence to guidelines 
may lead to different outcomes for patients. In future research, the relation between guide- 
line-based indicators and survival of NHL patients should be examined to fïirther clarify the 
importance of guideline adherence.
Furthermore, a tailored strategy is necessary to improve the quality of care for NHL pa­
tients in the future. The next step is to identify barriers and facilitators that hamper or aid 
guideline adherence. For example, stakeholders in the Netherlands may suggest that referral 
of patients to high volume hospitals specialized on NHL care may improve the quality of 
care. The results of this study can be used as a reference to develop and implement tailor- 
made programs that improve the quality of NHL care.34
In conclusion, 20 indicators were developed and measured in this study, which shows that 
most processes and structures for NHL need improvement. Factors such as comorbidities or 
age, but mainly the histological subtypes of lymphoma, influence indicator scores and are 
therefore arguments for nonadherence. However, after taking these factors into account, the 
indicators still had improvement potential, with one exception. Therefore, for all NHL 
patients, improvement in care is needed.
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A b s t r a c t
Background: From quality of care measures, incorrect conclusions may be drawn when 
they are not corrected for case mix. Outcome measures are usually corrected, process 
measures are typically not. This study examined the effect of case mix correction on 3 
process indicators on timely and multidisciplinary cancer care: the percentage of patients 1) 
diagnosed without delays, 2) treated without delays and 3) discussed in multidisciplinary 
consultation.
Methods: 2120 Patients with non-Hodgkin lymphoma (NHL), lung, breast or colorectal 
cancer from 27 Dutch hospitals were included in the study. Multivariate logistic regression 
analysis were used to identify the case mix factors predictive for indicator performance 
(gender, age, comorbidities, patiënt preferences (e.g. the patients’ wish not to receive part 
of the treatment or diagnostics), trial participation, disease stage or subtype) and to correct 
hospital scores. To assess the net effects of corrections, Intra Class Correlation Coefficients 
(ICC) examined the agreement between the observed and corrected hospital scores.
Results: For all malignancies, case mix factors predicted indicator performance, mostly the 
factors: stage, subtype (aggressive v indolent NHL, invasive breast cancer v DCIS, colon v 
rectum) and patiënt preferences. After correction, hospital indicator scores were highly 
similar to the observed scores (ICC’s>0.989).
Conclusions: Case mix corrections did not change conclusions on hospital variations in 
cancer care. Improvement is needed in hospitals with low indicator scores, especially 
compared to hospitals with the highest scores. The generic process indicators on timely and 
multidisciplinary cancer care can be used without case mix correction.
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INTRODUCTION
Providing care to patients with cancer is complex. Many medical disciplines are involved, 
diagnostic techniques or treatment options are constantly under development and patients 
should be provided with care according to their preferences and needs. Consequently, it is 
important to monitor the quality of care for cancer patients carefully, for example by using 
quality indicators. Quality indicators are defïned as ‘measurable elements of practice 
performance for which there is evidence or consensus that they can be used to assess the 
quality, and change the quality of care provided’.1 These indicators are often classifïed 
according to the framework of Donabedian in: outcome measures (e.g. mortality rates), 
process measures (reflecting on whether cancer patients are diagnosed and treated as 
recommended) and structure measures (related to the organizational aspects of cancer 
care).2
Measuring quality indicators may provide valuable information on outcomes, processes and 
structures that need improvement. Previous studies demonstrated variations in outcome and 
process measures between care providers for several malignancies, such as cancers of the 
lung, colon, breast and non-Hodgkin lymphoma. 3-16 These hospitals variations are often 
used in public reports to show room for improvement. In addition, hospitals are ranked 
accordingly to show which hospitals is best in caring for and curing patients.
There is a general agreement that outcome measures must be corrected for case mix before 
such reports on quality of care variations are published. The reason is that the variation in 
care outcomes can be caused by a variation in patiënt mix. Therefore, a correction for such 
a case mix is needed to avoid drawing incorrect conclusions on the quality of 
care. ’ ’ ’ ’15,16 Process indicators are typically not corrected.17 However, performances on 
processes may depend on case mix factors as well. For example, some cancer patients may 
be more difficult to treat or diagnose because of a high age, disease stage or comorbidities. 
In addition, a number of patients make the personal choice not to receive (part of) the 
diagnostic or treatment procedures. Indeed, research demonstrated that the performance on 
processes conceming the diagnosis and treatment of cancer patients does depend on patiënt 
and tumor related factors such as age, comorbidities and disease stage.3’7,10’12,15,18 Therefore, 
the question is whether conclusion on care variations can be drawn based on process 
indicators, when they are not corrected for case mix.
This study aimed to explore the need for case mix corrections by examining the effect of 
correction on 3 process indicators that are frequently used to measure and compare the 
quality of timely and multidisciplinary cancer care across hospitals. We included both 
patients with solid and nonsolid tumors in this study (patients with colorectal, non-small 
cell lung and breast cancer and patients with non-Hodgkin lymphomas).
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Design and study population
Process indicators on timely and multidisciplinary care were measured in a retrospective 
observational study including 27 hospitals of the north, east and south part of the 
Netherlands using data from the Comprehensive Cancer Centers (CCCs) (formally known 
as IKN, IKO, IKL and IKZ). Data were collected from the medical records of patients 
diagnosed in 2006-2007 with either non-small cell lung cancer (NSCLC), non-Hodgkin 
lymphoma (NHL), breast or colorectal cancer. For this study, next to Standard registry data, 
additional data were collected. For each hospital, around 40 patients each for NSCLC, 
breast or colorectal cancer were included in the study, and around 20 NHL patients. 
Patients were listed according to day of birth and data were collected list wise.
Data collection
Data were collected by trained registration employees from the CCCs or by a researcher 
(LW) who was trained by the IKO. Standard registry data were date of birth, gender, 
incidence date, morphology and disease stage according to registration employees (TNM 
classification, Ann Arbor for NHL). To calculate indicators on timely and multidisciplinary 
care, additional data were collected from the medical records on dates of first hospital visit, 
of final pathology diagnosis, of endoscopy (sigmoidoscopy or colonoscopy), of imaging 
techniques, of start of therapy (neo-adjuvant therapy, surgery, chemotherapy or 
radiotherapy) and of multidisciplinary consultation (before or after treatment). In addition, 
data were collected on the following case mix factors (patiënt and tumor related): disease 
stage as documented by the care provider, comorbidities, performance status, patiënt 
preferences, trial participation and on tumor subtype. After collection, the data (anonym) 
were processed and verifïed with intelligent document software (Teleform) into databases.
Quality indicators
In this study, 2 process indicators on timely care and on 1 process indicator on 
multidisciplinary care were measured. Indicators on timely care concemed the percentage 
of patients who received a diagnosis and treatment without a delay. The thresholds for 
delay are given in figure 1. These thresholds were recommended by multidisciplinary 
panels of clinical experts that independently developed indicators for the 4 malignancies 
using a RAND modifïed Delphi method. The procedure and results of the development 
procedures are described elsewhere.18-21 For NSCLC and NHL, the date of diagnosis was 
operationalized as the date of the last diagnostic procedure (last imaging technique or 
pathological examination performed), for breast cancer, as the date of pathological 
examination of breast tissue biopsy and for colorectal cancer, the date of colonoscopy or 
sigmoidoscopy. Start of treatment was the date of surgery, chemotherapy, radiotherapy or 
of neo-adjuvant therapy. The indicator on multidisciplinary care concemed the percentage 
of patients discussed in multidisciplinary consultation.
C a s e  m ix  a d ju s t m e n t  179
Indicator] Diagnosiswithout delajs
% of patients teceiving a diagnosis 








Breast cancer 7 (81%)
Colorectal cancer 28 (88%)
*or 35 in case a mediastinoscopy is performed
Indicator 2 Treatment without delays
% of patients receiving a treatment within 
the recommended munber of days.
Start of 
treatment




Breast cancer 28 (80%)
Colorectal cancer 28 (45%)
Observed overall indicator score 
Indicater 3 Multidisciplinary NSCLC 64%
consultation NHL 21%
*■4 of patienti discussed in Breast cancer 85%
multidisciplinaiy consultation. Colorectal cancer 62%
Figurs !. Definibons of and mdicator scores for 2 indicators on timely and 1 indicator on muitidisoipimary care 
for non-smal! ceil lung cancer (NSCLC), r.on-Hodgfcin lymphoma (NHL), breast and colorectal cancer.
Statistical anatysis 
Hospital variations
To show hospital variation in observed indicator scores, high and low plots were drawn. 
Observed indicator scores were the percentage of patients for whom the care, according to 
the data in the medical record, was provided as recommended in the indicator. Variations 
between hospitals in indicators scores were tested whether statistically significant nsing 
Chi-square tests.
Predictive models
Multivariate logistic regression analyses with calculation of Odd Ratio’s (ORs) were used 
to assess which case mix factors were predictive for the performance. A stepwise reverse 
approach (0.15 level of signifïcance for removal) was used to build predictive logistic 
regression models. Only case mix factors signifïcantly improving the prediction (P<0.05) of 
indicator performance were included in the final models. In addition, we tested the 
interaction between case mix factors. An interaction effect with a p-value<0.05 was 
considered significant. Case mix factors were dichotomized: gender (males v females), age 
(<median age v >median age), comorbidities (index according to Charlson22 0-1 v index>l), 
WHO performance status (0-1 v 2-4), patiënt preferences (objections v no objections), 
participation in a clinical trial (yes or no), disease stage (I-II v III-IV) and tumor subtype 
(aggressive v indolent lymphoma; Ductal Carcinoma In Situ (DCIS) v invasive breast 
cancer; or tumor located in the colon/ sigmoid v rectum). Disease stage was according to
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treating physician but was supplemented with the disease stage according to the registration 
employees of the CCCs in case of missings.
Case mix correction
The method to correct indicator scores for case mix was described before by others.23’24 We 
briefly describe the 3 steps here.
The first step to correct the process indicator scores for case mix is to assess an expected 
indicator score for each hospital. This is the indicator score that is expected in a hospital 
given the specific case mix of that hospital. This score was calculated by saving the 
predicted probability per patiënt after multivariate logistic regression analysis using the 
final predictive regression models. The mean predicted probability in that hospital is the 
expected hospital indicator score. Secondly, a hospital risk ratio is calculated by dividing 
the expected by the observed indicator score. Finally, corrected hospital indicator scores are 
obtained by multiplying the risk ratio of each hospital by the overall indicator score.
Expected indicator scores were tested whether they were significantly different between 
hospitals using Kruskal-Wallis tests. A scatterplot was drawn to visualize the relation 
between the observed and corrected hospital indicator scores. To assess the level of 
agreement between observed and corrected indicator scores, Intra class correlation 
coëfficiënt for agreement (ICCagreement) were calculated.
All statistical analyses were performed using SPSS for Windows (version 20.0 IBM) and a 
two-sided P-value of <.05 was considered significant.
R e s u l t s
Study popuiatioii
Table 1 presents the characteristics of all 2120 patients included in the study with NSCLC, 
NHL, breast or colorectal cancer from 27 different hospitals. Most patients were males and 
the mean age was 67 years (except breast cancer patients). Patients were included from an 
equal number of small, medium or large hospitals and at least 2 academic hospitals were 
included per malignancy.
Case mix factors
Most patients had a comorbidity index and a WHO performance status of 0-1. More 
NSCLC patients (16%) expressed objections to recommended care compared to NHL, 
breast or colorectal patients (<6% objected) and trial participation was highest for patients 
with breast cancer (8%). Most NSCLC and NHL patients were diagnosed with a disease 
stage III or IV, in contrast to breast and colorectal patients, who were mostly diagnosed 
with stage I or II.
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N % N % N % N %
Patiënt characteristics
Oen der
Men 286 CS 234 56 1 0 342 53
Women 149 34 185 44 603 100 307 47
Unknown 1 12
Age
Mcan i  SD 67±11 66±14 59+14 68±11
Comorbidilies
Index 0-1 236 55 281 66 455 77 376 59
Index >1 147 45 .i47 34 .135 23 260 41
Unkio'.vn 3 3 14 13
Performance status
0 1 163 82 89 99 06 100 99 89
>1 35 18 1 1 0 0 12. 11
Unlaiowu 238 341 5 i 8 538
Patiënt prefcrcrjces
Objcct ion 68 i6 24 6 28 5 ’}(? s
'Mo objeorion 369 «4 406 94 576 95 619 95
Unknown 1
Trial participaüoii
Yes 18 4 21 5 45 8 27 4




'l-II 94 23 134 44 42'; 7') 326 54
III-IV 315 77 177 56 116 21 2<S2 46




Rectum tumor 240 37
Colon tumor 409 63
DCIS 57 0
Invasive/ DCIS 547 91
Hospita! characteristics
Hospitals 1 i I0U 2 ioo 21 100 ? l 100
No. o f academis hospita's 2 18 3 14 0 10 3 14
Hospital si?c (No. ofbeds)
(1-250 -) 18 6 27 5 24 () 32
250-500 4 36 7 32 S 3M
>500 ï 45 q 4! S i' 4[............. ....... .................................. -•_______ V «-}
*; F vahse o f Chi Square test (tvvo-sided); * ?  value of ANOVA test (two-sided); -ï stage according to treating 
physician fsupplemented with information o f the cancer registiy). TNM dassification used or Ann Arbor 
dassification in case o f NHL
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Observed hospital variation
Significant differences in observed indicator scores between hospitals were identified for 
the 2 indicators conceming timely care for NSCLC, breast and colorectal cancer patients, 
but not for NHL (see figure 2). For all malignancies, there were significant differences 
between hospitals in the percentage of patients discussed in multidisciplinary consultation. 
Largest differences between hospitals were observed for the latter indicator, differences 
were between 76 and 85%. The percentage of patients receiving a treatment without a delay 
also differed largely between hospitals for breast and colorectal patients.
Predictive models
Table 2 shows the case mix factors predictive for the performance on 2 indicators on timely 
care and the indicator on multidisciplinary care. The factor performance status was 
excluded from the analysis because data were missing (not recorded in the medical records) 
for more than half of the patient populations.
The factors, disease stage, tumor subtype and patient preferences were most frequently 
predicting the performance on the 2 indicators on timely care, followed by comorbidities, 
age and gender. Trial participation had no significant influence.
NSCLC and colorectal patients with disease stage III or IV were more likely to receive a 
timely diagnosis or treatment compared to patients with stage I-II. An interaction effect 
was found for patients with colorectal cancer on the indicator on a timely diagnosis. The 
effect that patients with stage III-IV were more likely diagnosed without a delay compared 
to stage I-II patients was less present in patients with objections and mostly present in 
patients who expressed no objections. For NHL patients and breast cancer patients, 
inversely, patients with stage III-IV were less likely to receive an timely treatment than 
stage I-II patients. For NHL, this effect was mostly present in patients who expressed no 
objections to recommended care.
Conceming tumor subtype, NHL patients with an indolent lymphoma type v aggressive 
type were less likely to receive in time diagnosis (OR of 0.53) or treatment thereafter (OR
0.41). In addition, patients with colorectal cancer with a tumor located in the rectum v in the 
colon/ sigmoid were more likely to receive a timely diagnosis (OR 3.27) but less likely to 
receive timely therapy after diagnosis (OR 0.29). Breast cancer or colorectal patients 
without objections to recommended care were more likely to receive a timely treatment. 
NHL patients, in contrast, were more likely to receive a timely diagnosis when they did 
object to recommended care.
None of the case mix factors predicted the performance conceming multidisciplinary care 
for NSCLC or breast cancer patients (table 3). NHL patients were more likely discussed in 
multidisciplinary consultation when they had an aggressive lymphoma type and colorectal 
patients when they had a disease stage III-IV or a tumor located in the rectum.
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Figure 2. Kigh and low plois o f observcd and expected hospital indicator scores showing the variation in timely 
aiiü nuitidisciplmary care between hospitals. * dtfferences cre significant according to Chisquare tests (observed 
scores) or Kruskal Wallis test {expected scores)
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Table 2. Case mix factors that predict the performance on two indicators on timely care 
according to multivariate logistic regression analysis fo r  patients with NSCLC, NHL,
breast or colorectal cancer.
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Table 3. Case mix factors that predict the performance on indicators on timely and 
multidisciplinary care according to multivariate logistic regression analysis fo r  patients 
with NSCLC, NHL, breast or colorectal cancer.
Case mix factor OR 95% confirisnoe iaietvci P'-vaiue
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physician(si!pplerrented with irnormation c f ihe car.oer reglsiry) ÏHIVÏ c!assiricati«i usect or Ann Arbor
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Expected hospital variation
Figure 2 shows the hospital variation in expected indicator scores. There were no 
significant differences between hospitals in expected indicator scores conceming 
multidisciplinary care, for any of the malignancies. Hospitals differed signifïcantly in 
expected indicator scores on the percentage of NSCLC patients diagnosed without a delay 
(hospital scores ranged from 62 to 68%). In addition, expected indicator scores were 
signifïcantly different between hospitals conceming NSCLC and breast cancer patients 
treated without delays. Hospitals ranged from 24 to 31% on this indicator for NSCLC 
patients and from 77 to 83% for breast cancer patients.
Case mix correction
In figure 3 scatter plots are drawn for observed and corrected hospital scores for each of the 
indicators on timely care and multidisciplinary care. Agreement between the observed and 
corrected hospital indicator scores was high with ICCs between 0.989 and 0.999. There 
were no outliers of hospitals having a low observed and a high corrected indicator score or 
vice versa.















Figure 3. Scatterplots and Intra Class Correktion Coefficierts (ICC) and 95% confidence interval for the level of 
agreement between observed and corrected indicator scores (%) of patients 1) diagnosed without a delay, 2) 
treated without a delay and 3) discussed in multidisciplinary consultation.
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D i s c u s s i o n
This study explored the need for case mix correction by examining the effect of correction 
on 3 process indicators on timely and multidisciplinary care for around two thousand 
patients with NSCLC, NHL, breast or colorectal cancer. We showed that case mix factors, 
mostly disease stage, subtype (e.g. DCIS v invasive breast cancer or aggressive v indolent 
NHL) and patiënt preferences, did influence the performance on indicators. However, when 
subsequently correcting the hospital indicator scores for their patiënt case mix, it had no 
impact. Although we included different types of hospitals (academic versus non-academic) 
and hospitals of different sizes, we found no hospitals with substantially increased or 
decreased indicator scores after case mix correction for any of the indicators, for any of the 
malignancies.
There is an obvious explanation for why there was no effect of case mix correction on the 
indicators in this study. The expected performances on the 3 indicators in this study, which 
were assessed taking into account the specific case mix in each hospital, were not 
significantly varying across hospitals or when they were, the differences were small 
(around 7%). The fact that these expected scores are so comparable between hospitals 
shows that hospitals do not substantially vary in case mix, not in factors that are of 
influence to indicator performance.
To the best of our knowledge, this is the first study that explored the need for case mix 
correction on process indicators on timely and multidisciplinary cancer care by studying the 
effect of correction on hospital indicator scores. Sometimes, researcher do report on 
hospital variation on process indicators after corrections for case mix, for example on 
process indicators conceming re-resection rates after breast conserving surgery, 
administration of preoperative radiotherapy for rectal cancer or chemo radiation in lung 
cancer. ’ However, these studies do not show the net effect of these corrections and 
therefore it remains unclear whether there is a need to correct process indicators for cancer 
care for case mix when comparing hospitals. Similar to our results, hospital variations 
remained after case mix correction, which means that there is room for improvement in 
cancer care.
The effect of case mix corrections on process indicators were demonstrated for myocardial 
infarction.24 Mehta et al found that case mix correction on process indicators for this 
disease resulted in modest changes in ranking of hospitals of the United States: there was a 
general agreement between rankings before and after correction. However, for individuai 
hospitals, rankings could increase or decrease up to 200 places. In our study, a substantial 
increase or decrease was not observed in any of the hospitals. This indicates to larger 
differences in case mix across American hospitals included in the study of Mehta than we 
found in our study. In the United States, hospitals may be situated in areas where 
populations are more largely differing in social economic status and associated health than 
in the Netherlands. However, it may also be a result of having included patients with 
different disease in the studies. Therefore, this study should be repeated for other indicators 
conceming other diseases as well.
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In general, suboptimal indicator scores are often attributed to complex patients, for example 
patients with a higher disease stage. However, in this study we demonstrated that NSCLC 
and breast cancer patients with an advanced disease stage were more likely to receive a 
diagnosis without a delay than patients with a stage I or II. This was also found by others. 
We therefore suggest that assumptions on the negative effect of certain case mix factors on 
indicator performance should always be verified in observational studies.
From the patients point of view, waiting times for diagnosis and treatment are important 
and avoiding delays are appreciated.25 From a practical point of view, however, it may take 
more time to rule out any metastases to correctly classify a patiënt with stage I than to stage 
a patiënt whose metastases are immediately visible and diagnosed at the fïrst hospital visit. 
Therefore, it might be more transparent to calculate indicator scores on timely care 
separately for patients with advanced stages.
A strong point of our study is that the indicators that we used in this study are generic and 
frequently used for many cancer types. We performed case mix correction for four different 
malignancies, including both patients with solid tumor as well as lymphoma s to increase 
the chance that the results are applicable to other cancer types as well. These indicators are 
often used because they are easy to measure using electronically stored data. In this study, 
we showed that there is no need to correct for case mix, which will save the burden of 
extra, manual data collection on case mix factors.
There are some pitfalls of case mix corrections. Because of reasons of equity, one could 
question whether it is reasonable to correct indicators scores for factors such as gender. The 
Institute of Medicine states that care should not vary in quality because of personal 
characteristics, such as gender, geographic location and socioeconomic status. The aim of 
this study was to explore the effect of case mix correction and we showed that correcting 
process indicators, even when including gender, had no effect on indicators on timely and 
multidisciplinary care.
In conclusion, we found that variation in indicator scores on timely and multidisciplinary 
care is not resulting from variation in case mix. Therefore, the hospital with the lowest 
indicator scores should be able to improve their quality of care according to these 
indicators. These indicators can now be used to compare the quality of care without case 
mix corrections in Dutch hospitals.
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A b s t r a c t
Background: Because cancer care is multidisciplinary, the different care processes must be 
well-integrated to provide quality of care. In this study, we studied the level of integrated 
care for patients with non-metastasized colon cancer by measuring processes of diagnosis, 
staging, treatment and follow-up in relation to each other using a new composite method: 
pattem analysis. We used indicators that related to steps in the clinical pathway.
Methods: We used a RAND-modified Delphi method to develop indicators and applied 
them in a retrospective study including 295 patients in 22 hospitals. Eight indicators 
relating to crucial steps in the clinical pathway were included in the analysis. We used the 
SPSS “missing value analysis” to analyze the pattems and entered cases of non-adherence 
as “missing values”. The number of pattems and the content of the 10 most frequently 
occurring pattems were analyzed.
Results: We identifïed 43 pattems. The 10 most frequently occurring pattems related to 
80% of the population: all indicators were complete for 27% of the patients, one was 
missing for 33%, and two or more indicators were missing for 19%, usually conceming 
follow-up: liver imaging, the assessment of serum carcinoembryonic antigen and colon 
imaging (when incomplete at diagnosis). In six patients, liver imaging was missed before 
surgery and at follow-up.
Conclusion(s): The large number of pattems shows the diversity of care: only one-third 
received integrated care. Some pattems seem to indicate to a risk of overlooked 
recurrences/ metastases, especially when colon imaging or liver imaging was incomplete or 
missing respectively. This new method is of value to measure well-integrated quality of 
care. Improvement strategies should be developed and implemented to reduce the pattem 
variation and increase the number of colon cancer patients receiving integrated care.
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INTRODUCTION
Cancers of the colon are a major health problem in the developed countries. In Europe, it is 
estimated that 450 000 patients are newly diagnosed with colorectal cancer each year and 
that every year 230 000 patients die of this disease.1 Although the incidence and death rate 
have declined recently, colorectal cancer remains the fourth most frequently occurring 
malignancy and the fourth most frequent cause of cancer death.2 As for many oncologie 
diseases, the care for colon cancer is comprehensive and involves an increasing number of 
disciplines. The complexity of the care leads to inefficiency and suboptimal care.3'5 To 
ensure that the quality of care is good, integration of the care processes and good 
communication and coordination of the various medical disciplines are essential.
Some processes in integrated cancer care are needed for the appropriate performance of 
other crucial processes as well. For example, the lymph node examination after surgery is 
necessary for assessing the disease stage, and, in turn, the disease stage is necessary for 
deciding the appropriate treatment. In this example, not examining the lymph nodes may 
result in under-staging and under-treatment with possible serious consequences for the 
outcome.6'9
Quality indicators can be used to measure the quality of care. They are defmed as 
“measurable elements of practice performance for which there is evidence or consensus that 
they can be used to assess the quality, and change the quality of care provided”.10 
Individual process indicators give details about the single aspects of care, but the care for 
cancer patients is integrated and multidisciplinary. Composite measures are proposed to 
give a better sense of the quality of complex cancer care.11
This study uses a new method of combining multiple process indicators: pattem analysis. 
We aimed to show where improvement is needed in integrated care for patients with colon 
cancer by describing the pattems of non-adherence to multiple processes related to steps in 
the clinical pathway for patients with non-metastasized colon cancer from diagnosis to 
follow-up. Clinical pathways, also referred to as integrated care pathways, show the 
relationship between crucial steps in the care process and describe in detail the best 
diagnostic and treatment options according to the available scientific evidence or expert 
opinions, preferably described in evidence-based guidelines.12 To further illustrate the 
usefulness of the pattem analysis, we measured the levels of integrated care for patients 
with colon cancer with and without adequate lymph-node staging.
M e t h o d s
Development of the indicators and clinical pathway
First, we selected key recommendations from the Dutch colon cancer guideline and classed 
them in three domains: Diagnosis and staging, Treatment and follow-up, and Organization 
and coordination o f  care.13 Each key recommendation was associated with evidence as 
formulated in the guideline. We used these key recommendations as a basis on which to 
develop indicators and to design the clinical pathway for patients with colon cancer. We 
used the systematic RAND-modified Delphi method to develop the indicators.14 Our
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procedure is described in detail elsewhere, and we describe it briefly here. A 
multidisciplinary, national panel of 13 experts, who also developed the guidelines and who 
all specialized in the care of patients with colorectal cancer (two radiologists, one 
pathologist, three surgeons, two radiotherapists, three intemists/oncologists and two gastro- 
enterologists) rated and discussed these key recommendations in two rounds. After this, all 
panel members received the results of the previous rounds by e-mail for final approval. The 
research team (LW, RH, and PO together) operationalized the recommendations into 
indicators (defïning numerators and denominators).
The research team, an oncologist, and a surgeon placed the key recommendations that were 
crucial steps in the care of patients with non-metastatic cancer in a clinical pathway and put 
them in chronological order from Diagnosis and staging to Treatment and follow-up. A 
step was considered crucial if it was necessary for the appropriate performance of 
consecutive processes or played an important role in the improvement of patiënt outcome. 
After development, the indicators were checked to see if they related to steps on the 
pathway.
Measurement of the indicators 
Design, setting, and study population
Performances of indicators were measured in an observational study that took place in the 
north, east, and south parts of the Netherlands. The data were provided by the 
Comprehensive Cancer Centers (IKNL) (the 22 hospitals that participated in the study were 
19 regional hospitals and all 3 university hospitals). For this study, we collected the 
Standard registry data and additional data. Patients who were diagnosed with colon cancer 
in the period 2006-2007 according to the cancer registration were randomly included in the 
study. All patients were listed by day of birth, and 25-30 patients were registered list-wise 
per hospital.
Data collection
Trained registration employees and researcher LW collected all data from medical records. 
Standard registry data included the date of birth, sex, date of incidence, morphology, and 
tumor-node-metastasis (TNM) stage, as assessed by the registry employees. We collected 
additional data to calculate the indicator scores, namely, the date and type of diagnostic 
procedures (pathological tissue examination, imaging techniques, and endoscopy), the date 
and type of therapy (surgery, chemotherapy, and radiotherapy), multidisciplinary 
consultation and reporting of pathology examinations. In addition, we collected data about 
case mix factors (patiënt and tumor related): the disease stage as documented in the medical 
record by the care provider (TNM classification), comorbidities, performance status (WHO 
or Kamofsky), patiënt preferences (whether the patiënt wished not, or only partially, to be 
diagnosed or treated as recommended by the guideline), trial participation, double colon 
tumors and on emergency hospital admissions. The additional data were collected on paper 
by means of intelligent document software (Teleform) and were processed into databases: 
manual data entry is not necessary with this software.
In t e g r a t e d  c o l o n  c a n c f r  c a r ^: p a t t e r n  a n a l y s is  195
Statistica! analyses
Indicator calculations
In preparation for the calculation of indicators and the pattem analysis, all patients received 
1 of 4 labels per indicator: label 1 meant care with adherence to the indicator; label 2 meant 
not receiving care with adherence to the indicator; label 3 meant the indicator was not 
applicable to the patiënt, and label 4 meant that data for assessing the level of adherence 
were missing. Individuai indicator scores were subsequently calculated as the percentage of 
patients who received care as recommended: (patients with label 1)/ (patients with label 1 + 
patients with label 2) x 100%. If the indicators recommended several aspects of care, or 
included what, how, or when the care should be performed, then separate percentages were 
calculated for each aspect.
Pattem analysis
To describe the adherence to the different indicators on the clinical pathway, we used the 
SPSS “missing value analysis” to analyze the pattems. This analysis is normally used to 
check the most frequently occurring pattems of missing values in a study population. For 
example, in a sample of 100 patients with five variables measured, the analysis may 
identify three pattems: a pattem of patients (e.g., 50%) with missing data for all five study 
variables, a pattem in which values for two variables (variable 1 and 3) are missing for 30% 
of the patients, and a pattem of patients (20%) with values missing only for variable 5. In 
this study, we used the same type of analysis, but non-adherence labels (label 2) were coded 
as “missing values” in the analyses. The number of pattems and the content of the 10 most 
frequently occurring pattems were examined.
Case mix
We used Chi-square tests to test differences between the pattems in the case mix. Case mix 
factors were dichotomized: gender (men versus women), age (<median age versus >median 
age), comorbidities (index 0-1 versus index >1), WHO performance status (0-1 versus 2- 
4), patiënt preferences regarding recommended care (objections versus no objections), 
participation in a clinical trial (yes or no), disease stage (I—II versus III-IV), emergency 
case (yes or no), and double colon tumors (yes or no).
Lymph nodes
Because a high number of lymph node counts is associated with improved survival for 
patients with colon cancer,8 we examined the pattems of patients with and without a high 
number of lymph nodes examined. Four groups were distinguished (node positive (N+), 
<10 lymph nodes examined; N+, >10 lymph nodes; node negative (N0), <10 lymph nodes; 
and N0, >10 lymph nodes). We used univariate Chi-square tests to assess differences in 
pattems between the four groups. We considered a two-sided p<0.05 significant for all 
statistical analyses. We used IBM SPSS version 20.0 (SPSS, Chicago, 111.).
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Indicators and the clinical pathway
Table 1 presents the results of the indicator development. In total, we collected 42 
recommendations for colon cancer from the national evidence-based guideline, and we used 
them in a Rand-modified Delphi method (14 for Diagnosis and staging, 22 for Treatment 
and follow-up, and 6 for the Organization and coordination o f care).13 The indicator 
development resulted in the acceptance of 13 key recommendations. They were 
operationalized into 14 quality indicators, 12 of which were for patients with non-metastatic 
colon cancer (Table 1), and 2 were for patients with metastatic colon cancer. Eight 
indicators were related to steps in the clinical pathway (supplement figure 1).
Individuai indicator scores
Table 1 gives an overview of the adherence to the 12 quality indicators individually. 
Around 90% of the patients received care as recommended regarding “what” should be 
done in Diagnosis and staging', scores for Treatment and follow-up were between 42% and 
76%. When “when” or “how” the care should take place was taken into account, the scores 
were lower: between 43% and 73% for Diagnosis and staging and between 6 and 26% for 
Treatment and follow-up. Conceming the organization of care, 21% of the cases were 
discussed before surgery in a multidisciplinary consultation and 51%, after surgery. The 
pathology report included all the necessary items for at least 90% of the patients, except the 
gross description (78%).
Study population
Table 2 presents the characteristics of all 295 patients included in this study. Forty-nine 
percent of the patients were men, and the mean age was 70±11 years. Furthermore, 66% of 
the participants were diagnosed with stage I or II cancer, 85% had a WHO performance 
status of one or less, 46% had a co-morbidity index greater than one, and 11% were 
emergency patients. Most patients underwent a right hemicolectomy (40%), a sigmoid 
resection (32%), or a left hemicolectomy (10%).
Table 1. Adherence to individual quality indicators o f  the clinical pathway fo r  non- 
metastatic colon cancer
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Indicators 




IA l'lanned  o r  received Virtual co lo n o sco p y ... 90 263' 32“ 0
IB . ...withui 4 wiseks alter the fitst \ isit 10 the hoïpitaJ 73 257 ?'2~' 6
2 i f  colonoscopy Is complete, then the diagnosis should be büsed 
on rcproser.tat've bistoïogical materiai
90 HQ \92° 23
3A Livcr imaging 10 deteel metastases before surgicaj resection.... «y 295 0 0
3B .. ith C’T or MRI 43 295 0 0
4A Lymph node examination after surgeiy 98 284 9' 1
4 8  H sta Lus :s NO , then > 10 nodes exainined 
Domain: Treatment and follow-tip
54 196 99“ 0
5 Colon cancer slagc pllf tnxited vu'th adjuvant eljcmolherapy 
(FOLFOX or another regimen with capecitabine)
76 90 204' 1
6A Coior.osccpy after surgcry i f  preoperative coioncscopy was 
incomplete and no virtual imaging o f  the colon wa* 
perfbirned....
42 135 :i30‘ 3C
5B __within 3 montfrs 6 132 B 0 ‘ 33
7A Liver imaging for disease stage pi <pT2 NO), pil or pIII 49 275 2i>; 0
7B — \v ithin 3 -6  months after surgery 16 274 3 0 ;; !
8A Carcmoembryonic antigen assessment 70 293 0 2
8B — w ith in  3—6 montlis after surgeiy 
Doraata; Organizatiot» o f care
26 293 0 O
■■1 Cases disstisserj n:, mitkidiSnpjmaay consultiHion bcfore sar^erv 21 294 0 1
10 Cases disc’j.ssed iii multidiscipliiiary consultation after surgs.rv 51 2Ü9 0 6
11 The pathology report iv adetjtiaie and report^: 63 275 9 C li.
1A Tumourcell type 98 285 9 ‘
B Histological grade 91 286 9 C 0
1C Depth o f  invasion 96 285 9 ‘
D Margins 93 281 9 ‘ 5
E Number o f  exciscd lymph nodes 98 284 y ‘ "?
F Number o f  positive lymph nodes 98 .> i 9 “' 5
G Gross description 78 286 9 C (t
H Tumour size yi 286 9" 0
Ï2 Fatdents receive iadicated treatment wiüim 4 weeks after 52 26! 32" 2
Abbreviations: CT, computed tomogrsphy; MRI, magnetic resonance imagiiig: FOLFOX, foHnic'acid, iluorouraoil 
and oxahplatui
The total number o f patients w as 295 
“Emergency cases
Patients v/ho had an incomplete colonoscooy or had v>rtual colonoscopy 
'Patients wlio had stent or stoma oaly 
dFatierJs with (a) positive lymph node(s)
'Patients ’vitj, dtscass stage other than stage Iü
f?atients who had a complete visualization o f  &« colon (including emergency cases)
®Patients with stage ï (T l, NO) or stags W
*Coiofoscopy: complete virtusl imaging of the colon was retrievec for 1 ló o f 263 patients; 116 received 
incomplete imaging (99 bccaase o f obstmetions), 8 did not jeceivc any imaging, -.nd 23 paüenls rsosived 3 
ccicnoscopy, bat whether imaging was complete is on!aiov.T»
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*Stage according to treating physician (supplemented with stage according to registry employee) 
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Pattem analysis
We identified a total of 43 pattems of non-adherence by using the following eight 
indicators, indicators IA, 2, 3A, and 4A for Diagnosis and staging, indicator 5 for 
treatment, and indicators 6A, 7A, and 8A for follow-up. Table 3 shows the 10 most 
frequently occurring pattems of non-adherence with regard to these steps (see the 
supplement for an additional pattem analysis of “how” or “when” the care should take 
place). These 10 pattems accounted for almost 80% of the population. In the most 
frequently occurring pattem, the eight indicators were complete for 27% of the patients. 
One indicator was missing for most patients in the other nine pattems (for example, 15% of 
the patients had no liver re-imaging at follow-up, 10% had no colon re-imaging at follow- 
up when the image was incomplete at diagnosis, 4% had no assessment of semm 
carcinoembryonic antigen (CEA) levels at follow-up), and two or more steps (especially 
follow-up steps) had been omitted for 19% of the patients.
Table 3. The top ten o f  pattem s o f  non-adherence to indicators fo r  Diagnosis and staging 
and Treatment and folloyv-up
Paitems 1—ï 0
Other pattems 11—43 6/, ^
D&S, Diagnosis and staging; T. Treatment; FUF, Follow-up; CT, computed tomograpby; MRI, magnetic 
resonance mrngrng; FOLFOX, folinic acid, nmrouracil and oxaüplacin; CEA, carcinoembryonic antigen: NA  
non-adherence to indicator in the clinical pathway
Case mix
Univariate analysis showed that the pattems were not associated with the following case 
mix factors: gender, comorbidities, patients objecting to recommended care, double tumors, 
emergency cases or trial participation (Table 4). The patients in the pattems did 
significantly vary in age and stage. For example, in the pattem where no indicators were 
missed, 48% of the patients were older than 70 and 65% had stage I-II, compared to 67% 
and 50% respectively of the patients not in the top-10 pattems (pattems 11-43, table 4).
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Table 4. Frequency distribution o f  case mix factors per pattem  and significance o f  
differences in univariate analyses ____
>70 years Men Comorbidity 
index 0-1







j 48 55 55 65 » 4 1 1 6
2 40 47 63 72 5 12 14 0
75 47 38 96 3 3
A 50 54 44 64 14 4 14 0
(C 46 46 70 !> Li 23 0
6 39 46 46 92 8 8 0 0
7 100 50 33 100 0 u
0
oo 50 50 68 100 0 0 17 c
9 0 60 60 40 0
ƒ» 20 0
10 20 20 10C 20 0 0 0 0
1 1 -4 ? 67 4 4 59 50 9 2 : '■
2
P 0.001 0.934 0.230 <0,001 0.722 0.498 0.403 0.411
Lymph nodes
Because of the many pattems observed, we grouped pattems for this analysis based on the 
number of indicators missing (see fïgure 1). Two or more indicators were more frequently 
missing for patients with fewer thanlO lymph nodes examined than for those with 10 or 
more lymph nodes examined, and pattem 1 (all indicators completed) was identifïed less 
frequently (Figure 1, PO.OOl). This was true for patients with N+ or NO status. Pattem 1 
occurred most frequently for N+ patients withlO or more lymph nodes examined and least 
frequently for N+ patients with fewer than 10 nodes examined.
Figure 1 also shows that the four groups of patients differed in case mix for the proportion 
of emergency cases (highest for patients with N+ status), patients older than 70 years (as 
most patients with N0 status were), and patients with a comorbidity index of 0-1 (most 
patients with N+ status had an index of 0 or 1). These patiënt groups did not differ in other 
case mix factors.
INTEGR ATED COLON CANCER CARE: PATTEKN ANALYSiS ITO?
■ pattems 11 -43 (mostly 2  or more indicators were missing) 
" pattems 3,5,7,8 (2 or more indicators were missing)
pattems 2,4,6,9,10 (1 indicator was missing)




N + and < 10 nodes jN+ and >10 nodes examinedNO and <10 nodes examined N 0 and >  10 nodes
examinedexamined
(N=32) (N=57) (N=87) (N=96)
Case mix factors
Emergency cases 















Figure 1. The distdbution o f  oatteos for four groups o f  patients with z msdc n sg a tiv e  (N 0) or rode p o sjtiv e  (M+) 
sïan-.s and <10 or >••.; lymph isode* ssaiMnsd. The ftsqueocies src auly shown for case mix factors tfcst were 
significaaily di.ïerent b-stwecn groups in univariate analysis.
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D is c u s s io n
This study reflects the level of integrated care by describing the results of a pattem analysis 
using process indicators related to steps in the clinical pathway for patients with non- 
metastasized colon cancer. Only one-third of the patients with colon cancer received care as 
recommended without the omission of any of the eight steps in the clinical pathway. We 
identified more than 40 pattems of non-adherence for the remaining patients. This shows 
room for improvement of the quality of integrated care for patients with colon cancer.
In the 10 most frequently occurring pattems, the follow-up diagnostic steps were most 
frequently missed (liver re-imaging, assessment of CEA marker and colon imaging when 
incomplete at diagnosis). In six patients, liver imaging was missed both before surgery and 
after follow-up. These are important observations: the follow-up diagnostics can impact 
survival because of the curative options retained for colon carcinoma due to possible 
surgery for liver metastases and surveillance of polyps to prevent the recurrence of colon 
carcinoma.16 Liver metastases develop during the course of colorectal cancer in 50-70% of 
the patients.17 It is often argued that if the CEA level is not high at presentation, it is useless 
for monitoring recurrence. However, our current pattem analysis shows that missing 
indicators frequently represent a combination of CEA assessments and liver imaging. This 
suggests that the focus on follow-up is inadequate.
The patients with the top ten most frequently occurring pattems were usually younger and 
had less advanced disease stages than those in the other pathway pattems, but they did not 
differ in other case mix factors. This rules out the argument that care is not optimal for 
patients with co-morbidities because of less aggressive treatment and unnecessary follow- 
up.
Furthermore, because the number of lymph nodes examined is associated with survival of 
colon cancer patients,8 we scmtinized the level of integrated care for patients with and 
without a high count of lymph nodes examined. Our results are in line with the theory that 
adequate examination of the lymph nodes is a reflection of the overall quality of care. 
Usually, two or more steps of the clinical pathway (mostly liver imaging and CEA 
assessment at follow-up) were not taken for patients with a node-negative status based on 
fewer than 10 lymph nodes. In theory, these patients are at risk for being incorrectly staged 
as node-negative, for receiving under-treatment as a result and for having possible 
recurrences or metastases overlooked at follow-up. However, each pattem should be 
examined for its effectiveness and association with survival to determine whether certain 
steps are essential for patient outcomes.
Few studies combined the results on different indicators for cancer care mostly by 
calculating so called composite scores. 11,19-23 This composite score is the percentage of 
indicators for which adherence was observed. For example, when 3 out of 5 indicators are 
met for a patient, the composite score is 60%. Per hospital, a mean composite score can be 
calculated. However, from these composite measures it is not clear anymore which 
indicators are not met. This is the reason that Reilly et al. states that composite measures 
conceal relevant results that are needed for a correct clinical interpretation. The pattem
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analysis in this study contributes to the knowledge on how to measure the quality of 
integrated care for a number of reasons. The pattem analysis in this study does combine the 
multiple indicators, but still shows the adherence to individual indicators by showing the 
combination of indicator adherence. Consequently, no information is lost. This should 
reduce the risk of bias. In this study, we deliberately showed the large number of pattems 
to demonstrate the diversity in integrated care.
In future, studying the costs and outcome (e.g., survival) of patients in each pattem will 
provide more knowledge of how to achieve high value in cancer care.25,26 Furthermore, a 
first step to improve the quality of integrated care can be to identify the factors that hamper 
or aid well-integrated care. Medical professionals involved in colon cancer care can use the 
most frequently occurring pattems to discuss which factors would be most relevant. 
Subsequently, a tailored improvement strategy can be designed en implemented.
In conclusion, the pattem analysis in this study can be used to measure integrated care and 
has added value for the methods currently used for measuring the quality of care. The 
pattem analysis more clearly gives information about steps that need improvement in the 
care process.
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Supplement Table 1. The top ten patterns o f  non-adherence to indicators fo r Diagnosis and 
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D&S, Diagnosis and staging; T, Treatment; FUP, Follow-up; CT, computed tomography; M SI, magnetic 
resonance imaging; FOLFOX, folinic acid, fluorcuracil, and oxaliplatin; CEA, caroinoembryonic antigen; NA, 
nonadherence to indicator in the clinical pathway
Supplement Figure 1. Clinical pathway forpatientswith non-metastasized colon cancer
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A b s t r a c t
Background: The quality of care for patients with non-Hodgkin lymphoma (NHL) was 
proven suboptimal in the Netherlands, which may be related to worse survival according to 
scientific literature. The aim of this study was to examine whether guidelines adherence, 
measured with guideline-based quality indicators, is associated with survival of NHL 
patients.
Methods: Data were analyzed from 298 patients diagnosed with NHL in six hospitals in 
the Netherlands in 2000-2001 and for a homogeneous subgroup: 125 patients with diffuse 
large B-cell lymphoma (DLBCL). Twelve indicators were examined for: Diagnosis and 
staging (N=7), Treatment and follow-up (N=3) and the Organization of care (N=2). The 
association with five-year overall survival was examined for each indicator with Cox’s 
proportional hazard regression models, adjusted for survivor bias and confounders 
(International Prognostic index, Charlson comorbidity index, lymphoma type, presence of 
B-symptoms and received therapy).
Results: Guideline adherence was associated with improved survival for five indicators for 
all NHL patients, and for four for DLBCL, on Diagnosis and staging and Treatment and 
follow-up. Hazard ratio’s [95% confidence intervals] for these indicators were: 
performance of imaging of the neck, 0.57 [0.38-0.85] (all NHL patients) and 0.45 [0.23- 
0.90] (DLBCL); thorax, 0.51 [0.34-0.77] (all); abdomen, 0.59 [0.36-0.95] (all); 
performance of bone marrow biopsy, 0.56 [0.37-0.86] (all) and 0.43 [0.23-0.79] (DLBCL); 
administration of cyclophosphamide-doxorubicin-vincristin-prednisone-like chemotherapy 
0.59 [0.35-0.99] (DLBCL) and chemotherapy without a dose reduction, 0.52 [0.33-0.84] 
(all) and 0.46 [0.24-0.90] (DLBCL).
Conclusion: Care in adherence to guidelines, measured with guideline-based quality 
indicators, is associated with improved survival chances for NHL patients.
ASSOC'ATION BETWEEN PROCESS rNDICATORS AND SURVIVAL [ 1 1 i
INTRODUCTION
Malignant lymphomas comprise a heterogeneous group of more than 30 malignant diseases 
of lymphoid tissue. One main disease is Hodgkin’s lymphoma; the others are grouped as 
non-Hodgkin lymphoma’s (NHLs). Incidence and mortality for NHLs increased without a 
clear explanation between 1990-1999,1,2 but have stabilized more recently.3’4 Still, NHL is 
among the ten most lethal malignancies. In the United States, an estimated 19.500 of 
patients suffering from NHL died in 2009.5
The prognosis of patients depends on various factors. NHLs can be roughly subdivided into 
indolent and aggressive lymphomas on the basis of histological type and clinical behavior. 
Indolent lymphomas are usually not curable in advanced clinical stages, but have a 
relatively good prognosis. For patients with aggressive lymphomas, for example diffuse 
large-B cell lymphoma, a complete remission can be accomplished when diagnosed and 
treated appropriately.6 Patient-related factors, such as high age and bad performance status 
(according to Kamofsky for example), influence the prognosis.7’8 The International 
Prognostic Index (IPI), based on such factors, provides useful information on the prognosis 
for patients.7 Although IPI has been validated for patients with aggressive lymphoma, it has 
also a prognostic value for other lymphomas.9,10
Recently, a first study showed that not only patiënt- and tumor-related factors are related to 
survival, but also the quality of care provided to cancer patients: guideline adherence 
measured with indicators for breast cancer was related to improved overall and progression- 
free survival.11 From previous research it is known that NHL patients are not always treated 
as recommended by guidelines.12"14 For these patients, the consequences at patiënt outcome 
level are not yet known. The objective of this study was, to examine whether guideline 
adherence measured with guideline-based quality indicators is associated with improved 
fïve-year overall survival of NHL patients.
However, beside bias by confounding, studies with time-to-event outcomes are susceptible 
to survivor bias.1517 This bias relates to the fact that patients who die early in the care 
process have less opportunity to receive care in line with guideline recommendations. For 
example: chemotherapy may not be admmistered simply because a patiënt did not survive 
long enough to receive it. This bias can be controlled for by using a time-dependent 
variable in the analyses.15"18 Thus, we measured the association between guideline 
adherence and fïve-year overall survival, after adjustment for survivor bias and 
confounding factors.
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M e t h o d s
An observational population-based study was performed in the eastem part of the 
Netherlands; an area with five community hospitals and one university hospital. In the 
Netherlands, Comprehensive Cancer Centers maintain a basic national registration on 
cancer patients that is based on the coding system of the World Health Organization and the 
International Association of Cancer Registries, so that international comparisons of data are 
possible. For this study, we used the Standard registry data together with data that were 
extra collected on guideline adherence. All data were collected from medical records by 
trained registration employees of the Comprehensive Cancer Centre East.
Data collection was performed at two points in time. In 2002, data were retrospectively 
collected for patients who were diagnosed with NHL in 2000-2001 (N=298). In 2002, the 
aim of data collection was to develop a detailed database on NHL care to be used for future 
scientific research. At the second point in time, in 2007, information on (date of) death was 
obtained from the Dutch Municipal Personal Records Database (GBA), which contains the 
vital status of all inhabitants in the Netherlands.
Quality indicators
Guideline-based quality indicators for NHL conceming diagnosis, staging, treatment, 
follow-up and the organization of care were previously developed.14 The content of the 
database designed in 2002 enabled the examination of the relation between guideline 
adherence and survival for NHL patients for a part of this set: for seven indicators on 
Diagnosis and staging, three on Treatment and follow-up and two on the Organization of 
care.
Data collection
The details for data collection were as follows.
Patiënt- and disease-related characteristics
Standard registry data were: date of birth, gender, disease stage, lymphoma classification, 
number and localization of extra nodal localizations. Additional data were collected on B- 
symptoms, performance status, number and type of comorbidities and serum lactate 
dehydrogenase (LD) values. The performance status according to Kamofsky or ECOG 
(Eastem Cooperative Oncology Group) scale was collected from the medical record as 
assessed by the treating physician. In case it was not mentioned in the medical file, the 
registration staff extracted (if possible) the performance status based on descriptive 
information from the file.
Diagnosis and staging
Standard registry data were: date and localization of biopsy for the classification of NHL 
(in this article referred to as fïrst diagnosis). Additional data were collected on the
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completion and results of imaging techniques, of bone marrow examination (fïne needle 
aspiration cytology or histological examination of a biopsy) and the date and assessment of 
serum LD values.
Treatment andfollow-up
Standard registry data were type and start of treatment (chemotherapy, radiotherapy, 
surgery, transplantation). For chemotherapy, additional data were the initial treatment 
schedule and dose reduction and for treatment evaluation, the response to therapy according 
toCheson.
Organization o f  care
Standard registry data were collected on the date of first diagnosis (not the date of first 
hospital visit) and the date when the therapy was started. Additional data contained 
Information on the receipt of unfixed tissue to use for pathology examination.
Statistica! analysis
Survival follow-up was determined as the time between the date of first diagnosis until date 
of death or date of end of study (March l st 2007). Cox proportional hazard regression 
analyses were performed to evaluate the association between guideline adherence and fïve- 
year overall survival according to each indicator. Briefly, the steps of analysis for each 
indicator were: 1) crude survival analysis, 2) in case a significant association was observed, 
repetition of survival analysis with adjustment for survivor bias, 3) in case a significant 
association was observed after this adjustment, repetition of the analysis adjusted for both 
survivor bias and confounding factors. The details of these adjustments are described 
below. Statistical significance was defined as P value < .05 (two-sided). Analyses were 
performed for all NHL patients per individual indicator. As this is a heterogeneous 
population, we repeated survival analyses for the largest homogenous group: patients with 
diffuse large B-cell lymphoma (DLBCL).
Pattem  analysis
For indicators on Diagnosis and staging, also a pattem analysis was performed. A top ten of 
most frequently occurring adherence pattems was assessed and subsequently, these pattems 
were analyzed for their association with five year overall survival adjusted for survivor bias 
and confounding factors. Analyses were performed with SPSS 17.0.
Adjustments fo r  survivor bias and confounding factors
A time-dependent co-variable was introduced in the models to account for survivor bias. 
Another method to correct for survivor bias is to match on follow-up time, however this 
results in small sample sizes and is therefore more appropriate for larger study samples.18 
For indicators on Treatment and follow-up and the Organization of care, time-dependent 
proportional hazard models were constmcted using the dates of start of chemotherapy, of 
response evaluation and start of any treatment. However, for indicators on Diagnosis and 
staging, no dates of performances were available and adjusting for survivor bias using a 
statistical model was not possible.
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For the indicators on Diagnosis and staging, we adjusted for survivor bias by exclusion. We 
hypothesized that patients who die in the first weeks after the first diagnosis will have less 
chance to receive care in adherence to recommendations. Therefore, all patients who died 
within the first diagnosis period were excluded from the analyses. This period was set to 21 
days, as experts recommend 21 days to finish diagnostics.1 Sensitivity analyses were 
performed on this exclusion period (described below) using three different scenarios: 21 
days, 28 days and 42 days.
Adjustments for confounding were made using age, performance status, comorbidities, type 
of lymphoma, disease stage, number of extra nodal localizations, LD levels, B-symptoms 
and receipt of therapy. Comorbidities were indexed according to Charlson and 
dichotomized (0-1 versus >1 (median is 1)). Age, stage, performance status, extra nodal 
sites and serum LD were indexed to IPI into four risk groups: low, low-intermediate, high- 
intermediate and high. Other dichotomous variables were type of lymphoma (indolent or 
aggressive), presence of B-symptoms and therapy received (yes or no). Factors with a 
relevant contribution to the model were included. This was defïned as the introduction of a 
single factor having effected a more than 10% change in the hazard ratio for adherence. 
Multivariate Cox proportional hazard regression models were used to adjust for 
confounding.
Sensitivity analysis
We performed a sensitivity analysis on the exclusion period for diagnosis indicators. To 
adjust for survivor bias, we excluded patients within 21, 28 and 42 days after the first 
diagnosis. We adjusted for confounding factors and used the total adherence to indicators 
for diagnosis as a continuous variable in the survival analyses. The overall adherence rate 
for a patiënt was calculated as follows: [the number of indicators for which adherence was 
observed] divided by [the number of indicators for which adherence was supposed to be 
observed] *100%.
Treatment o f  missing data
We used multiple data imputation to treat missing data and imputed data in five cycles 
using the observed data.21 Missing data on confounding factors were imputed using 
observed data on patiënt and tumor-related factors: sex, age, performance status, 
comorbidities, type of lymphoma, disease stage, extra nodal localizations, LD levels, B- 
symptoms and receipt of therapy. Missing data on indicators were imputed using the same 
observed data on patiënt and tumor-related factors, but also using observed data on the 
performance of twelve indicators. For all indicators, data were imputed, except for three 
indicators for which we used time-dependent variables in the survival analysis.
R e s u l t s
Characteristics of the study populaticn
Table 1 presents the characteristics of the total study population of 298 patients and 125 
patients with DLBCL. Most patients (65%) were older than 60 years and 56% were male.
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Table 1. Baseline characteristics fo r  total NHL population and fo r  patients with diffuse 
large B-cell lymphoma
N %
No. o f  patients
Classificatio ii
D iffuse  large B -eell lym phorua 
Follicular lym phom a 
Sm all lym phocytie lyrnphnjma 
M antic «eil lym phom a 
MargumJ /tm e lym jflim m  
Peripheral T -c d l lym phom a 
O ther elussificarions
























Stage i o r il 
Stage IfJ or fV 
unknown 
No. o f  extra nodal localizations 
0-1 
>1










Abbreviations: No., number; LD, lactate dehydrcgenase 
cell lymphoma 
' missing completely at random 
3 more missings for females 
b more missings ;.f  PS>1 and LD>ULN 
 ̂more missings i f  PS>1 and for patients without B-symptoms 
 ̂more missings for patients who are treated. 
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Association between confounding factors and survival
The IPI was most predictive for survival (table 2): hazard ratio (HR) for patients from the 
high-risk group was 3.8 compared to the reference, patients with a low risk. Receipt of 
therapy was most predictive for DLBCL patients (HR 5.9 [3.2-11] [95% confidence 
interval]). Missing data was most profound for comorbidities (25% missing cases) and for 
the performance status (17%). Data imputation from 160 complete cases using data on 
patiënt- and tumor-related factors resulted in resembling frequency distributions and hazard 
ratio’s with one exception. For DLBCL, the IPI after data imputation more strongly 
predicted survival than before data imputation.
Table 2. Association between confounding factors and survival fo r  the total population and 
fo r  patients with diffuse large B-cell lymphoma.^ ___ ___  ______ ___ ____—
JLBCL
N 0/o HR 95 Cl P-
value















High- intemiediate 67 31 1.9 i_l.l-3.5j 0.034 20 21 2.4 11.0-5.5'j 0.049
High 16 3.8 [1 .S-7.9i 0 .000 8 9 3.0 [1.0-8.5J 0.036














Hiy:h inlcrmediaie <):■ 31 2.1 i 1.2-3.61 0.006 31 25 3.3 11.5-6.9J 0.002
High 26 9 .5.9 [2.1-7.03 0.000 ifl 8 3.6 [1,4-9.3] 0.007

























































5.9 [3.2-11] 0 .000














f II; .9-23! 0.090
Abbreviations: HR., hazard ratio; IPI, International Prognostic Index (based on age, 
number o f extra nodaï localizations and serum lactate dehydrogenase values), 95C1, 
DLBCL, diffuse large E-cell lymphoma, Ref, reference 
imputed a^er cjata jnlpUtation (pooled results)
95% confidence interval;
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Table 3. Crude association between 12 quality indicators and five-year overall survival 
according to Cox ’s proportional hazard regression models
Indicator N (missing) BR 95% Cl F-vaiue
score (%)
i Histological examination o f  Total 92 2 9 7 (1 ) Ref'
lymph node or e\tra uodai 0.75 [0.46-1.25J .27 i
site. DLBCL 94 125(0) Ref
0.60 [0.26-1,39] .234
2 Imaging ofncok are.i with. Total 30 28! (17) R ef
CT-scan or ultrasojnd for 0.4‘S [o.3i-ö.^s; .000
staging. DLBCL 25 T13 (7) R ef
3 Imaging o f  thorax with CT
0.32 Ï0.J7-0.631 .00*









f 0.32 (0.18-0.56) .000« 4 Imaging o f  abdomen ith Total 86 295 (2)
124(1)
R ef






5 Performance o f  a bone
0.22 10.11-0.42] .000
Total 56 278(20)* Ref0 marrovv aspirate for staging. 0.83 [0.60-1.13] .237
DLBCL 52 11?(8)* Ref
6 Performance o f  a bene
0.74 [0.47-1.18] .207
Total 81 294 (4) R ef
flSiU30W biopsy fcr staging. 0.37 [0.26-0.S3] .000
DLBCL 81 124(1) R ef
0.27 fO,16-Q.44j .003
7 Assessment of scrum lactatc Total 93 298 (0) Ref
dchydrogenasc value. 0.63 [0.36-1.09] 
[0.1 «-0,991
.099
DLBCL «5 125 (0) Ref
0.4(i M l
8 Chemotherapy Total 49 153 (20) R ef
a . admimsiration without e 049 [0.31-9.77] .002





*3 likc) for patients with
CS DLBCL DLBCL 68 124(1) Ref
1 0.34 10.21-0.54| .'300
II 10 Assessment o f  a response Total 32 205 (0) R ef
£ after radiotherapy cr 0.41 [0.27-0.6?,]
[0.08-0.271
.080
chemotherapy. DLBCL 86 104(0) R ef
9.J.S .000
! I S e ^ i n i ;  :M  iiijiïxeid matsris) Tx.-to] i j 1 -’n >S3! Ref




DLBCL 14 77(41.*) Kef
1.41 .379
'3 “ Admimstration or treatment Total 68 219 (18) Ref
v/ithi-i 5 weeks after fïrst 0.76 [0.50-1.13]
[0.53-1.671
.184
| QögüOSiS. DLBCL 71 103 (6) R sf
0.94 .838
Aborevialions: DLBCL, diffuse ’aige B-ce3 lymphoma; HR, hazard ratio: CJ, oosifidence interval; CHOP, 
oycIophosphamide- doxombicin-vincristin-prsdniEone; CT. computed. tomogrephy; R ef refarem» Hnonadherencs) 
' missing comjilctely at randoin
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Association between guideline adherence and survival
Missing data was imputed from 100 complete case using data on patiënt- and tumor-related 
factors and data on the performance of twelve indicators.
Diagnosis and staging
Recommended imaging of the neck was performed for 30% of the patients and performance 
of a bone marrow aspirate for 56%. Remaining indicators scored over 81%. This was 
similar for DLBCL. Crude survival analyses showed that guideline adherence was 
associated with improved survival according to four indicators: imaging of the neck, thorax 
and abdomen and performance of a bone marrow biopsy for the total study population and 
similar for patients with DLBCL. In addition, for the latter, the assessment of serum LD 
values was related to improved survival (0.40 [0.16-0.99]) (table 3).
For all NHL patients, survival analyses adjusted for both survivor bias and confounding 
(tables 4) showed that adherence was still related to improved survival for the same four 
indicators. For DLBCL, a significant association with survival was observed after 
adjustments according to two indicators: for imaging of neck, (0.45 [0.23-0.90]), and 
performance of bone marrow biopsy, (0.43 [0.23-0.79]) (figure 1 and 2).
Sensitivity analysis
In this sensitivity analysis using a continuous adherence rate for the indicators on Diagnosis 
and staging, we excluded patients who died within 21, 28 and 42 days. For 34 patients, data 
on indicator performance were missing (not MC AR) and data were imputed. Exclusion of 
patients who died within 21, 28 and 42 days led to samples of 279, 275 and 270 patients 
respectively. After adjustment for all confounding factors, per 1% increment of the 
adherence rate, hazard ratios were 0.984 [0.976-0.993] (P value 0.000), 0.985, [0.976-
0.994] (P value 0.001) and 0.987, [0.977-0.996] (P value 0.004).
Treatment andfollow-up
Tables 3, indicators 8-10, shows the results for three indicators for Treatment and follow-up 
for all NHL and for DLBCL patients. Scores were lowest for the administration of 
chemotherapy without a dose reduction (49% for the total population and 41% for 
DLBCL). For the other two indicators, scores were above 68%. Crude survival analyses 
showed an association with survival according to all three indicators for Treatment and 
follow-up. Missing data for the indicator on chemotherapy without a dose reduction was 
11% (data was imputed), but almost 0% for the other indicators.
Survival analyses after adjustment for survivor bias and confounding factors (table 4) 
demonstrated that two of these indicators regarding the administration of chemotherapy 
without a dose reduction (figure 3) and cyclophosphamide-doxorubicin-vincristin- 
prednisone (CHOP) or CHOP (-like) chemotherapy for DLBCL patients were associated 
with improved survival.
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Table 4. Corrected association between quality indicators and five-year overall survival 
according to Cox’s proportional hazard regression models fo r  the total NHL population 
and patients m th fo r  diffuse large B-cell lymphoma
Corrected foi-






2 imaging ofnecfc area Total 279 Ref A (PI
«.57 |0.38-0.85| •Uö-t
DLBCL ] 16 Ref A IPI. THER
0.45 |0.23-0.90| .024
3 Imaging o f  thorax Total 279 R ef A IPI,
0.51 [0.34-0.77] .002 TYPE
DLBCL i i6 R ef A THER
0.61 [0.29-1.28] .190
4 Imaging o f  abdomen Total 279 Ref A JP1. CO, TYPE
0.59 [0.36-0.951 .030
DLBCL i 16' Ref A IPI. THER
o r,7 i'0.24-i.S6| -445
6 BM biopsy Totai 279 R ef A CO
0.56 [0.37-0.86] .007
DLBCL 115 Ref A THER
0.43 [0.23-0.79] .00/
7 LD assessment DLBCL i -6 Ref A
0.40 0.15-1.11 ,080
Treatm ent and follow-up
8 No dose reduction Total 171 R ef A IFI
0.52 [0.33-0.84] .007
DLBCL 97 Ref A IFI
0.46 [9.24-0.901 .023
9 CHOP(-like) DLBCL 124 Ref B IPI
chtmotlierapy 0.59 [0.35-0.99| .046
i C Assess.-nem o f  a response Total 205 Ref B
1.05 [0.69-1.59] .815
DLBCL 104 R ef B _
0.91 0.51-1.67 .782
Abbreviations: DLBCL, diffuse large B-cell lymphoma;; HR, hazard ratio; Cl, confidence interval; CHOP, 
cyclophosphairide-doxonibicin-vincristin-prcdniscne; Ref, uference (=aoaadheMacs;; LD, lacïatè 
deiiydrogenase; BM, bone aiarrow; IFI, International Frognostic Index; TYFE, lymphoma type (aggressive or 
indolent) ; BSYMP, presence o f  B-symptoms; CO, comorbidities index; THER, therapy reoeived 
'* after data imputation from 100 complete casss (pooicd results)
A  adjustment for survivcr bias by exclusion o f  patients who died wfehin 21 days ?.fier the first diagnosis 
3  adjustment ior sup/ivor bias öy using a time-dependent cc variable
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Figure 1. Kaplan-Meier curves o f  survival for performance o f  imaging o f neck, adjusted for confounding and 
survivor bias for the total population and for patients with diffuse large B-cell lymphoma.
No. at risk
--------234 190 159 148 131 120 98 71 58 54
• '  41 22 20 16 18 12 17
Figure 2. Kaplan-Meier curves o f  survival for performance of performance c f  bone marrow biopüy, adjusted for 
confounding and survivor bias for the total population and for patients with diffuse large 3-cell lymphoma.
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' i'plaii-i.'ïoier cjtvwl: o smvival .-:or sdfnim^ti'aiion of ̂ i -jirioihc '~ry v/Dii-our a dose reduoiicn, acljusfcd 
for confounding and sarvivcr oiss for ihe total population and for patients with diiï’uso laige B-cel’ lymphoma.
Organization o f  care
Indicator scores were 11% for sending of unfïxed material and 68% for administration of 
treatment within five weeks for the total NHL population (table 3). Missing data for the 
indicator on unfïxed material were profound (30%). There was no association between 
adherence and survival according to the two indicators for the Organization of care.
Pattem  analysis
Pattem analysis of the performance on indicators in the domain Diagnosis and staging 
identified a top ten of most frequently occurring pattems, of which 6 accounted for 87% of 
the patients. These pattems could be categorized into: Full diagnostics I, Full diagnostics II, 
Basic diagnostics I and Basic diagnostics II (table 5). For most NHL patients (42%), all 
diagnostics were performed except for imaging of the neck area (but including bone 
marrow biopsy), followed by 25% of the NHL patients who received complete diagnostics 
(Full diagnostics II and I respectively). Analysis after adjustment for survivor bias and 
confounding factors (table 6) showed that survival was inferior (HR of 1.63 [1-03-2.59], P 
value of .036) for patients receiving complete diagnostics but no imaging of neck area 
compared to patients who did have all diagnostics. (see figure 4). In addition, patients who 
received other pattems of diagnostics also had inferior survival after five years compared to 
patients receiving complete diagnostics (see table 6).
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Table 5. Top ten o f  most frequently occurring patterns o f  adherence to seven indicator fo r  



















































Total DLCBL Total DLCBL
l 2 3 4 5 6 7 N N :- N N s % %s % % 5
Full diagnostics I 1 X X X X X X X 34 40 9 11 13 14 8
o
2 X X X X X X 27 32 12 13 11 11 11 10
subtutal ■51 72 21 24 24 25 19 19
Pull d ia g n o s t ic s  ([ 3 X X X X X X 69 S2 35 43 28 32 34
4 X X X X X 37 42 17 20 14 14 16 16
s u b tu ta l 106 124 51 63 41 42 48 50
Basic diagnostics I 5 X X X X X 12 13 5 6 5 4 5 5
6 X X X X 6 7 0 0 2 2 0 0
7 X X X X 7 8 6 6 3 3 6 5
subtutal 25 28 1) 12 10 9 11 10
Basic diagnostics U S X X ! ! 11 4 4 4 4 4 3
9 X X X 8 5 5 3 3 5 4
10 X 6 6 4 4 2 2 4 3
s u b tu ta l 25 25 13 13 9 9 13 10
Other patterns 41 50 12 13 u 17 4 10
Missing 40“ 0 16* 0
1 \\ i-|L 2 9 8 398 125 125 10®i 100 1GQ ÏQG
Abbreviations: DLBCL. diffuse large B-cell lymphoma; EM, bone marrow; LD, lactate dehydrogenase; 
x, indicator performed5 after data imputation from 100 complete cases (pooled results)
¥ 34 o f  40 missing pattems because o f  one missing indicator for total NKL population; for DLuBL: ! 5 o f  16
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Table 6. Corrected association between adherence pattem s andfive-year overall survival 
according to Cox’s proportional hazard regression models fo r  the total NHL population
Corrected
N J HR 95% Cl P value su n iv o r  Bias confoandcrs
Total (N=279)
ïul.1 tliagnoslics ! 72 H ef
Full diagnostics II i 23 1.63 11.03-2.59J .036 Lympliotrui ivpe
Basic d.iagnoslics 
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Bp.iic diagnostics II 8 3.34 [1.00-11.1] .049 therapy received
Cther pattems 12 3.02 [1.07-8.56] .037
AODrevuuar.s: Uj- oCL,, dittuse large d-celi lymphoma; HR, hazard ratio; Cl, confidence interval; § after data 
impi.tation fron  100 complete cases (pooied results) A adjisstinents for survivor bias by exelusion o f  patients who 
diad within 21 days after ihc ürst diagnosis
Time (years)
No. atrisk
Full I 72  60  55 52 48
FuUI 124 98 76 72 64
B asicI 28  16 15 12 7
Basic II 25 6 4  3 3
Other 49  34  31 26 23
Time (years)
—• I Full diagnostics I 
—'"“ ■Full diagnostics H 
Basic diagnostics I 
— Basic  diagnostics 
-1  “  O ther pattem s
Figure Kaplau-Mei®- curve o f  survival for categories Full diagnostics 1 and II and Basic Diagnostics I and II, 
adjusted fcr survivor bias and confounding factors for total NHL population (A) and diffuse large B-cell 
iymphcma (3 ).
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Discus s io n
In this study, we demonstrated that, after adjustments for survivor bias and confounding, 
guideline adherence is associated with improved five-year overall survival according to six 
guideline-based indicators for NHL care. These indicators not only concemed the treatment 
of patients, such as administration of chemotherapy without a dose reduction and CHOP- 
like chemotherapy for DLBCL patients, but also referred to recommended staging 
examinations: imaging of neck, thorax and abdomen and performance of a bone marrow 
biopsy. These indicators were recently identified with improvement potential. Other 
indicators on reporting of a response after therapy and the organization of care were not 
related to survival of NHL patients.
The results of this study are in agreement with the evidence from few studies for patients 
with NHL, breast, colon and endometrial cancer that have found an association between 
performing adequate staging or treatment and improved survival.11’22'25 For example, Bosly 
et al. concluded that optimal dose-intensity of chemotherapy is associated with improved 
survival for DLBCL patients with a HR similar to the one in this study.22 In the study of 
Bosly et al., reduced treatment intensity was commonly associated with hematologie 
toxicity. A study similar to this study was performed for breast cancer patients: guideline 
adherence according to ten indicators was associated with improved survival. However, 
Cheng et al did not adjust for survivor bias.11 Furthermore, adequate staging was found to 
be related to improved survival for patients with colon cancer and endometrial cancer.
There are several possible explanations for the findings in this study. One is that the 
patients, who do not receive care in adherence to indicators, are patients who are not likely 
to benefit from it because of multiple co-morbidities or other reasons. We adjusted, 
however, for main confounding factors (the International Prognostic Index, comorbidities, 
lymphoma type, presence of B-symptoms and therapy received) and still survival was 
inferior for patients who did not receive care in adherence to indicators. One might suggest 
that is difficult to control for all factors that play a role in the decision for performing 
certain diagnostic. For example, patients who do not have a bone marrow biopsy are 
possibly those patients for whom treatment is not recommendable for reasons that may not 
be obvious in retrospect. Other diagnostics may then also be skipped as a result. Our pattem 
analysis indeed showed that patients who did not have a bone marrow biopsy, were also 
those patients not having other diagnostics, amongst others imaging of neck, thorax or bone 
marrow aspirate. For these patients survival was highly inferior. It is however not so likely, 
that such reasons can explain why patients did not receive imaging of the neck area. In 
particular because these patients have had a bone marrow biopsy. This examination is 
painful for patients and it will be the first to be skipped when further treatment is pointless. 
It is more likely that palpation of the neck was used as an altemative for staging of the 
disease in patients not receiving imaging of the neck area.
A second idea is that nonadherence to one (or more) indicator(s) may interfere with disease 
management. For example, not performing imaging of neck, thorax or abdomen for NHL 
patients may result in a different stage, subsequently in different treatment decisions when 
compared to patients with all imaging performed and may therefore impact survival 
chances. A previous study demonstrated that the detection of additional lesions with
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imaging with PET resulted in a change in stage and indeed impacted treatment management 
for patients with indolent NHL. Moreover, survival was inferior for patients with additional 
lesions detected by PET.26 What was remarkable in this study, was that NHL patients 
receiving all diagnostics except for imaging of neck had inferior survival compared to 
patients receiving complete diagnostics, also for patients with diffuse large B-cell 
lymphoma, however not significant (P value of 0.058). It should be confirmed in future 
studies, whether not performing imaging of neck area does result in an actual change in 
stage and subsequent disease management compared to no imaging or the altemative: 
palpation of the neck.
A third idea is that performance on an individual indicator may actually be a reflection of 
the quality of care of the entire care process. Indeed, from our pattem analysis, it was 
demonstrated that patients receiving imaging of the neck area in all cases received the other 
recommended diagnostics as well. As mentioned, survival was superior for these patients. 
Adequate staging as a proxy marker of overall quality was also proposed by other 
researchers, relating to an observed association between staging quality and improved 
survival of women with endometrial cancer.25
This study does have its limitations. Firstly, the patients included in this study were 
diagnosed in 2000-2001 and data were collected in 2002, whereas the indicators in this 
study were developed in 2006. Therefore, some data were incomplete. For indicators on 
diagnosis and staging, dates of performances were not available and it was not possible to 
use a time-dependent statistical model to account for survivor bias. However, by excluding 
patients who died within 21 days, we did eventually adjust for survivor bias, and performed 
a sensitivity analysis excluding patients who died within 28 and 42 days as well. Adherence 
stül proved to be related to survival for all periods. In addition, multiple data imputation 
was used to impute missings for confounding factors and indicators. Others have 
successively imputed 90% of missing data from 80 complete cases. In our study, 
missingness was highest for the variable comorbidities (25% missing cases), which was 
imputed from 160 complete cases.27 Unfortunately, the database did not allow for the 
measurement of all indicators developed in 2006. Thus, future research is needed to 
examine all NHL indicators.
The indicator scores in this study were generally similar to those more recently measured in 
the Netherlands.14 Scientific literature indicates that NHL patients outside the Netherlands 
also do not seem to receive care as recommended.1214 This study shows the potential 
impact on outcome when not adhering to guidelines. However, these results should be 
verified by other countries and for other malignancies as well. Furthermore, research is 
needed to examine the underlying causes for the strong association between adherence and 
improved survival for NHL patients. In general, randomized controlled trials are to be 
performed to demonstrate the effect of intervention on patiënt outcomes. However, for the 
indicators in this study, it would not be appropriate due to ethical concerns to perform 
suboptimal quality of care, e.g. intentionally administering suboptimal doses of 
chemotherapy or not performing bone marrow examination. A prospective study such as 
performed by Scott et al. would be appropriate to see whether complete staging with 
imaging of neck, thorax and abdomen and examination of bone marrow would result in 
disease stage and treatment changes compared to suboptimal staging.26
126  I C h a p t e r  7
In conclusion, this study demonstrated that guideline adherence is associated with improved 
fïve-year overall survival of patients with NHL according to six indicators. These indicators 
not only refer to treatment but also to staging, indicating the importance of indicators on 
diagnosis as well.
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Backg ro un d
Cancer is a major public health problem in many countries in the world. Every year among 
19.200 Dutch patients die with lung, colorectal, breast cancer or NHL. In addition, the care 
for patients with cancer is complex. It involves multiple medical disciplines and new diag- 
nostic and treatment options are constantly under deveiopment. Moreover, the disease has a 
great impact on the lives of patients and their families. Delivery of high quality in curing of 
and caring for patients with cancer is essential, however, is challenged by this complexity.
There is a continuous need to measure the quality of care to examine if and where im­
provement in cancer care is necessary. A first step within a system of continuously improv- 
ing the quality of cancer care, is to measure it with good quality indicators. To do so, indi­
cators should meet criteria for validity. This thesis describes research in the field of the 
deveiopment (part 1) and validation of indicators (part 2) for cancer care. In this last chap­
ter, the main fïndings are described and discussed. In addition, the limitations of the study 
are described and the implications for future research, medical practice and policy making 
are given.
MAIN FINDINGS
The answers to the main research questions in this study were:
Deveiopment of quality indicators for cancer care
• There are few differences in the content of recommendations in national cancer- 
specifïc breast cancer guidelines of the Netherlands and Germany, indicating that 
indicators developed based on the German guidelines are applicable to the Nether­
lands as well, and vice versa. (Chapter 2)
• Indicators should be developed with the involvement of experts (e.g. cancer pa­
tients or medical professionals involved in cancer care). This is important for the 
face and content validity of indicators. (Chapter 3 and 4)
• It is possible to develop generic process indicators for cancer care, in addition to 
developing generic (patient-reported) outcome measures. (Chapter 3 and this 
Chapter)
Validation of Quality indica tors for cancer care
• There are currently no differences in case mix between hospitals in the Nether­
lands that require the correction of process indicators on timely and multidiscipli­
nary care for patients with NHL, breast, lung and colorectal cancer. (Chapter 5)
• Quality indicators can be used to assess the level of integrated cancer care using 
pattem analysis. (Chapter 6)
• Adequate performance on process indicators is associated with improved survival 
of patients with NHL. (Chapter 7)
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Development of quality indicators for cancer care
Each set of quality indicators should meet criteria for validity in order to use the indicators 
to measure and compare the quality of care across care providers. We will now discuss 
fïndings of our studies that contributed to the knowledge on how to develop valid indicators 
for cancer care.
Indicators based on evidence-based guidelines
The indicators in this thesis were based on (inter)national evidence-based guidelines. In 
Chapter 2 we examined the comparability of national evidence-based guidelines on breast 
cancer care from two neighboring countries: Germany and the Netherlands. Fortunately, 
there were few differences between the evidence-based guidelines regarding the content of 
recommendations. This indicates that indicators developed based on the German guidelines 
will apply to the Netherlands as well, and vice versa. The applicability of the indicators 
from another country for the own setting can be easily checked by comparing the content of 
the indicators with the national guidelines of that country. When quality indicators are 
based on clinical guidelines, we often suppose that, in particular the recommendations sup- 
ported with high-level evidence, will be developed into indicators. However, this does not 
mean that the entire content of the recommendations used for indicators is fully supported 
with evidence. Also in the development of indicators, other considerations then just evi­
dence play a role in defining the best care option. Verkerk et al. made a list of considera­
tions made in formulating recommendations in guidelines in case evidence is incomplete, 
controversial or lacking. These considerations may also apply to formulating quality indica­
tors. They concern the clinical relevance, safety of patients, the patients’ perspective, the 
availability of resources, health care cost, the professionals’ perspective and legal conse- 
quences. The outcome of such considerations may differ as we saw in Chapter 2 of this 
thesis. Therefore, we strongly advice that such considerations and the consensus on the 
considerations are made transparent in guidelines, as well as in quality indicators, so that all 
relevant information is known to the reader and user of the guideline or indicator.
Face and content validity
In this thesis, we observed that expert involvement in the development of indicators is im­
portant for the face and content validity of indicators. In order for indicators to have face 
validity, stakeholders should have a fïrst impression that indicators are usefiil and able to 
measure the quality of care.2 Indicators are considered content valid when it is plausible 
that all indicators cover relevant aspects of cancer care and that the indicators have been 
developed using a systematic method in which all relevant information (scientifically and 
practical) has been processed.2
One of the fïndings in this thesis was that the face-to-face meeting between experts contrib­
uted to the face validity of the indicators. Sometimes, according to the ratings in the fïrst 
postal round of the RAND modified Delphi procedure, there was disagreement (on paper) 
between the experts for a potential indicator. It has been demonstrated by others that panel 
members from different stakeholders groups make systematically different judgments in
1 3 2 1 C h a p t e r  8
consensus procedures. For example, Campbell showed that healthcare managers are more 
likely to give high ratings compared to primary physicians.3 Mixed Delphi groups instead 
of single specialty groups may therefore result in fewer consensuses. In our study, the 
panel members were asked in the second round for the possible reasons for their disagree­
ment. The personal discussions on this disagreement resulted in more complete or revised 
indicators that finally incorporated the views of all experts. In a study by Hutchings et al., it 
was examined whether the outcome of consensus procedures differed between Delphi panel 
members who met and discussed the results after a first postal round and panels that only 
rated recommendations in two postal rounds without meeting. They found that indeed opin- 
ions of experts are more likely to shift when groups meet. When a face-to-face meeting is 
organized, differences in opinions are actually solved which result in indicators that better 
represent ’views of all experts.5 6 Therefore, developing indicators using a mixed panel of 
experts from different stakeholder groups and discussing the indictors in a face-to-face 
meeting will increase the chance that the indicators developed have face validity. Further- 
more, experts contributed to the content validity of indicators because they interpreted 
recommendations from evidence-based guidelines and mixed scientific information with 
information known from daily medical practical. The experts eventually developed indica­
tors that were both feasible to use and able to measure, and could differentiate in the quality 
of care between different care providers.
Generic indicators
Generic indicators for cancer care are measures that are applicable for the measurement of 
the quality of care given to most patients with cancer. Outcome measures, such as mortality 
or satisfaction, are examples of generic measures. Because they are generic, they can allow 
more easily comparison between hospitals and different cancer types. Process indicators are 
expected to be applicable for one cancer type and are therefore developed for each cancer 
type separately using different panels of experts. This way, they require more time to de­
velop. Furthermore, process indicators are considered unpractical because they need regular 
updates.7 However, in this thesis, we observed that next to generic outcomes, there are 
possibilities to developed generic process indicators as well. In Chapter 3 of this thesis, we 
reported how we developed generic indicators for patient-centered cancer care with the 
involvement of both patients and medical professionals. Here, we will discuss the opportu- 
nities for developing generic indicators for Diagnosis and staging, Treatment and follow-up 
and the Organization of care.
We used recommendations in evidence-based guidelines as a starting point to develop indi­
cators for cancer care in this thesis. Therefore, most indicators developed were process 
indicators. Interestingly, the four cancer specific sets in this thesis contained similarities: 
although the details of each process indicator differed between the specific cancer types, 
they measured the same aspects of care. For the domain Diagnosis and Staging for exam­
ple, all four sets described an indicator conceming the assessment of the spread of the dis- 
eas’e. For the domain Treatment and follow-up, indicators were developed conceming ther­
apy aiming specifically at those patients with a disease stage for which curative treatment 
was possible. For the Organization of care, all four sets contained an indicator conceming 
the content of the pathology report. In Chapter 5 of this thesis, we described other examples 
of similar indicators on timely and multidisciplinary care. Using these similarities, a
G e n e r a l  d ïs c u s s io n  [ 133
framework of generic indicators can be developed (table 1). Such a framework can be used 
as a tooi to develop indicators for all cancer types. In table 2 as an example, we formulated 
a generic indicator on staging. To develop indicators for other cancer types, one needs to 
fill in the generic indicators with details that account for that specific cancer type. For ex­
ample, in table 3 we have filled the generic indicator with details from the Dutch guideline 
on prostate cancer. The indicator in table 3 was actually developed before in 2003 by Spen­
cer at al. for patients with prostate cancer using a RAND consensus method.8
Table 1. Similarities in care recommendations
Domains
Breast cancer Colorectal Non small-cell Non-Hodgkin lym- 
________________ cancer__________ lung cancer phoma
Diagnosis 
and staging
Adequate assessment of 
tumor stage
T realment Adrai nistration of (sy<*~ 
and follow- temic) therapy to patients 
»p for whom curative treat-
ment is (just) ptmible 
Organization Adequate pathology 
of care reporting on excision 
tissue
Details o f the indicator
using TNM using TNM using TNM Ann Arbor classification
classification classification classification
adjuvant chemo­ FOLFOX for stage Chemu-radtation Rituximab-CHOP for




• Type • Type • Surgical • Morphology
• Size • Size procedure * Immune phenotype
• Receptor • Grade • localization • location
status • T stage • size • fixation
• Grade • Margins • Margins • frozen tissue
• Margins • Vascular, 
lymph invasion
• tumor characteristics
There are no studies yet that compared cancer-specifïc indicator sets for such similarities or 
that developed generic process indicators for cancer care other than for patient-centered 
care. Of course, this theory of filling in generic indicators needs to be further explored in 
future research but it could be a first step towards gaining efficiency in developing and 
using process indicators for patients with cancer. A major advantage of developing generic 
process indicators is that efforts can be combined. Instead of developing sets for each can­
cer type, one set can be used to measure the quality of care for many cancer types. Moreo- 
ver, it creates possibilities to measure the quality of care for the more rare cancer types as 
well.
Table 2. Example o f  a generic indicator fo r  staging
Generic indicator
Tsiiimerator Number of patients w ith A cancer who are staged by their treatmg physician accord­
ing to } classification within Z weeks after the first hospital visit
Denominator Number o f  patients with X  cancer
iyPe ofconcv; Y, type o f  chssificrlion; Z is number o f  weeks
Table 3. Indicator fo r  staging o f  patients with prostate cancer 
Indicator
134  | CHAPTER «__________________________________________________________________
Numerator Number o f  patients with prostate cancer who are staged b> their treatmg physician
according to TNM dassification 20029 within . * weeks after the first hospital visit
Denominator Number o f  patients with prostate cancer
* A time period was not specified in the Dutch guideline on prostate cancer and is therefore notfilled in
Another proposed benefit of these generic process indicators, is that they are not so liable to 
change. For example, all four sets contained an indicator on the pathology report that states 
the precise information to be documented in the pathology report (the techniques used or 
the features of the tumor or the resection). Of course, when new techniques become availa- 
ble, the details in the content of this generic indicator need updating. However, the generic 
aspect that the pathology report should contain correct and relevant information to assess 
the quality of the resection or the tumor features is not so liable to change and probably 
does not need updating regularly.
Box 1: When and how to update?
Not much is known on when to update quality indicators. Shekelle et al. described numer- 
ous changes that may provide an indication that a recommendation in a clinical guideline 
needs updating.10 These changes may apply to indicators as well. For example, updates on 
an intervention are needed when there are changes in evidenee on the existing harms and 
benefits of the intervention, changes in important outcomes, in other intervention becoming 
available, in considerations (economic, fïnancial, cultural e.g.) and the availability of re­
sources. Moreover, in the study by Shekelle a model was proposed to update recommenda­
tions.10 In this model, clinicians are first asked if they are aware of new evidenee or devel- 
opments in the field of the existing intervention or that a new intervention should be added. 
In case of a positive answer, a limited literature search is needed to support this decision 
with evidenee. Then, in combinations with multidisciplinary expert opinions, the recom­
mendations on the intervention in the guidelines are updated. This model may also apply as 
a model to update indicators. In future, opening a website where clinician may give feed­
back on existing indicators may help to fïnd clear and in-time indications of the need for 
updating.10___________________________________________________________ _ _____
VALIDATION OF QUALITY INDICATORS FOR CANCER CARE
Testing of the indicators in this thesis was done for two reasons: 1) to make sure that data 
collection can be performed without measurement errors and 2) to assure the validity of the 
indicators. Indicators should measure what they intent to measure, namely the quality of 
care. To make sure that the data collection is performed without errors, we tested the inter- 
rater reliability between the data collectors and assessed the extent of missing data for each 
indicator. The testing of other validity aspects of these indicators is complex and there is no
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workable protocol that can be followed. However, the studies in this thesis have contributed 
to the knowledge on indicator validity that we will now discuss.
Case mix
Measuring the quality of care using indicators shows which processes, structures and out- 
comes need improvement. In this thesis, a need for improvement according to process indi­
cators was associated to indicator scores under 90%. This cut off percentage is rather arbi- 
trary, and from a clinical point of view, any score lower than 100% may address the need 
for improvement. In addition to low indicator scores, variation in scores between care pro­
viders may therefore give a second indication of a need for improvement. In theory, hospi­
tals with low indicator scores should be able to improve their quality of care, at least when 
compared to hospitals with highest scores.
However, care providers may differ in the population they treat. Because patiënt and tumor 
related factors like comorbidities and performance status may influence the performance on 
quality indicators, outcome indicators are Standard corrected for such case mix factors.7,11 
For process indicators too, care providers argue that case mix factors explain suboptimal 
indicator scores or variation in care. This thesis showed that this is not necessarily true. 
Indeed, we showed that some individuai patiënt or tumor characteristics were reasons to 
deviate from the care as described by indicators. However, after correction for case mix, 
suboptimal indicator scores or hospital variations remained. This is probably because of 
different reasons such as:
1) no profound variation is present in case mix between hospitals in the Netherlands
2) the original indicator scores are very low, so that after corrections for case mix the 
corrected indicator scores will still be under 90%.
3) the prevalence of case mix factors that influence the performance on indicators is 
low (e.g. only 6% of the patients express objections to recommended Standard 
care)
Policy makers currently advocate that hospitals should make regional agreements on the 
segment of patients they wish to treat. Such policy developments may lead to a shift in 
patiënt populations: for example, complex patients may shift entirely to academic hospitals 
and the more Standard care entirely to non-academic hospitals. When this happens, it should 
be re-examined whether indicator scores on timely and multidisciplinary care can be com­
pared across hospitals without case mix corrections.
Good process and good outcomes
Few studies, including ours, have been performed to examine the relationship between 
processes and outcomes for cancer patients. For breast cancer care for example, Cheng at 
al. found that 100% adherence to process indicators was related to improved survival.12 For 
endometrial cancer and colon cancer, adequate staging was associated with improved sur­
vival. In our thesis, we found such an association between six process indicators from 
the domains Diagnostics and staging and Treatment and follow-up and survival. This was 
not the case for indicators in the domain Organization of care (Chapter 6). These were all
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indicators for which we had observed suboptimal scoring and regional variations based 
(Chapter 4). The underlying mechanism for the association between good processed and 
good outcomes is not yet understood.
One theory is that indicators are interrelating and that the inadequate performance on an 
individual indicator does not only affect the indicator but also influences subsequent pro- 
cesses. For example, not adequately performing staging examination may lead to under 
staged patients, which in result may influence further decision making on treatment. Patiënt 
can potentially be undertreated. In a study by Scott et al., it was demonstrated that the de- 
tection of additional lesions with imaging with PET in patients with indolent NHL resulted 
in a change in stage in 28% and this change in stage impacted treatment management in 
34% of the patients. Treatment mostly shifted from radiotherapy to chemotherapy.17
This mechanism as a reason for the associations between processes and survival has also 
been proposed by others.18 For example, the number of lymph nodes examined for colon 
cancer has been shown to have an association with improved survival. ’ A more extensive 
lymph node evaluation may reduce the risk of under staging and may therefore optimize 
further treatment. The evaluation of a minimum of 10 nodes is therefore often proposed as a 
quality indicator for colon cancer patients, also in this thesis. Parsons at al. investigated the 
evaluation of lymph nodes in a longitudinal study. He theorized that if it is true that patients 
with less nodes examined are under staged, he would observe a shift towards higher staged 
colon cancer, when more lymph nodes are examined over time. In his study, he confïrmed a 
significant increased number of lymph nodes evaluated in the last two decades (from 1988 
to 2008), but he could not show an overall shift towards higher staged colon cancer. He 
therefore questioned the proposed mechanism of under staging. However, when looking at 
the individual T-stages in his study, there was a statistically significant increase in the pro- 
portion of patients with node positive stages: 38.8% of patients with T3 tumor were node 
positive in 1988-1990 compared to 49.8% in 2006-2008.19
If it is true that indicators are interrelated and are therefore, in combination, important for 
the outcomes of patients, the pattem analysis in Chapter 6 in this thesis is very useful to 
check which pattems exists in performing care according to the best care options. We 
demonstrated for patiënt with colon cancer that only 27% received all the care as recom­
mended in the guideline for diagnosis, staging, treatment and follow-up. For the other 73% 
of the patients, 40 different pattems of performing care were identified. In a future study, 
we would like to examine the cost-effectiveness and the outcomes for patients in these 
different pattems. In conclusion, for patients with NHL, we were able to show that process­
es of care are associated with survival, indicating criterion validity of the indicators devel- 
oped. In future, this should be examined for other types of cancer as well.
METHODOLOGICAL CONSIDERATIONS
Indicator development
Because we used recommendations from clinical guidelines as a starting point to develop 
indicators from, most indicators in this thesis were process indicators. Nowadays, there is a 
trend to focus on outcomes, like disease specifïc mortality and survival or patient-reported
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outcomes measurements (PROMS).20,21 However, in choosing the type of measurement one 
should ask oneself: “Who are the target users and what is the purpose of the measure­
ment? Process indicators usually involve more effort to measure than outcome indicators, 
but they can give precise information on the improvement potential of specific care pro- 
cesses. Outcome measures, on the other hand, may provide prompt information, leading up 
to improvement activities shortly after. Furthermore, the value of outcomes is that they 
measure more exactly what is important for patients, such as their survival or satisfaction 
with the care provided. However, without process measurement, it may be difficult to fmd 
out why outcome measurements are showing suboptimal results. The aim in this thesis was 
to develop guideline-based indicators that can be used to measure the quality of care to give 
insight to clinicians into the care that is actually provided to patients and where improve­
ment may be needed. Outcome indicators such as mortality, morbidity, quality of life or 
patiënt satisfaction were not included in the final set and adding such measures to the set 
can be very useful to see whether the performance of processes have an effect, especially 
for the details of indicators for which no (high-level) evidence is present.
Indicator validation
When measuring quality indicators in a retrospective study, it may be difficult in interpret- 
ing the results to distinguish between a lack of documentation and actual insufficiënt adher­
ence to guidelines. In other words, it is possible that the care in certain indicators was actu­
ally performed, however, was not documented as such. Indeed, in our thesis we noticed that 
the registration of information in medical records -for example the pathology report - is not 
always complete. However, there are numerous examples of indicators in our study that are 
not influenced by this documentation” bias. For example, when the laboratory assesses 
blood counts for a patiënt, the results of these tests are automatically distributed to the pa­
tiënt s electronic medical record. Thus, for indicators conceming laboratory results it is 
very unlikely that the blood count is performed but not documented. This is a major ad- 
vantage of using an automated order system in hospitals: when an order is placed and per­
formed, the information will automatically and uniformly appear in the medical file. There­
fore, indicators conceming pathology and laboratory tests and radiology examinations are 
not liable to large documentation bias. Moreover, because the data are stored electronically, 
they are easy to find for data collectors or can be electronically extracted from the medical 
files. We think that information/ documentation management (such as assessment and doc­
umentation of prognostic information) is important for the quality of care because a lack of 
information may increase the chance that care is being provided to patients that is not safe 
or effective. Moreover, in a multidisciplinary setting, the medical information of cancer 
patients should be known to all disciplines involved, especially when there is a transfer of 
care for a patiënt with cancer from one care provider to another.
For all measurement instruments, it is important to evaluate their validity. When measuring 
the criterion validity of our process indicators, we considered survival after five year as the 
gold Standard. However, a real gold Standard for the quality of care is of course lacking. 
Therefore, one can debate whether the indicators for which an association with survival was 
found are really criterion valid. Moreover, in this thesis, this was only examined for NHL 
and only few other studies have been performed on this association. This is because indica­
tor developers generally need to wait 5 years after the development and measurement of a
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set before they can follow-up on survival. This thesis provides a clear method on how to 
perform such a study, with a correction for survivor bias that is often overlooked by others.
Process indicators may have associations with other outcomes as well, such as patient satis- 
faction, disease free survival or quality of life that we did not examine in this thesis. How­
ever, there is no knowledge on how limited or extensive a validation study needs to be, to 
make a reliable conclusion on the validity of indicators. Because there is no direct measure 
of the quality of care, the validation of indicators should not rely on one type of validity but 
need to be composed of in examining different types of validity and theories, which all 
together give insight whether or not an indicator is valid. Like de Vet at al. states:
'Every test o f  validity and every hypothesis adds to the body o f  evidence with regards to the 
validity o f  the instrument in a specific context
We examined the inter-rater reliability, the amount of missing data, the need for case mix 
correction and the criterion validity and made sure that our indicators were developed with 
content and face validity. We did not examine the construct validity of indicators and more 
measurements should be performed for other malignancies as well. In general, much more 
research is needed on the types of validity and the knowledge on validations studies that are 
mostly contributing to the evidence of the validity of indicators. We hope this thesis pro­
vides a good starting point.
IMPLICATIONS FOR RESEARCH, CLINICAL PRACTICE AND POLICY 
MAKING
Summary points
■ttesearch________________________  Climeai practice__________________ Policy iiiakmg
Generic indicators should be devei- Strategies ncsd to t»  developed to There are indications that focusing 
opod and tested for cance” care improve the quality o f  cancer care oïï quality o f  care imaroves effi­
ciency. However, there is no strong 
evidence to support this.
More research should be performed Randomized controlled trials To achieve an optimum in care. 
on variations in cancer care should be performed to provide policy makers arc controlling
strong evidence that a strategy is volumes. It would be wise to 
working or not. validate these volumes before they
. ars us*} on -a large seal*.
In future, the eititiency c f  processes The work on the validation o f Invest time and financial resources 
and uie consequences for survival indicators hss onlyjust started. The in infotmstion technology io 
shomd bs examined support o f oünicai experts is reed- fecüitate fee real-iime measure-
ed to validate indicators step by rneiit o f  indicators. 
____________________________________ step.______________________________
Implications for research
For the deveiopment of generic indicators, more research is needed on whether the similari- 
ties in the sets we described can be used to develop generic indicators for: Diagnosis and 
staging, Treatment and follow-up and the Organization of cancer care. All cancer specific 
indicator sets, systematically developed using a RAND-modified Delphi method, should be 
compared to examine whether a framework of generic indicators can be formulated. Of 
course, experts from stakeholder groups should be involved to ensure the face and content 
validity of these generic indicators. These generic indicators, also the ones for patient- 
centered cancer care, should be tested for their validity and should be measured.
In addition to suboptimal indicator scores, our measurements also showed that there were 
geographical differences in the quality of care between three regions, the north, south and 
middle areas of the Netherlands for patients with NHL and for patients with breast, colorec­
tal and non-small cell lung cancer on timely and multidisciplinary care. Variations in cancer 
care by geographic areas were also observed by other researcher for cancers of the lung, 
rectum, bladder, ovarian and prostate and on NHL.23 29 In addition, variations between 
hospitals were observed for colon cancer and NSCLC.30,31 These are first implications that 
it is important to study variation between sites and that efforts should be taken to improve 
the care of these diseases. It would be interesting to measure whether there is variation in 
care across different countries as well. International efforts should then be taken to improve 
the quality of care for cancer. This thesis showed that suboptimal process indicator scores 
for NHL are not explained by patiënt and tumor characteristics and that indicators on timely 
and multidisciplinary care do not need case mix correction. This should be verified for 
other indicators as well.
For an optimal use of quality indicators, much more research is needed on the association 
between process indicators and desired outcomes. Firstly, our study on NHL patients 
should be repeated for other cancer types to verify whether the strong association we found
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is present for other malignancies as well. In future research, the pattem analyses like in 
Chapter 6 of this thesis will show which indicators are not adequately performed and will 
show which pattems are associated with survival. Secondly, research is needed that helps to 
understand the association between processes and outcomes. One of the mechanisms pro- 
posed for this association is that improper performance of specific indicators may have 
consequences for the entire disease management. In future, we would like to examine this 
theory. One prospective approach is to let clinicians document a treatment plan on the basis 
of staging information from an indicator that is not adequately performed (e.g. less than 10 
lymph nodes examined for colon cancer). Subsequently, to ask them if they would change 
their initial treatment plan when they are presented with the information from the same 
indicator, although then adequately performed (more than 10 lymph nodes examine). An- 
other approach is to retrospectively examine and discuss the medical records of patients for 
whom indicator scores were suboptimal. The discussion should focus on whether the care 
was adequately performed and the consequences for the patient of the choices made later.
ïmplications for clinical practice
Nowadays, quality of care research receives attention from many, including from the physi- 
cians delivering the care. Guidelines are developed to increase the efficiency in care by 
preventing under-, over- and misuse of care. A first step towards implementing guidelines 
is to gain insight into the care that is actually provided. In this thesis, indicators were devel­
oped based on guidelines for the entire care process, from diagnosis to follow-up, therefore 
making it possible to measure multiple care processes. A second step is to use the processes 
with improvement potential to develop a tailored improvement strategy. For this, a qualita- 
tive study should be conducted to understand the barriers and facilitators that hamper of 
promote performing the care as recommended in indicators. For example, if a barrier for 
not reporting all recommended items in the pathology report would be that items are some- 
times forgotten, the standardization of the pathology form with pre-defined items could be 
part of an improvement strategy. In general for cancer care, effective interventions to im- 
prove the quality of patient-centered care are the provision of an audiotape of the consulta­
tion of the patient, provision of information to patients and use of decision aids and (for the 
organization of care) the introduction of follow-up and case-management, especially by 
nurses.32 Just recently, a tailored strategy was designed to improve the care for patients with 
NHL in the Netherlands, which is now tested in a randomized controlled trial.33
Others have also performed indicator measurements that are used to improve the quality of 
care. In the Netherlands, the Dutch Institute for Clinical Auditing (DICA) has developed a 
system to measure and improve the quality of care for colorectal, breast, lung, esophageal 
and stomach cancer. In this system, care providers, usually surgeons, register the care that 
is provided to patients with a specific cancer type in an online database. Subsequently, they 
receive feedback and benchmark information based on that data. The registry provides an 
opportunity to measure and compare the quality of care across different care providers, 
clearly showing where improvement is needed. After the release of the DICA system, a 
profound increase in the quality of care as measured with quality indicators was observed. 
Many attributed this to the audit system. For example, colorectal patients receivedadequate 
preoperative screening in 79% and after three years of registration this was 87%. Also in 
other countries similar results were found.35 However, the conclusion that these improve-
ments were a result of the audit system were made without control group measurements. It 
might therefore also be a result of a trend in time or a result of improved registration. A 
Cochrane review that included RCTs to assess the effects of audit and feedback showed 
that only a small (around 4,3%) improvement in professional practice is usually established. 
The effectiveness seems to depend on baseline performance and how the feedback is pro- 
vided. To improve the quality improvement of cancer care, a tailored strategy is important 
in which feedback and benchmark information should play a role as well. Whether or not 
this strategy is effective should be tested in a randomized controlled trial.
Implications for policy making
In the Netherlands, policy makers have put much effort in the liberalization of healthcare 
and in making the quality of care transparent for hospitals in the last years. Just recently, 
there is a new focus in improving the health care system. This focus lies on actively con- 
trolling the quality of care in hospitals. Policy makers believe that this controlling will shift 
the current quality of care to a higher level, which should increase the efficiency in care for 
patients. In turn, this efficiency increment should decrease costs.37’38 In this thesis, there are 
some indications that this theory may apply to cancer care as well. Firstly, we have de- 
scribed that the performance on specific process indicators may be of influence to further 
decisions in the care process. Secondly, we have shown that there is an association between 
these process indicators and outcomes: patients who receive the care according to these 
process indicators have a higher chance of surviving five years compared to patients not 
receiving this care. On the other hand, the underlying mechanisms of this association is not 
yet understood and should be further examined. Moreover, it was beyond the scope of this 
study to examine the cost-effectiveness and therefore we do not know whether the care 
performed according to what indicators recommend will decrease costs. However, suppose 
that actively controlling the quality of care indeed would increase the quality of care and 
will subsequently decrease cost. The fïrst step to control to quality of care is to gain insight 
into where improvement is needed. Policy makers have concluded that the volumes of sur- 
gical treatments in the Netherlands are too low and that these low volumes will inhibit 
adequate specialization in care whereas this specialization is needed to increase the effi­
ciency. Therefore, they advocate that improving the quality of care should be done by con- 
centrating care, meaning that some hospitals will not perform certain care anymore, whilst 
others will treat three times more patients. Hospitals in the Netherlands are now in the lead 
to take the fïrst initiatives to re-organize the care in their region. However, without doubt- 
ing the evidence that centralization may lead to better quality of cancer care in terms of 
improved outcomes after surgery,39 there is no validated number of patients known that 
need to be treated to achieve an optimum of the quality of care (see figure 1). In addition, 
Ke et al. performed a systematic review on the costs of centralization of cancer services and 
concluded that the evidence on the economic impact of centralization is limited and of poor 
quality. More research is needed to determine aspects of centralization that are effïcient 
and for which cancer type.
1 4 2 1 C h a p t e r  8
Shape of the Benefit-Utilization Curve:
Figure 1. Benefit-utilization curve41
The discussion on which indicators to use to validly measure the quality of care is often 
focused on selecting the ones that are easy to measure. This is understandable because, 
quality of care measurements can be time consuming as we saw in this thesis. However, we 
think that it is much more worthwhile putting efforts in discussing how to facilitate fast 
measurements of the quality of care than to choose indicators that are not entirely sufficiënt. 
In addition, because there is no gold Standard of the quality of care, we believe it is of value 
to consider measuring multiple types of indicators, such as processes, (patient-reported) 
outcomes on different levels42 and volumes, that all contribute to an overall image of the 
quality of care in a hospital for example.
Feedback should be provided more than once to have the best effect.36 With the manual 
measurement of indicators, usually only once per year feedback is provided to care provid­
ers. One option to facilitate multiple measurements per year is to invest time and fmancial 
resources in information technology. More and more information, not only administrative 
but also clinical information is imbedded into electronic medical records. With the current 
technical possibilities, there are many opportunities to develop digital feedback systems for 
medical professionals to see real-time where improvement in care is necessary and to moni­
tor outcomes on patiënt level. However, garbage in is garbage out.43 So the reliability of 
digital data from electronic medical records files should be examined, for example by com- 
paring the data gained from electronic medical records with data of manual extraction from 
medical files. The Dutch cancer registry together with hospitals can be leading in this type 
of research, because they are experts on collecting data on oncology care. Moreover, they 
regularly perform quality control on their own work. Taking up the indicators in this thesis 
in the cancer registry can help to measure and monitor the quality of care more frequently 
and compare the quality across the different care providers/ regions in the Netherlands.
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Development of quality indicators for cancer care
For an optimal use o f quality indicators for cancer care, indicators are preferably developed 
in a systematic way with the involvement of experts representing the different stakeholders 
(the groups for whom the indicators are developed) and with a RAND modified Delphi 
method containing a face-to-face meeting. There are similarities between cancer specific 
indicator sets, although developed by independent panels. These similar indicators can be 
used to develop generic indicators for processes of cancer care, and can be used for many 
cancer patients and in many hospitals.
Vaiidation of quality indicators for cancer care
The vaiidation of indicators is important to establish that indicators can be measured with­
out measurement errors and are measuring what they intend to measure, namely the quality 
of care. Indicators should be examined for different types of validity because every test of 
validity adds to the body of evidence of the indicators. In this thesis, we showed how to 
examine inter-rater reliability, missing data, the need for case mix adjustment and criterion 
validity. Most important results were that patiënt and tumor related factors do influence the 
performance on process indicators, however, this does not necessarily mean that indicators 
need corrections in order to make a valid conclusion on improvement potential or differ­
ences between care providers. More research is needed to verify the results of this thesis for 
other malignancies, especially the association between the performance on process indica­
tors and survival, which is not understood yet.
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SUMMARY
INTRODUCTION
In the Netherlands, about 40 000 patients are newly diagnosed every year with lung cancer, 
colorectal cancer, breast cancer and NHL and among 19 200 Dutch patients die with these 
malignancies every year. Delivery of high quality in curing of and caring for patients with 
cancer is essential. However, the diagnostic and treatment options are constantly revised 
due to new developments in cancer care, which makes the care for cancer patients very 
complex. Guidelines aim to improve the quality of care by describing best care options. 
However, patients are not always receiving the care in adherence to guidelines.
There is a continuous need to measure the quality of care to examine if and where 
improvement in cancer care is needed. A first step within a system of continuously 
improving the quality of cancer care, is to measure it with good quality indicators. To do so, 
indicators should meet criteria for validity. This thesis describes research in the field of the 
development (part 1) and validation of indicators (part 2) for cancer care. The mam 
research questions in this thesis are:
Part I Development of quality indicators for cancer care
What are the differences in evidence-based guidelines of two neighboring countries 
and are there consequences if  indicators are based on national guidelines?
Is it possible to develop generic indicators for patient-centered cancer care?
How should quality of care indicators for patients with a specific cancer type be 
developed and measured?
Part II Validation of quality indicators for cancer care
Do process indicators conceming timely and multidisciplinary cancer care need case 
mix corrections?
Can quality indicators be used to assess the level o f integrated cancer care?
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Part I - general outlrne
We developed and measured cancer-specific sets of quality indicators for colorectal, breast, 
non-small cell lung cancer (NSCLC) and non-Hodgkin lymphoma (NHL). In addition, a 
generic set of indicators for patient-centered cancer care was developed (see page 163 for 
all indicator sets). Key recommendations were selected from national and international 
guidelines and rated for their potential to use as quality indicators. A systematic RAND 
modified Delphi procedure consisting of a postal round and a face-to-face meeting was 
used to develop the indicators. Each set of indicators was developed using panels of experts 
who were representatives of the different stakeholders groups. In cancer care, there are 
different groups of stakeholders. Stakeholder(s) is/are defïned as: an individual, group, 
institution, or govemment with an interest or concern, economical, societal, or 
environmental, in a particular measure, proposal, or event. In our thesis, we developed 
indicators to be used for in-hospital measurements of the quality of care for medical 
professionals to monitor and improve their quality of care. Stakeholders who were invited 
in our panels were therefore medical professionals (and patients when developing indicators 
for patient-centered cancer care) but were not insurance companies or policy makers.
Chapter 2-4
Indicators are often developed based on evidence-based guidelines. Therefore, we 
examined the comparability of national evidence-based guidelines on breast cancers care 
from Germany and the Netherlands (Chapter 2). We found that the guidelines were 
generally comparable as far as the methodological quality of the development of the 
guidelines and the content, conceming those recommendations that were discussed in both. 
This may facilitate transborder cooperation in cancer care between Germany and the 
Netherlands in border areas between both countries. Remarkably, a few recommendations 
in the guidelines were based on the same high level evidence but were different in content 
between the two countries. Looking closer at the evidence (scientific publications), it 
appeared that indeed the research results were clear, however, were not sufficiënt for a 
direct translation in to practice. In formulating best care options, guideline developers take 
into account numerous factors such as potential side effects, patiënt preferences, cost- 
effectiveness and availability of (financial and material) resources. Such consideration may 
differ between countries, probably because of cultural differences.
At the start of this thesis, few indicator sets were available for cancer care that were 
developed using a systematic method like the RAND modified Delphi method. In addition, 
some were focused on a single medical discipline such as surgery or specifically developed 
for one cancer type only. In this thesis, we developed a generic indicator set for patient- 
centered cancer care to be used for many patients with cancer (Chapter 3). Using a 
systematic RAND modified Delphi method and a panel of both medical professionals (from 
multiple disciplines) and patients, we managed to create a generic set of 17 patient-centered 
quality indicators for cancer care for the domains: Communication, Physical support, 
Psychosocial care, After care and the organization of care. This set of generic indicators can
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be used to assess and improve the quality of patient-centered cancer care. Future research 
has to establish whether practicing patient-centered cancer care according to the set of 
quality indicators we developed, will positively influence patiënt outcomes such as 
satisfaction or quality of life.
For NHL, no indicator sets for quality of care measurements were available. In the study in 
Chapter 4 we developed guideline-based indicators for patients with NHL, covering 
diagnostics, therapy, follow-up and the organization of care. We examined whether the 
indicators developed could be used to assess improvement potential. We examined 
improvement potential in the Netherlands defïned as an overall indicator score <90% and 
included 431 patients from 22 hospitals from the north, east and south part of the 
Netherlands (IKNL locations Nijmegen, Groningen, Maastricht). In addition, as a second 
indication of improvement potential, we examined whether there were regional differences 
on the indicator scores. From 99 guideline recommendations, a set of 20 indicators was 
developed. Almost all indicators for NHL needed improvement. Lowest scores were 
observed for the assessment of prognostic factors (IPI), staging (performance of imaging 
techniques and bone marrow examinations) and adequate reporting of pathology and 
multidisciplinary discussion of patients. For 5 guideline-based indicators, also regional 
differences were observed.
However, guidelines document on Standard care recommendations. These 
recommendations may do well for the majority of patients but may sometimes do harm in 
individual patients. For example, patients with a low performance status may not benefit 
from recommended chemotherapy. Therefore, we took in consideration relevant arguments 
for non-adherence when assessing the need for improvement. After adjustments for 
arguments, overall indicator scores remained under 90%, except for one indicator 
conceming therapy (administration of R-CHOP). Therefore, the NHL indicators clearly 
showed were improvement is needed in the domains Diagnosis and staging, Treatment and 
follow-up and the Organization of care for patients with NHL.
VALIDATION OF QUALITY INDICATORS FOR CANCER CARE
Part II — genera! outiine
All cancer-specific sets in this thesis were measured in three regions in the Netherlands. 
Data were retrospectively collected from the medical records of patients by employees of 
the Comprehensive Cancer Centers or by a researcher trained by the CCC. For all sets that 
were measured, we assessed the amount of missing data and tested inter-rater reliability. 
For the latter, a number of patients was measured in duplicate by two different data 
collectors and the level of agreement between the two collectors was examined. The 
agreement was generally high. In the final part of this thesis, we explored in depth the more 
complex aspect of validity and reliability: the need for case mix correction, the usefulness 
of pattem analysis and the assessment of criterion validity.
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Chapter 5-7
Case mix corrections are usually needed to compare the quality of care across hospitals 
using outcome indicators (mortality rates for example). There is, however, limited 
knowledge on the need for case mix corrections for process indicators. In this thesis, the 
usefulness o f case mix corrections for process indicators was examined in a retrospective 
observational study which included more than 2100 patients with NHL, lung, breast and 
colorectal cancer from 27 Dutch hospitals (Chapter 5). This was examined for 3 indicators 
that are generic and often used for patients with cancer to measure timely and 
multidisciplinary care. Our study showed that the performance on all 3 process indicators 
was influenced by patient and tumor characteristics. The performance on these indicators 
was generally better for patients with a higher disease stage, for patients who did not object 
to care and for patients without comorbidities. However, after case mix correction, there 
were no differences between the corrected and uncorrected hospital scores. In other words, 
the low hospital indicator scores remained low after correction and the high scores 
remained high. This means that hospitals with low scores should be able to improve their 
scores, especially when compared to hospitals with the highest scores (best practices). The 
generic process indicators on timely and multidisciplinary cancer care can be used without 
case mix correction.
Because cancer care is multidisciplinary, the different care processes must be well- 
integrated to provide good quality of care. In Chapter 6 of this thesis, we examined the 
usefulness of a new method to measure the level of integration of multiple processes: 
pattem analysis. This method summarizes the measurements of multiple indicators without 
losing insights on details of individual processes. We used eight process indicators that 
related to steps in the clinical pathway for patients with non-metastasized colon cancer. The 
study in Chapter 6 showed that only one-third of the patients with colon cancer received 
care as recommended without the omission of any of the eight steps in the clinical pathway. 
We identified more than 40 pattems of non-adherence for the remaining patients. In the 10 
most frequently occurring pattems, patients received all steps except the follow-up 
diagnostics (e.g., no liver re-imaging or assessment of CEA markers after surgery). Follow- 
up is important for the early detection of recurrent disease. Moreover, we found that 
patients who have had more than 10 nodes examined more frequently received all the steps 
of the clinical pathway than patients with fewer nodes examined. This was observed for 
both node-negative and node-positive patients. From scientific literature, we have leamed 
that in both groups, survival is better in patients with more than 10 lymph nodes examined. 
In future, studying the costs and outcome (e.g., survival) o f patients in each pattem will 
provide more knowledge of how to achieve high value in health care for patients with 
cancer.
Criterion validity is defïned as ‘the degree to which scores of a measurement instrument are 
an adequate reflection of a gold Standard’. An often proposed method for the criterion 
validation of indicators is to study their association with disease-related outcome. To care 
providers, such studies are important because it shows the clinical relevancy of indicator 
measurements. In Chapter 7, we examined whether the process indicators for NHL care 
(develop in Chapter 4) were associated with 5-year overall survival. Data were analyzed
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from 298 patients diagnosed with NHL in six hospitals in the Netherlands and for a 
homogeneous subgroup: 125 patients with diffuse large B-cell lymphoma. For five of the 
12 indicators in the study, there was an association with survival. This association was 
corrected for survivor bias and confounders. Patients who received imaging of the neck, 
thorax and abdomen or who received a bone marrow biopsy had a better chance of survival. 
In addition, the administration of chemotherapy (R-CHOP) without a dose reduction was 
related to increased survival. Thus, providing care to patients according to what is 
recommended in guidelines is associated with improved survival chances of NHL patients.
DlSCUSSION
Finally, in Chapter 8 the main fmdings of this thesis were given and discussed. In addition, 
we described the methodological consideration of developing and validation of indicators 
for cancer care as well as the implications for research, medical practice and policy makers. 
The overall conclusions are that the involvement of experts representing the different 
stakeholder in the deveiopment of indicators is important for the face and content validity 
of indicators. Especially, when experts meet, differences in opinion are solved. In this 
thesis, indicators were developed based on guidelines and were therefore much often 
process indicators. Interestingly, there were similarities in the different cancer specific sets 
of indicators. In chapter 8, we described that these can be used to develop generic process 
indicators. Conceming the validation of indicators, we were able to show that suboptimal 
process indicator scores for NHL in the Netherlands are not resulting from patiënt or tumor 
factors of the population being measured. In addition, when comparing the quality of care 
across hospitals for breast, lung, colorectal cancer and NHL, there was no need for case mix 
correction on process indicators on timely and multidisciplinary care. However, this may 
change when there are extreme shifts in patiënt populations. Policy makers believe that a 
high level of quality will increase efficiency in care and will therefore decreases costs. 
There are indications in this thesis that good processes do lead to good outcomes. Future 
research should be performed to understand the underlying mechanism conceming the 
association we found between performance on process indicators and survival of NHL 
patients. The new method of pattem analysis will be useful to examine this association.
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Elk jaar wordt er in Nederland bij zo’n 40 000 patiënten een non-Hodkgin lymfoom, long-, 
borst- of colorectaal kanker vastgesteld en jaarlijks sterven er ongeveer 19200 patiënten 
met één van deze aandoeningen in Nederland. Het is essentieel dat kwaliteit van zorg 
gewaarborgd wordt bij het behandelen of verzorgen van patiënten met kanker, echter de 
diagnostiek- en behandelopties van deze patiënten veranderen voortdurend door nieuwe 
(technische) ontwikkelingen in de zorg. Bovendien zijn meerdere medische disciplines 
betrokken bij de zorg voor kankerpatiënten. Dit alles maakt de zorg voor deze patiënten erg 
complex. Om kwaliteit van zorg te waarborgen worden richtlijnen geschreven. In deze 
richtlijnen wordt precies beschreven welke zorg het beste is voor de patiënt volgens recente 
wetenschappelijke inzichten o f volgens experts. Echter, het blijkt dat niet alle patiënten de 
zorg krijgen zoals aanbevolen in deze richtlijnen.
Er is daarom een voortdurende behoefte om te weten hoe het met de kwaliteit van de zorg 
staat, het meten van kwaliteit van zorg kan precies laten zien of en waar verbeteringen 
nodig zijn. Het meten van kwaliteit met goede kwaliteitsindicatoren is een goede eerste stap 
in een systeem waarin continue kwaliteitsverbetering wordt doorgevoerd. Deze indicatoren 
moeten dan wel voldoen aan criteria van validiteit. In dit proefschrift wordt onderzoek 
beschreven op het gebied van de ontwikkeling van (deel 1) en de validatie van indicatoren 
(deel 2) voor kankerzorg. De hoofdvragen in dit proefschrift zijn:
Deel I Ontwikkeling van kwaliteitsindicatoren voor kankerzorg
Welke verschillen zijn er tussen nationale evidence-based richtlijnen van twee Hoofdstuk 2
aangrenzende landen en zijn er consequenties als indicatoren worden gebaseerd op 
nationale richtlijnen?
Is het mogelijk om generieke indicatoren te ontwikkelen voor patiëntgerichte Hoofdstuk 3
kankerzorg?
Hoe zouden kwaliteitsindicatoren voor kankerzorg ontwikkeld en gemeten moeten Hoofdstuk 4 
worden?
Deel IIValidatie van kwaliteitsindicatoren voor kankerzorg
Is het nodig om procesindicatoren waarmee tijdige en multidisciplinaire kankerzorg Hoofdstuk 5 
gemeten kan worden, te corrigeren voor case mix?
Kunnen kwaliteitsindicatoren gebruikt worden voor het meten van geïntegreerde Hoofdstuk 6 
zorg?
Is er een relatie tussen procesindicatoren voor kankerzorg en patiëntuitkomsten Hoofdstuk 7
(zoals overleving)?
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Deel I - Algemeen
In dit proefschrift werden kankerspecifieke sets kwaliteitsindicatoren ontwikkeld en 
gemeten voor colorectaal, borst- en niet-kleincellig longcarcinoom (NSCLC) en non- 
Hodgkin lymfoom (NHL). Daarnaast werd een generieke set van indicatoren ontwikkeld 
voor patiëntgerichte kankerzorg (zie pagina 163 voor alle indicatorsets). Een systematische 
RAND gemodificeerde Delphi procedure werd gebruikt om de indicatoren te ontwikkelen 
bestaande uit een schriftelijke ronde en een bijeenkomst met experts. Voor elke set 
indicatoren werden kemaanbevelingen geselecteerd uit nationale of internationale 
evidence-based richtlijnen en deze werden beoordeeld door experts op hun bruikbaarheid 
als kwaliteitsindicatoren. Experts zijn personen die de verschillende “stakeholders” 
vertegenwoordigden. De algemene definitie van stakeholders: een individu, groep, instituut 
of overheid met een belang (economisch, sociaal of omgevingsbelang) in een bepaalde 
meting, voorstel of gebeurtenis. Voor kankerzorg zijn er verschillende groepen 
stakeholders. In dit proefschrift werden indicatoren ontwikkeld ten behoeve van medische 
professionals zodat zij hun kwaliteit van zorg kunnen monitoren en verbeteren. 
Stakeholders die als experts optraden in onze panels waren daarom medische professionals 
(en patiënten bij het ontwikkelen van patiëntgerichte indicatoren) maar geen verzekeraars 
of beleidsmakers.
Hoofdstuk 2-4
Richtlijnen worden vaak als basis gebruikt om indicatoren op te ontwikkelen. Daarom 
onderzochten wij de vergelijkbaarheid van evidence-based richtlijnen. We onderzochten 
borstkankerrichtlijnen uit Duitsland en Nederland (hoofdstuk 2). Het bleek dat deze 
vergelijkbaar waren voor wat betreft de kwaliteit van de ontwikkelmethode en ook dat ze 
inhoudelijk vergelijkbaar waren, in ieder geval voor de aanbevelingen die in beide 
richtlijnen voorkwamen. Dit zou bevorderend kunnen werken voor grensoverschrijdende 
samenwerking in kankerzorg tussen Nederland en Duitsland. Het was opmerkelijk dat 
sommige aanbevelingen in de richtlijnen onderbouwd werden met hetzelfde bewijs 
(wetenschappelijke studies van hoge kwaliteit) maar toch inhoudelijk verschillend waren 
tussen de twee landen. Het bleek dat de resultaten van de studies duidelijk waren, maar dat 
deze resultaten niet direct bruikbaar waren in de dagelijkse praktijk. Bij het formuleren van 
aanbevelingen houden richtlijnontwikkelaars namelijk ook rekening met factoren zoals 
bijwerkingen, patiëntvoorkeuren, kosteneffectiviteit en de beschikbaarheid van (financiële 
en materiele) middelen. De overwegingen die daarbij gemaakt worden kunnen verschillen 
tussen landen, waarschijnlijk als gevolg van cultuur.
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Toen deze studie begon waren er slechts enkele indicatorsets beschikbaar voor kankerzorg 
(via Pubmed) die ontwikkeld waren met een systematische methode zoals de RAND 
gemodificeerde Delphi. Ook waren de sets vaak niet multidisciplinair maar voor 1 enkele 
medische discipline zoals chirurgie of radiotherapie ontwikkeld of voor één tumortype. In 
dit proefschrift ontwikkelden we een generieke set van indicatoren voor patiëntgerichte 
kankerzorg (hoofdstuk 3). We werkten samen met een panel van zowel medische 
professionals (van meerdere disciplines) en patiënten en gebruikten een systematische 
RAND gemodificeerde Delphi methode. Dit leidde tot een generieke set van 17 
patiëntgerichte kwaliteitsindicatoren voor kankerzorg voor de domeinen: Communicatie, 
Fysieke ondersteuning, Psychosociale zorg, Nazorg en de Organisatie van zorg. Deze set 
kan gebruikt worden voor het vaststellen en verbeteren van kwaliteit van patiëntgerichte 
zorg. Toekomstig onderzoek zal uitwijzen of deze zorg ook echt wordt gegeven volgens de 
kwaliteitsindicatoren die ontwikkeld zijn en of dit van positieve invloed is op 
patiëntuitkomsten zoals patiënttevredenheid en kwaliteit van leven.
Er waren aan het begin van deze studie nog geen indicatoren gepubliceerd waarmee 
kwaliteit van zorg voor patiënten met NHL gemeten kon worden. In hoofdstuk 4 van dit 
proefschrift werden NHL indicatoren ontwikkeld op basis van beschikbare richtlijnen en 
gemeten voor de diagnostiek, behandeling, nazorg en de organisatie van zorg. We 
onderzochten of de ontwikkelde indicatoren gebruikt konden worden om vast te stellen of 
er verbeterpotentieel was. Dit werd onderzocht in een studie waarin 431 NHL patiënten 
werden geïncludeerd uit 22 ziekenhuizen uit drie regio’s: de noordelijke, oostelijke en 
zuidelijke regio’s in Nederland (voormalig kankercentrumregio’s IKO, IKN en IKL). 
Verbeterpotentieel werd gedefinieerd als een indicatorscore <90%. Daarnaast keken we als 
extra aanwijzing voor verbeterpotentieel ook naar regionale verschillen. Uiteindelijk werd 
uit 99 kemaanbevelingen een set van 20 indicatoren ontwikkeld. Op bijna alle indicatoren 
(N—16) was er ruimte voor verbetering. De laagste indicatorscores werden gevonden voor 
het vaststellen van IPI (een prognostische index), voor stadiëring (het uitvoeren van 
complete beeldvorming en beenmergonderzoek), rapportage over pathologiebevindingen en 
het bespreken van patiënten in multidisciplinair overleg. Voor 5 indicatoren werden ook 
regionale verschillen gevonden. In richtlijnen wordt vaak standaard zorg beschreven zoals 
aanbevolen voor de meerderheid van de patiënten. Echter, voor een individu kan 
standaardzorg soms juist meer schade berokkenen dan goed doen, bijvoorbeeld omdat de 
patiënt te zwak is of meerdere bijkomende medische problemen heeft. Bij die patiënten 
moet de richtlijn wellicht juist niet gevolgd worden en zijn er dus goede argumenten om 
van de standaardzorg af te wijken. Vaak wordt dit genoemd als verklaring voor lage 
indicatorscores. In hoofdstuk 4 hielden we rekeningen met argumenten voor het afwijken 
van richtlijnen bij het vaststellen van het verbeterpotentieel bij NHL indicatoren 
(indicatorscores lager dan 90%). Na correctie voor deze argumenten, bleef het 
verbeterpotentieel intact op de indicatoren, met uitzondering van 1 indicator betreffende het 
toedienen van chemotherapie (R-CHOP bij diffuus grootcellig lymfoom). De ontwikkelde 
indicatoren konden duidelijk maken waar verbeteringen nodig zijn in de domeinen 
Diagnostiek en stadiëring, Behandeling en follow-up en de Organisatie van zorg voor NHL 
patiënten.
1 5 6  I K W A L IT E IT S IN D IC A T O R E N  VOUK KANKERZORG
V a l i d a t i e  v a n  k w a l i t e i t s i n d i c a t o r e n
Deel II -Algemeen
De kankerspecifieke indicatorsets uit dit proefschrift werden steeds gemeten in drie regio’s 
in Nederland. De data werd retrospectief verzameld uit de medische dossiers door 
medewerkers van de Integrale Kankercentra Nederland (IKNL) of door een onderzoeker 
van het project die getraind was door de het IKNL. Voor elke set werd standaard gemeten 
hoeveel data er miste om de indicatoren te kunnen berekenen (“missing data) en werd inter- 
beoordelaarsbetrouwbaarheid getest. Voor deze betrouwbaarheid werd een aantal patiënten 
in duplicaat gemeten door twee verschillende dataverzamelaars en werd de mate van 
overeenstemming vastgesteld tussen de twee verzamelaars. De overeenstemming was goed. 
In het laatste deel van dit proefschrift worden de meer complexe aspecten van validiteit 
besproken: case mix correcties, het nut van patroonanalyses en het vaststellen van 
criteriumvaliditeit.
Hoofdstuk 5-7
Het is gebruikelijk om uitkomsten, zoals sterftecijfers, te corrigeren voor de verschillen in 
ziekenhuispopulaties (case mix) wanneer deze uitkomsten gebruikt worden om 
ziekenhuizen onderling te vergelijken. Er is echter weinig kennis over het nut van case mix 
correcties bij procesindicatoren. In dit proefschrift werd in een studie met meer dan 2100 
patiënten met NHL, long-, borst- of colorectaal kanker onderzocht of het nuttig is om 
procesindicatoren te corrigeren voor case mix (hoofdstuk 5). De patiënten kwamen uit 27 
Nederlandse ziekenhuizen. Het nut van case mix correctie werd onderzocht voor drie 
generieke indicatoren die vaak gebruikt worden om de kwaliteit van tijdige en 
multidisciplinaire kankerzorg te meten. Het bleek dat voor bepaalde patiëntengroepen 
minder goed op de indicatoren rondom tijdige en multidisciplinaire zorg werd gescoord 
bijvoorbeeld: voor patiënten die geen zorg wilden ontvangen of voor patiënten met 
bijkomende aandoeningen (comorbiditeiten). Echter, na correctie voor case mix waren de 
gecorrigeerde indicatorscores nagenoeg gelijk aan de originele indicatorscores (Intra-class 
correlatie >0.992). Dit betekent dat lage indicatorscores, laag blijven na case mix correctie 
op deze indicatoren en de hoge scores, hoog. Ziekenhuizen met lage scores zouden zich 
moeten kunnen verbeteren, zeker in vergelijking met de ziekenhuizen met hoge scores (best 
practices). Deze generieke indicatoren betreffende tijdige en multidisciplinaire zorg kunnen 
dus gebruikt worden om ziekenhuizen te vergelijken zonder dat case mix correctie nodig is.
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Omdat de zorg voor patiënten met kanker multidisciplinair is, moeten de verschillende 
zorgprocessen goed op elkaar afgestemd worden. Met andere woorden: de zorg moet 
geïntegreerd worden aangeboden om goede kwaliteit van zorg te kunnen leveren. In 
hoofdstuk 6 van dit proefschrift onderzochten we een nieuwe methode om vast te stellen in 
welke mate geïntegreerde zorg wordt geleverd aan kankerpatiënten. Deze nieuwe methode 
heet: patroonanalyse. We gebruikten in hoofdstuk 6 acht indicatoren die te vinden zijn op 
een klinisch pad voor patiënten met niet-uitgezaaide darmkanker. Elke individuele indicator 
draagt in belangrijke mate bij aan de rest van de zorg en het niet uitvoeren van de indicator 
kan gevolgen hebben voor de rest van de zorg. We zagen dat slechts eenderde van de 
patiënten alle aanbevolen zorg kreeg zonder het overslaan van één van de acht stappen op 
het klinische pad. Het bleek ook dat er meer dan 40 verschillende patronen waren waarop 
de zorg werd geleverd. In de tien meest voorkomende patronen kregen patiënten bijna alle 
stappen behalve de nazorgdiagnostiek (zoals beeldvorming van de lever tijdens nacontrole 
en het vaststellen van tumormarkers (CEA) na chirurgie). Deze nazorg is belangrijk om 
tijdig eventuele terugkeer van de tumoren (recidieven) te kunnen detecteren, zodat 
behandeling ervan nog mogelijk is. Bovendien, we vonden ook dat patiënten bij wie meer 
dan 10 lymfeklieren onderzocht zijn vaker geïntegreerde zorg kregen (dus alle stappen van 
het klinische pad) dan patiënten bij wie minder klieren onderzocht werden. Andere 
onderzoekers hebben eerder aangetoond dat patiënten met meer dan 10 lymfeklieren 
onderzocht een hogere kans op overleving hebben dan patiënten met minder onderzochte 
lymfeklieren. In toekomstig onderzoek zou gekeken moeten worden welke kosten en 
uitkomsten (zoals overleving) bij elk patroon horen. Deze patroonanalyse is in ieder geval 
een nuttige methode om geïntegreerde zorg te meten.
Criteriumvaliditeit is gedefinieerd als “de mate waarin de scores van een meetinstrument 
een goede reflectie zijn van een goudenstandaard”. Een veel voorgestelde methode om 
criteriumvaliditeit vast te stellen voor kwaliteitsindicatoren is de scores van 
procesindicatoren te relateren aan uitkomsten. Voor zorgverleners zijn zulke studies 
belangrijk omdat het de klinische relevantie kan aantonen van het meten en verbeteren van 
procesindicatoren. In hoofdstuk 7 bekeken we of procesindicatoren voor de zorg voor 
NHL-patiënten gerelateerd zijn aan hun 5-jaarsoverleving. Van 298 patiënten uit 6 
ziekenhuizen in Nederland werd data geanalyseerd en ook voor een homogene subgroep 
van 125 patiënten met diffuus grootcellig B-cel lymfoom. Voor 5 procesindicatoren werd er 
een verband gevonden met overleving. Deze relatie werd statistisch gecorrigeerd voor 
verstorende factoren (zogenaamde confounders) en overlevingsbias. Patiënten die 
beeldvorming kregen van de hals, thorax en abdomen of een beenmergbiopt hadden een 
hogere kans op overleving. Daarnaast bleek de toediening van chemotherapie (CHOP) 
zonder de dosis te reduceren gerelateerd te zijn aan een betere overlevingskans. Het leveren 
van zorg zoals aanbevolen door de richtlijnen is gerelateerd aan een verbeterde 
overlevingskans voor NHL patiënten. Hoe deze relatie precies tot stand komt is nog 
onbegrepen en zal in de toekomst verder onderzocht moeten worden.
D i s c u s s i e
Tot slot werden in hoofdstuk 8 de kembevindingen in dit proefschrift beschreven en 
bediscussieerd. Daarnaast werden de methodologische overwegingen in het ontwikkelen en
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valideren van indicatoren gegeven en ook de toekomstige implicaties voor onderzoek, 
medische zorg en beleid. De algemene conclusies waren dat de betrokkenheid van experts 
van verschillende stakeholder groepen van belang is bij het ontwikkelen van face-valide en 
inhoudsvalide indicatoren. In het bijzonder wanneer experts samenkomen om de 
indicatoren te bespreken worden meningsverschillen opgelost. Dit draagt bij aan een betere 
indicatorset. In dit proefschrift werden vooral indicatoren ontwikkeld gebaseerd op 
richtlijnen en daarom waren dit hoofdzakelijk procesindicatoren. Het was interessant om te 
zien dat er overeenkomsten waren tussen de verschillende kankerspecifïeke sets. In 
hoofdstuk 8 beschrijven we hoe deze overeenkomsten gebruikt kunnen worden om 
generieke indicatoren te ontwikkelen voor diagnostiek, behandeling en nacontrole van alle 
kankerpatiënten. Deze kunnen dan ook ingezet worden voor kankertypes die minder vaak 
voorkomen. Betreffende de validatie van indicatoren hebben we aangetoond dat er 
suboptimale indicatorscores zijn voor de NHL zorg in Nederland die niet te verklaren zijn 
door patiënt- of tumorfactoren. Daarnaast zagen we dat het corrigeren voor case mix geen 
effect had op indicatoren voor tijdige en multidisciplinaire zorg gemeten voor patiënten met 
NHL, long-, borst- en colorectaal kanker. Dit kan wel veranderen als er extreme 
verschuivingen optreden in patiëntpopulaties bijvoorbeeld door centralisatie van zorg. 
Beleidsmaker stellen steeds vaker dat een hoog niveau van kwaliteit de efficiëntie in de 
zorg zal verbeteren en daardoor een kostenvermindering zal optreden. In dit proefschrift 
zijn er aanwijzingen dat kwalitatief goede processen leiden tot betere uitkomsten. 
Toekomstig onderzoek zal uitgevoerd moeten worden om te begrijpen hoe deze relatie tot 
stand komt. De patroonanalyse in dit proefschrift zal aan dit begrip kunnen bijdragen.
iMPRESSION OF MEASUREMENTS
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COLORECTAAL KANKER
“Pa t ië n t  k r e e g  c o m p l ic a t ie  n a  o p e r a t ie  d a a r o m  w e r d  c h e m o t h e r a p ie
UITGESTELD. DAARNA BLEEK BIJ NACONTROLE EEN METASTASE.”
“Pa t ië n t  w o r d t  g e a d v is e e r d  o p  k o r t e  t e r m ijn  e e n  s c o p ie  t e  l a t e n  
HERHALEN. PATIËNT VERTELT NAAR EGYPTE GAAN IN VERBAND MET WERK 
VOOR LANGERE TIJD.”
“V o o r  p a t ië n t  w o r d t  e e n  v o o r s t e l  g e d a a n  v o o r  n a c o n t r o l e , m a a r
LATER DAN DE AANBEVOLEN 8 MAANDEN NA CURATIEVE RESECTIE.”
“Z e e r  v it a a l  v o o r  d e  l e e f t ijd ”
“G e e n  v e r d e r e  n a c o n t r o l e  v o o r  d a r m k a n k e r , g e e n  v e r s l a g l e g g in g . 
P a t ië n t  k o m t  w e l  st e e d s  b ij  in t e r n is t /n e u r o l o o g  v o o r  a n d e r e  z a k e n .” 
“D e l a y  d o o r  o v e r l ijd e n  e c h t g e n o o t . H e m ic o l e c t o m ie  in  v e r b a n d  m e t  
PERFORATIE; TUMOR AL VERWIJDERD BIJ LAR”
N o n -h o d g k in  l y m f o o m
“PATIËNT IS OP EIGEN VERZOEK NA TWEEDE CHEMOKUUR GESTOPT EN EEN PAAR 
DAGEN LATER OVERLEDEN.”
“Tw ijf e l s  o f  p a t ië n t  f y s ie k  in  s t a a t  is  c h e m o t h e r a p ie  t e  o n t v a n g e n  op  
15 MAART. PATIËNT KREEG OP 20 NOVEMBER BEROERTE”
“W il d e  g e e n  d ia g n o s t ie k  e n  b e h a n d e l in g  a a n v a n k e l ijk .” 
“M a a g o p e r a t ie  v a n  b io p t e n  N H L  e n  t e g e l ijk e r t ijd  a n e u r y s m a  
g e v o n d e n  e n  b e h a n d e l d ! !”
“P a t ië n t e  in  v o o r  h a a r  l e e f t ijd  g o e d e  a l g e h e l e  c o n d it ie . N a g e n o e g  
c o m p l e t e  r e m is s ie .”
“Z e e r  f o r s  o v e r g e w ic h t  b e m o e il ijk t  in it ië l e  d ia g n o s t ie k .”
“H e t  k a n  o o k  e e n  d if f u u s  g r o o t c e l l ig  B -c e l  l y m f o o m  z ijn  m a a r  d a t  is 
n ie t  g o e d  t e  b e o o r d e l e n  v a n w e g e  n a a l d b io p t  (m e t  b e t r e k k in g  t o t
MORFOLOGIE).”
“IN OVERLEG MET PATIËNT EN FAMILIE GEKOZEN VOOR PALLIATIEF BELEID, 
GEZIEN DE HOGE LEEFTIJD.”
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L o n g k a n k e r  (N S C L C )
“2 WEKEN VOOR LONGCARCINOOM WORDT OOK B-CLL GEDIAGNOSTICEERD 
WAARVOOR GEEN BEHANDELING. METATASTASEN IN LONG EN PLEURA.”
“K in d e r e n  o p  v a k a n t ie , w il  d a a r o m  n o g  n ie t  g e o p e r e e r d  w o r d e n .”
“PATIËNT WIL NIETS; ZIET ALLES ZEER SOMBER IN (CHRONISCH DEPRESSIEF).” 
“IN BRIEVEN STAAT EERST MRI HERSENEN EN DAN DAARNA WANNEER DEZE 
NEGATIEF IS, START CHEMOTHERAPIE. MAAR CHEMO AL EERDER GESTART.”
“M a t ig e  c o n d it ie , a f z ie n  v a n  v e r d e r  b e h a n d e l in g .” 
“G o e d e  c o n d it ie  v o o r  l e e f t ijd .” 
“G e l ijk t ijd ig  m a m m a t u m o r  o n t d e k t .” 
“H e e f t  s e c o n d  o p in io n  a a n g e v r a a g d  d a a r o m  k l e in e  v e r t r a g in g  b ij
STARTEN CHEMOTHERAPIE.”
“Pa t ië n t  is  p a n is c h  v o o r  o n d e r z o e k e n  e n  h e e f t  n a d e r e  d ia g n o s t ie k
AFGEHOUDEN.”
” H e t  is  n ie t  z e k e r  d a t  e r  m a l ig n it e it  is  EN d a a r  is  v e r d e r e  d ia g n o s t ie k
VOOR NODIG, DIT WIL PATIËNT NIET. “
B o r st k a n k e r
“M u l t ip l e  in f a r c t e n  in  h e r s e n e n . Pa t ië n t e  w e n s t  g e e n  v e r d e r e
DIAGNOSTIEK, DAAR ZIJ ER TOCH NIETS MEE WOU DOEN.” 
“TE WEINIG TUMORCELLEN OM HER2NEU TE KUNNEN BEPALEN OP BIOPT” 
“ STADIUM PTNM: VOLGENS CHIRURG, T2N4MX, VOLGENS INTERNIST, T2N2M0 
EN RADIOTHERAPEUT T2N3M0. IN RE-EXCISIE GEEN RESTTUMOR GEVONDEN.
B o o s t  r a d io t h e r a p ie  =13,7” 
“R a d io t h e r a p ie : b o o s t  t e g e l ijk  g e g e v e n  m e t  n o r m a l e  f r a c t ie s , d o sis
ONBEKEND”
“Pa t ië n t e  h e e f t  v o o r g e s c h r e v e n  t a m o x if e n  n ie t  in g e n o m e n .” 
“M e v r o u w  is  e n ig e  t ijd  in  A u s t r a l ië  g e w e e s t , v a n d a a r  d e  l a n g e r e  
p e r io d e  t u s s e n  1e  p o l ib e z o e k  e n  d e f in it ie v e  d ia g n o s e .” 
“Om  o n d u id e l ijk e  r e d e n  w o r d t  h e t  a d v ie s  v a n  d e  o n c o l o g ie c o m m is s ie
n ie t  o p g e v o l g d .”
“In  v e r b a n d  m e t  l e e f t ijd  g e e n  c h e m o t h e r a p ie  o f  a d ju v a n t e  h o r m o n a l e
t h e r a p ie .”

In d ic a to r  sets

In d ic a t o r s  f o r  b r e a s t  c a n c e r  1165
B r ea st  c a n c e r
Diagnosties and staging
• The care provider should assess the N stage of patients with breast cancer by 
performing a sentinel node biopsy or an axillaiy lymph node dissection level I or II.
• An axillary lymph node dissection should only be performed, until after a sentinel node 
biopsy, or, in case a sentinel node biopsy has failed or is impossible to perform.
• When an axillary lymph node dissection is performed, the pathologist should examine 
a minimum of 10 nodes (including the lymph nodes from the sentinel node biopsy)
Treatment and follow-up
• When breast conserving surgery is performed, the excision of the tumor should be 
microscopically complete.
• A re-excision should be performed after breast conserving surgery in case the excision 
of the tumor is not microscopically complete.
• The pathologist should examine the surgically excised breast tissue with micro 
calcifications after breast conserving surgery with radiography of the entire specimen 
and of the lamellas.
• The radiotherapist should provide a breast cancer patiënt with stage pTl-2, pNO-1 with 
a boost of 14-16 Gy after fractionated radiation and breast conserving surgery with 
tumor free margins.
• The oncologist should treat pre-menopausal women (node positive and hormone 
receptor positive) with adjuvant chemo- and endocrine therapy.
• Patients with a node negative status who have unfavorable tumor characteristics should 
be treated similar to a node positive patiënt. Patients with a node negative status with 
favorable characteristics should not be treated with adjuvant systemic therapy.
• The radiotherapist should treat patients with a stage pN2 of pN3 with loco regional 
radiotherapy.
• If chemotherapy is administered, the dose should be (maintained) optimal.
• Patients with treated breast cancer should receive a mammography each year until the 
age of 60.
The organization of care
• The surgeon should advice a physiotherapy consult or intervention to patients who 
have had a mastectomy or breast conserving surgery with an axillary lymph node 
dissection.
• The pathology report should contain:
o primary tumor characteristics: size, grade according to Bloom-Richardson, 
including the quantifïcation of mitoses 
o type according to WHO 
o estrogen receptor status in % 
o progesterone status in %
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o HER-2-neu-status
• In case o f  breast conserving surgery:
o tumor free margins in mm, for invasive breast cancer as well as for DCIS
• Sentinel node biopsy
o number of nodes biopted 
o number of positive nodes
o number of nodes with macro, micro and isolated tumor cells
• Lymph node dissection
o number of nodes biopted 
o number of positive nodes
o number of nodes with macro, micro and IHC-solitaire tumor cells
• Patients with breast cancer should be discussed in a multidisciplinary meeting before 
any treatment if given.
• Patients with breast cancer should be discussed in a multidisciplinary meeting after 
surgical treatment.
• The care providers should treat patiënt with breast cancer within four weeks after the 
final diagnosis (pathological diagnosis).
In d ic a t o r s  f o r  NSCLC 1167
N o n - s m a l l  c e l l  l u n g  c a n c e r
Diagnosis and staging
• A mediastinoscopy should only be performed in patients with non-small cell lung 
cancer when a FDG-PET has preceded it.
• A mediastinoscopy is not recommended when on the PET scans there is no focal 
activity in the mediastinum or hilum. (The primary tumor should be clearly visible and 
should not be close to the mediastinum and the previous CT-scan should not 
demonstrate lymph nodes larger than 1 cm in the mediastium (short axis))
• A mediastinoscopy is recommended when on the CT-scan there is at least one lymph 
node of which the short axis is larger than 1 cm or for patients for whom the PET scan 
showed focal activity in the hilum or mediastium
• When a cervical mediastinoscopy is performed, at least 4 the 6 accessible lymph node 
stations should be biopted (2 ipsilateral, 1 contralateral and lymph node station number
Treatment and follow-up
• For patients with a clinical stage III a skeletal scintigraphy and a CT or MRI of the 
brain should be performed before the start of the combination therapy
• Patients with locally advanced NSCLC with WHO performance status 0 or 1 should be 
treated with combination therapy
The Organization of Care
• The diagnostic trajectory should be completed within 21 calendar days from the first 
visit to pulmonologist (chest CT-scan, bronchoscope, FDG-PET (mediastinoscopy 
(=35 days))
• Therapy should start within 35 (or 49) calendar days from the first visit to the 
pulmonologist
• All NSLC cancer patients should be discussed in multidisciplinary consultation
• The pathology report should contain:
o type of resection 
o localization of the tumor 
o tumor characteristics
o margins
hermens RP, Ouv.-sm MM, Vonk-Okhuijsen SY, et al. Development o f  quality indicators fo r  diagnosis and
treatment o f  patier,r:s with non-small cell lung cancer: a first step toward implementing a mvltidisciplinarv
evidence-based guideline. Li/ng Cancer. 2006;54(1):117-124.
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C o l o r e c t a l  c a n c e r
Diagnosis and staging
• The care provider should base the diagnosis of colorectal cancer on the histological 
examination in patients for whom a complete colonoscopy can be performed.
• The pathologist should examine a minimum number of 10 lymph nodes after resection 
of colon tumor to assess a negative node status.
• The care provider should detect potential lesions in the liver through imaging 
techniques, a CT-scan or MRI before the resection of the colorectal tumor.
• In case of a superficial tumor, patients with rectal cancer should be staged using an 
MRI.
• The care provider should pre-operatively asses the tumor size, lymph node status and 
the circumferential margins with imaging techniques for rectal cancer
• The pathologist should determine the margins and the radicality of the resection of the 
rectum tumor.
Treatment and follow-up
• The care provider should treat patients with a colon carcinoma stage III with adjuvant 
chemotherapy with FOLFOX of with a scheme in where 5-FU is replaced with 
capecitabine.
• The care provider should treat patients with a rectum cancer with pre-operative 
radiotherapy with a biologically effective dose of > 30 Gy.
• The care provider should treat patients with (clinically) locally advanced rectum 
carcinoma with chemo-radiotherapy prior to surgery.
• Locally advance tumors are tumors that on imaging are a:
o T4 tumor
o T3 tumor with a potential positive circumferential margin 
o lymph node positive (at least 4 nodes positive)
• In case of a metastasized colon carcinoma and a good performance status (WHO 0 or 
1), then the care providers should treat the patients with firstline combination 
chemotherapy containing fluorpyrimidine and bevacizumab (preferably an oral 
fluoropyrimidine).
• In case a patiënt with colorectal cancer has asymptomatic metastases that are not 
operable, the care providers should start palliative systemic therapy and should not 
wait until symptoms occur.
• In case imaging of the entire colon was incomplete pre-operatively (because of an 
incomplete colonoscopy for example), the care providers should perform a 
postoperative colonoscopy within 3 months after surgery.
• The care provider should follow-up on patients with a colorectal carcinoma with stage
I (T2, NO, MO), stadium II and III by checking the liver with ultrasound* and assessing 
the CEA within 3-6 months after surgery. The ultrasound can be replaced with CT in 
case the ultrasound is technically impossible to perform.
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The organization of care
• All patients with colorectal cancer should be discussed in the multidisciplinary 
consultation.
• The pathology report should contain:
o histological type 
o histological grade 
o invasion depth (T stage) 
o margins and the radicality 
o number of excised lymph nodes 
o number of positive lymph nodes 
o size of the tumor 
o perineural invasions 
o macroscopic description of the tumor 
o vascular invasion 
o lymphatic invasion
• The pathologist should assess the quality of the surgical the total mesorectal excision 
by judging the level of resection.
• In case the circumferential margins are positive (1 mm or less), then de exact margins 
should be described in the pathology report of patients with a rectum carcinoma.
• Patients with colorectal cancer should have a colonoscopy within 4 weeks after the first 
hospital visit.
• Patients with colorectal cancer should have therapy started within 4 weeks after the 
colonoscopy.
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N o n -H o d g k i n  l y m p h o m a
Diagnosis and staging
• The diagnosis should be based on the histological examination of an excision or wide 
incision biopsy
• Patients should be staged according to Ann Arbor dassification
• Diagnosis for NHL should be based on morphology and immune phenotype (molecular 
clonality only supplementary)
• Staging techniques should include CT scans of neck, thorax, and abdomen; bone 
marrow aspirate; and bone biopsy
• For patients with an aggressive type of lymphoma, the International Prognostic Index 
should be assessed.
• For all patients with NHL serum lactate dehydrogenase should be assessed.
• For all patients with NHL total blood counts should be performed (Leukocyte count 
Leukocyte differentiation, Thrombocyte count and Hemoglobin)
Treatment and fbliow-up
• Patients should have a report of a response to therapy in their medical files using terms: 
complete remission (unconfirmed), partial remission, stable disease, progression and 
recurrence.
• The radiologist should document lesions in the radiology report before (possible) 
therapy: the locations of lesions on CT scans, the sizes of lesions on CT scans and the 
sizes of lesions on CT scans reported in millimeters.
• The radiologist should document lesions in the radiology report after therapy: the 
locations of lesions on CT scans, the sizes of lesions on CT scans and the sizes of 
lesions on CT scans reported in millimeters.
• Patients should be re-evaluated after chemotherapy with CT scans (or PET); bone 
marrow aspirate; and bone biopsy (in stage IV cases)
• Patients with diffuse large B-cell lymphoma should receive chemotherapy with 
rituximab-CHOP
• The dose of rituximab-CHOP should not be reduced or the reason for the reduction was 
reported.
The organizaticn of care
• Biopsy material should be unfixed when sent to and received by the pathologist
• There should be an integrated reporting of pathology techniques
• The pathology report should contain:
o Origin of tissue documented 
o Tissue characteristics documented 
o Biopsy method documented 
o Receipt of material documented 
o Noted whether tissue was frozen
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• All NHL patients should be discussed in a multidisciplinary consultation
• The results of pathology should be known before the start of treatment
• The diagnostic period should be no longer than 3 weeks after the fïrst visit to the 
hospital
• Therapy should start within 2 weeks after the diagnostic period
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Communication
A l. The healthcare provider should meet the following criteria for good communication:
a. Making use of open-ended questions in a conversation with the patiënt.
b. Summarizing and repeating important information.
c. Giving the most important information first.
d. Adjusting information to the condition of the individuai patiënt.
e. Explaining medical terminology to the patiënt.
f. Adjusting information to the language skills of the patiënt and when necessary 
providing information in the native language of the patiënt.
A2. The healthcare provider should guarantee the following preconditions for a suitable 
conversation:
a. Providing a room with adequate privacy, with enough time for an accurate 
conversation.
b. Involving family and friends in the conversation, by inviting the patiënt to bring 
someone to appointments.
A3. Communicative skills of all healthcare providers should regularly be evaluated and 
feed-back should be given.
A4. The healthcare provider should guarantee the following preconditions for an informed 
consent:
a. Giving verbal information about the probability of recovery.
b. Giving verbal information about the possible physical and psychosocial impact of 
diagnostics and the treatment on the patiënt.
c. Asking the patiënt if he/she received adequate verbal and written information.
d. Asking the patiënt if he/she understood the provided information.
e. Asking the patiënt if he/she is satisfïed with the involvement in decision making.
f. Respecting the freedom of choice of the patiënt throughout the complete process 
of care and treatment and guarantee the autonomy of the patiënt.
A5. If no curative options are available, the healthcare provider should emphasize that the 
patiënt will receive optimal palliative care and that the healthcare provider will not leave 
the patiënt to his/her fate.
A6. Depending on the setting, the healthcare provider should hand over a list of sources of 
information to the patiënt that is adjusted to the condition of the patiënt.
Physical support
Bl. The healthcare provider should make an inventory of complaints and problems that 
hmder the patiënt, search for causes, educate the patiënt on this subject and start medical or 
non-medical treatment with use of relevant medical disciplines.
Psychosocial care
Cl. The healthcare provider should gather information on the psychosocial and emotional 
health status of the patiënt on important moments in the process of care and adequately 
refer to specialists, depending on the diagnosed problems.
C2. The care provider should gather information on the psychosocial and emotional health 
status of family and friends of the patiënt and adequately refer to specialists, depending on 
the diagnosed problems.
After Care
D l. The healthcare provider should guarantee sufficiënt time and attention to the patiënt 
during appointments after the primary treatment has fmished.
D2. The healthcare provider should inform the patiënt on the most important complaints 
that can occur after primary treatment has fïnished and that can be a sign of progression of 
the disease.
D3. The healthcare provider should inform the patiënt on possibilities for rehabilitation in 
the region and if desired, the patiënt will be referred to these rehabilitation options.
Organization of patient-centered care
El. One healthcare provider should be installed as coordinator of care, to guarantee 
continuity of care for the patiënt.
E2. The mpmmal waiting time between the visit to the general practitioner and the fïrst visit 
to the hospital should be five working days.
E3. The ma-ximal duration of the diagnostic process should be in accordance with the 
professional measures for the specific type of cancer.
E4. The healthcare provider should pay attention to the psychosocial effects of waiting 
times on the patiënt and adequately reply to this.
E5. Depending on the individual patiënt, the healthcare provider should stimulate self 
management and offer the proper information and support.
1741 G e n e r ic  in d ic a t o r s  f o r  p a t ie n t -c e n t e r e d  c a n c e r  c a r e ____________________________________________________
D a n k w o o r d

D a n k w o o r d  1177
Een project van deze omvang is niet uit te voeren zonder een goede samenwerking met en 
medewerking van veel verschillende partijen. Bij dezen wil ik een ieder bedanken die zich 
heeft ingezet voor dit project. Een aantal mensen/partijen noem ik in het bijzonder.
Ten eerste wil ik alle ziekenhuizen en experts in de Delphi panels bedanken die hun 
medewerking aan dit project hebben gegeven. Zonder hen was dit project nooit van de 
grond gekomen. Ook wil ik mijn dank uitspreken aan het KWF kankerfonds dat het 
mogelijk maakte om dit project uit te voeren. Ik ben me zeer bewust dat donaties aan het 
KWF kankerfonds vaak worden gedaan door donateurs die zelf kanker hebben gehad of er 
in directe kring mee te maken hebben gehad. Ik heb daarom mijn uiterste best gedaan om 
met dit onderzoek een bijdrage te leveren aan verbeteringen in kankerzorg.
Geachte prof. dr. Grol, beste Richard. Ondanks je drukke agenda, wist je altijd met rust en 
kundigheid mij te helpen om het project de goede kant op te laten gaan. Soms zat ik vast in 
een bepaalde denkwijze en kon ik met jouw aanwijzingen het weer overzien en een 
helikopterview inzetten. Dit heeft bijgedragen aan de kwaliteit van dit onderzoek, maar ook 
aan mijn persoonlijke ontwikkeling. Hartelijk dank daarvoor.
Prof. dr. de Mulder (Pieter) heeft mij in de eerste periode kunnen begeleiden van dit 
promotietraject maar is helaas in 2007 overleden. Zijn inzichten in kwaliteit van zorg waren 
voor mij nieuw en inspirerend en hebben mij een goede start meegegeven om dit project te 
kunnen voltooien. Prof. dr. Punt heeft daarna de rol van promotor vervult. Beste Kees, 
hartelijk dank datje mijn promotor wilde zijn. Je hebt me altijd met enthousiasme begeleid 
en mij van de nodige input voorzien op klinisch gebied.
Geachte mw. dr. Hermens, beste Rosella. Jouw woorden van vertrouwen en enthousiasme 
hebben mij er in onzekere tijden menigmaal bovenop geholpen. Je bent ook nog eens een 
kanjer in je werk en staat altijd klaar voor je promovendi wanneer ze je nodig hebben. En er 
was ook nog tijd om af en toe eens hard te lachen. Nog steeds als ik Koningin Maxima op 
televisie zie, moet ik aan jou denken.
Geachte mw. dr. Ottevanger, beste Nelleke. Ik waardeer jouw eerlijkheid, doortastendheid 
en nuchterheid. Met jouw klinische input kon ik beter werk afleveren. En als mijn artikel 
weer eens was afgewezen, dan gaven we niet op, maar schreven we een protestbrief. Ook al 
had het misschien geen zin, dan hadden wij er in ieder geval alles aan gedaan. Dat was bet 
motto! Jij en Rosella, vormen wat mij betreft een perfect team. En ik wil jullie nog 
bijzonder bedanken voor de steun die ik van jullie heb gekregen in de periode dat ik ziek 
was.
Geachte dr. Wollersheim, beste Hub. Hartelijk dank voor jouw betrokkenheid en interesse 
in dit project. Jij weet wat er in het veld speelt en deelt graag je kennis en kunde. Dat kan 
ik zeer waarderen.
Graag wil ik mijn dank uitspreken voor het IKNL. Tijdens dit onderzoek heeft het IKNL de 
ontwikkeling en metingen van de indicatoren gefaciliteerd. Dankzij de medewerkers van 
het IKNL (locaties Groningen, Nijmegen, Maastricht en IKZ) zijn de metingen uitgevoerd 
in verschillende ziekenhuizen in Nederland. De medewerkers van het IKNL zijn expert op 
het gebied van deze metingen en hebben mij altijd met zorg geholpen om betrouwbare
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gegevens boven te halen. In het bijzonder bedank ik Marjorie de Kok voor haar hulp bij de 
organisatie van metingen en daarnaast nog de kankerregistratiemedewerkers Kees Ebben, 
Jolanda van Beek, Marina Janssen, Gertie Lummen, Jeanette Schraa, Monique de Groot en 
Sanne Boerboom. De regionale tumorwerkgroepen wil ik bedanken voor de interesse en het 
meedenken bij het opzetten van dit KWF project.
Lieve Sanne (Kroft). Toen jij net afgestudeerd was van je studie Geneeskunde, kwam je me 
ondersteunen met het verzamelen en nakijken van de gegevens die gebruikt werden voor 
het berekenen van de indicatoren. Het gaf jou een kijkje in de keuken van het onderzoek 
doen en mij heel wat lucht dat er ondersteuning was. Ook hebben we samen de hele 
noordelijke en zuidelijke regio van Nederland afgereisd om metingen uit te voeren. Dank je 
dat je me toen heb geholpen en (ook mentaal) ondersteund hebt. Het zijn voor mij 
herinneringen aan een leuke tijd!
Noortje (Uphoff), jij zocht in 2009 een stage in het kader van je studie Biomedische 
Wetenschappen. Gelukkig wilde je die stage bij ons uitvoeren! In die tijd, kreeg ik een 
virusinfectie waardoor ik uitgeschakeld raakte, precies op een moment dat het niet uitkwam 
(het komt natuurlijk nooit uit). Wat was ik blij dat jij het onderzoek continueerde. Voor 
iemand die een stage komt lopen wellicht te veel gevraagd, maar het ging je goed af. En 
uiteindelijk heb je er een artikel over kunnen publiceren en nu ben je zelf aan het 
promoveren. Ik heb er alle vertrouwen in.
Ik heb in de tijd nog meer ondersteuning ontvangen waarvoor ik dankbaar ben. Lisette van 
der Heijden heeft voor mij meetformulieren geverifieerd. Reinier Akkermans en Remco 
Feskens, hartelijk HanV voor jullie hulp met de statistiek. Dat is echt een vak apart! Ik was 
altijd blij met jullie uitleg en tomeloos geduld om het te blijven uitleggen als ik het nog 
steeds niet snapte. Het secreteriaat bij IQ healtcare, hartelijk dank voor alle ondersteuning, 
in het bijzonder bedank ik Jeannette Holtman-van Wijk. Jolanda (van Haren), dank je voor 
het meehelpen met het klaarmaken van dit proefschrift voor de drukker en de 
manuscriptcommissie. Ik was van de spanning soms de tel kwijt, maar jij hield het hoofd 
koel gelukkig.
Han van Krieken en Katja Aben. Van jullie kreeg ik een database om een artikel over de 
relatie kwaliteit van zorg en overleving te schrijven. Het lukt niet goed om dit artikel 
gepubliceerd te krijgen, het is inmiddels 4 keer gereviewed door verschillende bladen, maar 
gelukkig staat het nu wel in dit proefschrift. Hopelijk lukt het alsnog met 
tienjaarsoverleving in plaats van vijijaarsoverleving. Hartelijk dank dat ik dat mooie artikel 
mocht schrijven. Het IKNL (locatie Nijmegen) wil ik bedanken voor het verzamelen van de 
data.
Collega’s bij IQ healthcare. Jullie zorgen voor een inspirerende omgeving en wat heb ik 
veel van iedereen geleerd. Naast hard werken was er gelukkig ook tijd voor hier en daar een 
alledaags praatje of een goed gesprek over huizen, vakantiepret, ziekte en gezondheid, 
hobby’s en over familie en vrienden. Ook lief en leed gedeeld met kamergenoten: Mariëlle 
Ouwens, Jeroen Schouten, Marjan Faber, Bart Staal, Laura van Hulst, Margot Tacken en 
Maud Graff. Er was ook tijd voor ontspanning: paintballen, ski-en en films kijken (welk 
verstandig persoon kijkt nu de film Paranormal Activity in een donker verlaten 
universiteitsgebouw?!). En soms een borrel in het Aesculaef. Team LINH (onder leiding
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van Jozé Braspenning), leuk dat ik ook een tijd bij het LINH team hoorde! Mijn huidige 
collega’s bij de unit Managementinformatie en concernstaf Kwaliteit en Veiligheid wil ik 
graag bedanken voor hun support en bemoedigingen bij de laatste loodjes.
Vrienden en familie. Ik voel me gezegend met zulke leuke, lieve mensen in mijn omgeving. 
Sommige van jullie hebben al twee jaar de cadeaus in de kast staan of ik heb ze zelfs al 
gekregen (vakantie Kroatië) maar nu eindelijk is het zover! We kunnen het feest vieren. 
Bedankt voor jullie tomeloze geduld en toch maar steeds de interesse hoe het met mij en dit 
project ervoor stond. Ik heb ook de nodige afleiding gehad in de vorm van weekendjes weg 
met het Genootschap, campingbezoeken, BBQ’s met de familie de Koster en familie 
Wennekes Beverwijk, etentjes, goede gesprekken en shoppen met vriendinnetjes, golfen, 
koffiedrinken met (schoon)ouders Gerard, Hanneke, Vicky en Michiel, Zumba met Lynn en 
feestjes en borrels met een hele hoop mensen die nu te veel zijn om op te noemen. Het 
laatste halfjaar heb ik mezelf geïsoleerd om het af te krijgen. Nu heb ik weer tijd! Dus kom 
maar op met alle leuke dingen in het leven!
Carlijn en Lucas, super dat jullie mijn paranimfen willen zijn. Vaak hebben we gepraat over 
onze onderzoeken en de werkervaringen die we opdeden. Carlijn, jij bent al gepromoveerd 
en Lucas zal snel volgen. Best bijzonder eigenlijk. Maar eigenlijk is het meest bijzondere 
wat een mooie vrienden jullie zijn voor mij. Ik hoop dat ik die goede band met jullie nog 
lang mag houden. Carlijn, aan ons de taak om Lucas en Martijn door de laatste loodjes heen 
te slepen straks.
Lieve Cleo, heel erg bedankt voor je hulp met het maken van de voorkant van dit 
proefschrift en de uitnodiging. Als dit feestje voorbij is, gaan we naar het volgende feestje 
waar jij samen met Karin ceremoniemeester voor wilde zijn. Mijn HanV js groot!
Gerard, Hanneke, Daan, Leonie, Ivan, Sasha, Dewi, Indy, Jessey, Shanaya en Jaimey. Wat 
een mooi rijtje namen! Dank voor het geduld en de steun en vooral de afleiding. Ik hoop dat 
jullie genieten van het feestje dat na zoveel jaren nu eindelijk gevierd mag worden. Pap en 
mam, zonder jullie steun was ik hier echt niet gekomen. Dus de eer is op 29 oktober geheel 
aan jullie wat mij betreft. Jullie zijn trots op alle (klein)kinderen, maar wat mij betreft 
mogen jullie vooral trots zijn op jezelf!
Lieve Jeroen. Zo! Klaar met de berg werk en nu echt tijd en rust om te genieten. En 
genieten: dat kunnen wij heel goed samen. Je bent mijn steun en toeverlaat. Echt gaaf dat ik 
straks jouw vrouw mag zijn!

C u r r i c u l u m  v it a e

Op 3 januari 1979 werd Lianne Wennekes geboren te Alphen 
aan den Rijn. Na haar VWO diploma behaald te hebben, besloot 
zij een jaar te werken bij IATA Netherlands bv., een 
internationaal bedrijf gericht op transport en logistiek in het 
luchtvaartwezen, op Schiphol.
Op haar 19e verhuisde ze naar Nijmegen om de studie 
Biomedische Gezondheidswetenschappen te volgen aan de 
Radboud Universiteit in Nijmegen. Zij koos het hoofdvak 
Pathobiologie. Gedurende haar studie zag zij de tal van 
technische mogelijkheden om (kanker)patiënten te 
diagnosticeren en te behandelen. Zij vroeg zich af: tot wat voor 
keuzes leiden al deze mogelijkheden en wat is eigenlijk het beste 
voor de patiënt? Zij specialiseerde zich daarom naast haar 
hoofdvak op de vakken ‘Evaluatie in de Geneeskunde’ en ‘Genetica & kanker’. Het laatste 
jaar van haar studie rondde ze af aan de Universiteit van Utrecht met de studie 
Fundamentals of Business & Economics. Tijdens haar studie was zij actief als 
jaarvertegenwoordiger, mentor, tutor en was zij lid van de opleidingscommissie 
Biomedische Wetenschappen. Naast haar studie werkte ze bij ABN AMRO bv. In februari 
2005 studeerde ze af.
Na een korte periode als clinical datamanager te hebben gewerkt bij Organon te Oss, begon 
ze in juni 2005 aan het project: Grensoverschrijdende zorg voor borstkankerpatiënten, 
gesubsidieerd door Euregio Rijn-Waal. In december 2005 startte ze met haar 
promotieproject, met dit proefschrift als resultaat: het ontwikkelen en valideren van 
kwaliteitsindicatoren voor kankerzorg. Dit project werd gesubsidieerd door het KWF 
kankerfonds.
Vanaf 2008 werkte zij naast haar promotie parttime als onderzoeker bij het Landelijke 
Informatie Netwerk Huisartsenzorg (LINH). Zij ontwikkelde een website waarvoor zij 
jaarlijks kwaliteitsindicatoren berekende en publiceerde, in het bijzonder bedoeld voor de 
huisartsenzorg. Gedurende deze periode werd haar interesse gewekt voor het 
geautomatiseerd berekenen van indicatoren en het beschikbaar stellen van de indicatoren in 
een dashboard. Vanaf 2010 werkte zij in een team van het Instituut Waarborging Kwaliteit 
en Veiligheid dat een Kwaliteitsmonitor ontwikkelde voor het UMC St Radboud. In deze 
monitor kunnen Raad van Bestuur, afdelingsleiding, zorgmanagers, verpleegkundigen en 
artsen real-time gegevens opvragen over kwaliteit van zorg. Op dit moment werkt zij als 
adviseur Kwaliteit en Veiligheid bij de unit Managementinformatie, Concernstaf Kwaliteit 
en Veiligheid in het UMC St Radboud.
Zij is verloofd met Jeroen ter Weeme en samen wonen zij in Nijmegen.

Stellingen
Deveiopment and validation o f  quality indicators for cancer care
Betrokkenheid van en interactie tussen medische professionals vanuit verschillende 
oncologische disciplines is van grote toegevoegde waarde bij het ontwikkelen van 
valide kwaliteitsindicatoren, (d it proefschrift)
H e t is mogelijk om naast de bestaande generieke uitkomstindicatoren voor 
kankerzorg zoals mortaliteit ook generieke procesindicatoren te ontwikkelen voor 
patiëntgerichtheid, diagnostiek, behandeling, nazorg en de organisatie van 
kankerzorg. (d it proefschrift)
H e t meten van procesindicatoren heeft niet to t doel om  te weten o f  een medisch 
professional zich strikt aan de richdijnen houdt, m aar is bedoeld om 
verbeterpotentieel zichtbaar te maken, (d it proefschrift)
E r is geen case mix correctie nodig voor het onderling vergelijken van de 
Nederlandse ziekenhuizen op indicatoren zoals het bespreken van kankerpatiënten in 
multidisciplinair overleg en de wachttijd voor diagnostiek o f  behandeling, (d it 
proefschrift)
Patroonanalyse, een nieuwe methode waarin de metingen van meerdere 
procesindicatoren samengevat worden zonder het inzicht in details over individuele 
processen te verliezen, is van toegevoegde waarde voor het meten van kwaliteit van 
geïntegreerde kankerzorg. (d it proefschrift)
E r m oet meer onderzoek komen naar de achterliggende redenen waarom 
richtlijnadherentie —gemeten met procesindicatoren- geassocieerd is met een betere 
overleving van patiënten m et een non-H odgkin lymfoom. (d it proefschrift)
Analyse van het probleem, is de helft van de oplossing. (Gerard Wennekes)
V anuit het perspectief van de burger staat kwaliteit van zorg niet altijd hoog genoeg 
op de agenda van de ziekenhuisbesturen. (Jeroen ter W eeme)
Any intelligent fooi can make things bigger and more complex. I t takes a touch o f  
genius — and a lo t o f  courage — to  move in the opposite direction. (Albert Einstein)
Beter een kleine taak goed volbracht dan vele taken half. (Plato)



